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Abstract 
 
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a key enzyme in the conversion of 
cortisone to the functional glucocorticoid hormone cortisol.  This activation has been 
implicated in several human disorders, notably the metabolic syndrome where 11β-HSD1 has 
been identified as a novel target for potential therapeutic drugs. Crystal structures have 
revealed the presence of a pronounced hydrophobic surface patch lying on two helices at the 
C-terminus.  The physiological significance of this region has been attributed to facilitating 
substrate access by allowing interactions with the endoplasmic reticulum membrane. 
In order to initiate investigations into the potential interaction between 11β-HSD1 and 
membrane, hydrophobic residues in the C-terminal helices of human and guinea pig 11β-
HSD1 were mutated to glutamic acid. One of these mutants, F278E, displayed greatly 
increased yields of soluble protein on expression in E.coli together with an increase in both 
monodispersity and activity. No change in structure was observed when compared to the  
previously reported wild-type structure. 
Human F278E 11β-HSD1 enzyme was then used as a background to construct a hybrid dimer 
system to analyse novel heterozygous mutations in the HSD11B1 gene (R137C and K187N) 
which are thought to give rise to cortisone reductase deficiency (CRD). Expression of the 
heterodimers in E.coli revealed that the negative effects of both mutations can extend to the 
normally-active WT partner, leading to a marked suppression of 11β-HSD1 activity, which 
could account for the phenotype observed in patients presenting with CRD.  
Finally, a comparison of human WT and F278E 11β-HSD1 enzymes was used to probe the 
membrane association of 11β-HSD1. A combination of western blot analysis and fluorescence 
quenching experiments revealed that the binding of 11β-HSD1 to membrane is via both 
hydrophobic and electrostatic interactions.  
	   
Acknowledgements 
 
Firstly, I would like to thank Dr Jon Ride for his patience, knowledge and guidance 
throughout this PhD. I must also show appreciation for our almost daily chats on football, 
music, guitars and computers. I would also like to thank Dr Elizabeth Walker for helping me 
to see the wider picture of the work, helping me to understand endocrinology and not blaming 
me too much when all the lab computers broke. I must also thank Dr Scott White, Dr Tim 
Dafforn and Dr Nick Davies for their contributions to this work (X-ray crystallography, 
analytical ultracentrifugation and excellent chit chat respectively). 
On a personal level, I must thank my amazing girlfriend Anna, my family (Mum, Dad and 
Tom) and my friends for all the support. I know you’ll all be glad not to hear me talk about 
11β-HSD1 for a while. I would also like to thank my cats Ralphie and Molly for sitting next 
to me while I wrote up this PhD. 
Finally, I would like to thank the MRC and the School of Biosciences for funding the work 
presented. 
	   
Table of Contents 
	  
Chapter 1. General introduction ................................................................................................. 1 
1.1. Hormones......................................................................................................................... 3 
1.1.1. Steroid hormone synthesis ........................................................................................ 5 
1.1.2. Steroid hormone action ........................................................................................... 11 
1.2. Cortisol .......................................................................................................................... 13 
1.2.1. Systemic regulation of cortisol ............................................................................... 13 
1.2.2. Mechanism of action of cortisol ............................................................................. 14 
1.2.3. Physiological effects of cortisol.............................................................................. 17 
1.2.4. Metabolism of cortisol ............................................................................................ 19 
1.3. 11β-hydroxysteroid dehydrogenase enzymes................................................................ 21 
1.3.1. 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) ........................................ 21 
1.3.2. 11β-hydroxysteroid dehydrogenase type I (11β-HSD1)......................................... 25 
1.3.3. Primary structure of 11β-HSD1.............................................................................. 25 
1.3.4. Kinetics and enzymology of 11β-HSD1................................................................. 28 
1.4. 11β-HSD1 and the Metabolic Syndrome....................................................................... 35 
1.4.1. Function and expression of 11β-HSD1 in other tissues.......................................... 45 
1.4.2. Inhibitors of 11β-HSD1 activity ............................................................................. 47 
1.5. Regulation of 11β-HSD1 activity via hexose-6-phosphate dehydrogenase .................. 50 
1.5.1. Structure and localization of H6PDH ..................................................................... 51 
1.5.2. Direct interaction of H6PDH and 11β-HSD1 ......................................................... 53 
1.5.3. Regulation of H6PDH activity................................................................................ 54 
1.6. 11β-HSD1, H6PDH and Cortisone Reductase Deficiency............................................ 56 
1.7. Short Chain Dehydrogenase/Reductases ....................................................................... 62 
1.8. Structural studies of 11β-HSD1..................................................................................... 69 
1.9. Aims............................................................................................................................... 88 
Chapter 2. Mutation of key hydrophobic C-terminal residues of 11β-hydroxysteroid 
dehydrogenase type 1 ............................................................................................................... 89 
2.1. Introduction ................................................................................................................... 89 
2.1.1. Improvements in the expression and purification of 11β-HSD1 ............................ 89 
2.1.2. Investigation into the solvent exposed hydrophobic region in 11β-HSD1 and other 
proteins.............................................................................................................................. 91 
	  2.2. Materials and Methods .................................................................................................. 94 
2.2.1. Cloning and Expression of Recombinant 11β-HSD1 ............................................. 94 
2.2.2. Purification of 11β-HSD1....................................................................................... 94 
2.2.3. Measurement of 11β-HSD1 activity ....................................................................... 95 
2.2.4. Measurement of turnover of enzyme-bound NADP+ ............................................. 98 
2.2.5. Analytical Ultracentrifugation ................................................................................ 98 
2.2.6. Structure determination of the F278E mutant......................................................... 98 
2.3. Results ......................................................................................................................... 101 
2.3.1. Effect of Mutations on the Expression and Purification of Recombinant 11β-HSD1
......................................................................................................................................... 101 
2.3.2. Effect of Mutations on Enzyme Kinetics.............................................................. 101 
2.3.3. Crystal Structure of Guinea Pig F278E ................................................................ 106 
2.3.4. Estimation of proportion of active molecules in the human F278E and wild-type 
enzymes........................................................................................................................... 108 
2.4. Discussion.................................................................................................................... 109 
Chapter 3. Identification and functional impact of novel mutations in the gene encoding 11β-
hydroxysteroid dehydrogenase type 1 in patients with hyperandrogenism ........................... 114 
3.1. Introduction ................................................................................................................. 114 
3.1.1. Urinary steroid metabolite analysis ...................................................................... 114 
3.1.2. Molecular analysis of H6PD and HSD11B1 genes .............................................. 115 
3.1.3. Functional analysis of HSD11B1 mutations......................................................... 117 
3.1.4. Expression in mammalian cells ............................................................................ 119 
3.1.5. Hybrid dimers ....................................................................................................... 121 
3.2. Materials and Methods ................................................................................................ 125 
3.2.1. Cloning and Expression of Recombinant 11β-HSD1 ........................................... 125 
3.2.2. Purification of HIS6-tagged 11β-HSD1 ................................................................ 126 
3.2.3. Purification of Strep-tagged 11β-HSD1................................................................ 127 
3.2.4. Estimation of protein concentration...................................................................... 127 
3.2.5. Purification of 11β-HSD1 heterodimers ............................................................... 127 
3.2.6. Measurement of 11β-HSD1 activity ..................................................................... 128 
3.2.7. Western Blot Analysis .......................................................................................... 128 
3.3. Results ......................................................................................................................... 129 
3.3.1. Expression and purification of recombinant 11β-HSD1 homodimers using the 
pET-28b(+) vector .......................................................................................................... 129 
3.3.2. Expression and purification of recombinant 11β-HSD1 homo-oligomers using 
pRSF-1b and pET-51b(+) vectors................................................................................... 130 
	  3.3.3. Analysis of 11β-HSD1 hetero-oligomers in cleared lysates of bacterial cells...... 134 
3.3.4. Purification and kinetic analysis of 11β-HSD1 heterodimers............................... 137 
3.4. Discussion.................................................................................................................... 143 
Chapter 4. Membrane binding properties of 11β-hydroxysteroid dehydrogenase type 1...... 147 
4.1. Techniques to examine the potential association of proteins with biological membranes
............................................................................................................................................ 147 
4.1.1. Fluorescence ......................................................................................................... 147 
4.1.2. Quenching ............................................................................................................. 148 
4.1.3. Western Blotting ................................................................................................... 149 
4.1.4. Substrate association with membranes. ................................................................ 149 
4.1.5. Choice of membrane ............................................................................................. 150 
4.2. Materials and Methods ................................................................................................ 152 
4.2.1. Expression and purification of 11β-HSD1............................................................ 152 
4.2.2. Preparation of microsomes ................................................................................... 152 
4.2.3. Binding of 11β-HSD1 to microsomes................................................................... 152 
4.2.4. Western blot analysis of membrane bound protein............................................... 153 
4.2.5. Binding of steroids to microsomes ....................................................................... 153 
4.2.6. Preparation of DMPG liposomes .......................................................................... 154 
4.2.7. Quenching of 11β-HSD1 fluorescence by acrylamide ......................................... 154 
4.3. Results ......................................................................................................................... 156 
4.3.1. Binding of human 11β-HSD1 to microsomes....................................................... 156 
4.3.2. Effect of salt on the binding of human 11β-HSD1 to microsomes....................... 158 
4.3.3. Binding of steroid substrates of 11β-HSD1 to microsomes.................................. 160 
4.3.4. Fluorescence quenching studies on human 11β-HSD1 ........................................ 163 
4.4. Discussion.................................................................................................................... 166 
Chapter 5. General Discussion ............................................................................................... 173 
References .............................................................................................................................. 179 
Appendix One – Published Work........................................................................................... 205	  
 
	   
List of Figures 
Chapter 1. 
Figure 1.1.  Inter-conversion of glucocorticoids in man (A) and rodents (B)............2 
Figure 1.2. Corticosteroids are synthesized in the adrenal cortex of the adrenal 
gland........................................................................................................6 
Figure 1.3 Common steroidogenic pathways and enzymes in humans....................7 
Figure 1.4.  Cholesterol is the precursor to all steroid 
hormones.................................................................................................8 
Figure 1.5.  Pathway for the formation of the prohormone 
pregnenolone...........................................................................................9 
Figure 1.6.  The hypothalamic-pituitary-adrenal (HPA) axis is a system to control 
cortisol homeostasis..............................................................................14 
Figure 1.7.  Domain structure (A) and nucleocytoplasmic shuffling (B) of the hGRα 
...............................................................................................................17 
Figure 1.8.  Diagrammatic representation of the 11β-HSD1 (left) and 11β-HSD2 
(right) enzymes and their position in the cell........................................21 
Figure 1.9.  Analysis of the amino acid sequence of 11β-HSD2 indicates a potential 
membrane association...........................................................................23 
Figure 1.10. Multiple sequence alignment of the available amino acid sequences of 
11β-HSD1 across 11 species.................................................................27 
Figure 1.11.  Diagrammatic representation of the apparent equilibrium constant (Keq) 
of 11β-HSD1 at pH 7.0.........................................................................30 
Figure 1.12.  Alternative reactions catalyzed by 11β-HSD1......................................33 
Figure 1.13.  Modelling studies showing the theory behind the preference for the 
formation of 7β-metabolites from 7-keto substrates by 11β-HSD1......34 
Figure 1.14.  The possible detrimental effects of production of cortisol by 11β-HSD1 
...............................................................................................................37 
Figure 1.15.  In vivo activity of 11β-HSD1 is conventionally measured by the ratio of 
urinary E to F metabolites.....................................................................41 
Figure 1.16.  Some examples of the types of 11β-HSD1 inhibitors proposed for the 
treatment of the metabolic syndrome....................................................48 
Figure 1.17.  Showing the oxidative stage of the pentose phosphate pathway in the 
cytosol...................................................................................................52 
Figure 1.18.  The G6PT-H6PDH-11β-HSD1 system in liver and adipose tissue......55 
	  Figure 1.19.  Showing the possible involvement of 11β-HSD1 in the pathogenesis of 
CRD......................................................................................................57 
Figure 1.20.  H6PD gene mutations which give rise to ACRD.................................60 
Figure 1.21. The various reactions catalyzed by SDR enzymes………...................63 
Figure 1.22. Ribbon diagram displaying the Rossmann fold of a monomer of 
3α/17βHSD (PDB code 1xhx)..............................................................64 
Figure 1.23.  The N-terminal T-G-X-X-X-G-X-G motif involved with binding 
cofactor, in this case NAD+, in the SDR family member 3α /20β-HSD 
(PDB code 2HSD).................................................................................65 
Figure 1.24.  The catalytic mechanism of 11β-HSD1 and other “classical” SDRs....66 
Figure 1.25 A comparison of the crystal structures of 11β-HSD1 from different 
species...................................................................................................72 
Figure 1.26.  A topology diagram of human 11β-HSD1 (1XU9) coloured according 
to secondary structure...........................................................................74 
Figure 1.27.  The amino acid sequence of human 11β-HSD1 aligned with secondary 
structure.................................................................................................75 
Figure 1.28.  Ribbon representation of a monomer of human 11β-HSD1 (1XU9) 
using a colour gradient from blue (residues near the N-terminus) to red 
(residues near the C-terminus)..............................................................76 
Figure 1.29.  The N-S-Y-K active site of 11β-HSD1.................................................77 
Figure 1.30.  Ribbon representation of the dimerisation domain of human 11β-HSD1 
(1XU9)..................................................................................................79 
Figure 1.31.  Showing the possible domain swap in 11β-HSD1 (1XU9)..................80 
Figure 1.32.  Putative membrane-dipping region of the guinea pig 11β-HSD1 
structure (PDB code: 1XSE).................................................................81 
Figure 1.33.  Diagrammatic representation of how the membrane dipping hypothesis 
would function in vivo...........................................................................83 
Figure 1.34.  Possible tetrameric arrangement of human 11β-HSD1 (1XU7/1XU9).... 
...............................................................................................................86 
Chapter 2. 
Figure 2.1.  SDS-Page analysis of WT and mutant 11β-HSD1 recombinant proteins 
................................................................................................................93 
Figure 2.2.   An example of a typical HPLC chromatogram to analyse the reductive 
activity of 11β-HSD1..............................................................................97 
Figure 2.3.  Relative yields of wild type and mutant human and guinea pig 11β-
HSD1 proteins.......................................................................................101 
Figure 2.4.  AUC analysis of the aggregation states of the human (A) and guinea 
pig (B) wild-type and F278E proteins.................................................105 
	  Figure 2.5.  Crystal structure of the guinea pig F278E enzyme.............................107 
 
Chapter 3. 
Figure 3.1.   Urinary steroid analysis and molecular genetic assessments of cases A 
and B.....................................................................................................116 
Figure 3.2. The structural importance of the 11β-HSD1 mutations R137C and 
K187N...................................................................................................118 
Figure 3.3.  11β-HSD1 ketoreductase activity, mRNA levels, and protein 
expression from homodimers expressed in stably transfected HEK293 
cells.......................................................................................................120 
Figure 3.4.  The construction of hybrid dimers has shown that the active caspase-7 
dimer does not form by interdigitation................................................123 
Figure 3.5.  SDS-Page analysis of expression in E.coli of the human 11 β -HSD1 
mutants (R137C and K187N) in both wild-type (A) and F278E (B) 
backgrounds..........................................................................................130 
Figure 3.6. SDS-PAGE of the purification of the pET-51b(+) 11β-HSD1 F278E 
construct via the Strep-Tactin Superflow column…………………...131 
Figure 3.7.  Yield of soluble protein and kinetic parameters of homodimers of 11β-
HSD1 in the bacterial expression system............................................133 
Figure 3.8.  AUC analysis of the aggregation states of the homodimeric 
R137C/F278E protein when expressed in the pRSF-1b vector……..134 
Figure 3.9.  Effect of co-expression of mutant and WT 11β-HSD1 constructs in 
E.coli.....................................................................................................136 
Figure 3.10.  SDS-PAGE demonstrating that, with a dilution step, no aggregation of 
11β-HSD1 dimers occurs.....................................................................138 
Figure 3.11.  An illustration of the purification strategy for the production of hybrid 
dimer human 11β-HSD1.......................................................................139 
Figure 3.12.  Western blot analysis of the hybrid dimers of 11β-HSD1 purified from 
the bacterial expression system...........................................................140 
Chapter 4. 
Figure 4.1.  Fluorescence emission spectrum of 11β-HSD1 either in buffer (blue 
line) or in a liposome suspension (black line) using an excitation 
wavelength of 278nm..........................................................................155 
Figure 4.2.  Western blot of mouse liver microsomes with (B) or without (A) 
human 11β-HSD1...............................................................................157 
Figure 4.3.  Binding of human 11β-HSD1 to microsomes from both mouse liver 
and HEK-293 cells..............................................................................158 
Figure 4.4.  The effect of salt on the binding of human 11β-HSD1 to microsomes 
from mouse livers................................................................................160 
	  Figure 4.5.  HPLC traces showing the binding of cortisone (B) and 7-
ketocholesterol (C) to mouse liver microsomes..................................162 
Figure 4.6.  The binding of steroid substrates of 11β-HSD1 to mouse liver 
microsomes.........................................................................................163 
Figure 4.7.  Stern-Volmer plots of acrylamide quenching of 11β-HSD1 (WT or 
F278E) either in buffer (top two lines) or inserted into DPMG 
liposomes (bottom two lines)…..........................................................164 
 
 
	   
List of Tables 
Chapter 1. 
Table 1.1.   List of physiological effects of cortisol.................................................19 
Table 1.2.  Apparent Km values for steroid substrate calculated for 11β-HSD1 from 
rat and human........................................................................................32 
Table 1.3.  Mutations which have been postulated to be involved with CRD and 
ACRD....................................................................................................61 
Table 1.4.  Active site and cofactor binding site sequence motifs for the five SDR 
families..................................................................................................68 
Table 1.5.  Comparison of the 23 11β-HSD1 structures in the pdb database.........70 
Chapter 2. 
Table 2.1.  X-ray data and refinement statistics....................................................100 
Table 2.2.  Kinetic analysis of human 11β-HSD1 wild type and mutant proteins. 
...................................................................................................................103 
Table 2.3.  Kinetic analysis of guinea pig 11β-HSD1 wild type and mutant proteins 
.................................................................................................................103 
Chapter 3. 
Table 3.1.  Plasmids used for the expression of 11β-HSD1 and chaperonins 
throughout this thesis............................................................................125 
Table 3.2.  Yield of soluble protein and kinetic parameters and for the various 
hybrid dimers of 11β-HSD1 purified from the bacterial expression 
system...................................................................................................142 
Chapter 4. 
Table 4.1.  Stern-Volmer constants (mean ± SEM) of acrylamide quenching of 
11β-HSD1 (WT or F278E) either in buffer or inserted into DPMG 
liposomes…........................................................................................165 
	  
 
 
 
	   
Abbreviations 
ACRD   Apparent Cortisone Reductase Deficiency 
ACTH   Adrenocorticotropic Hormone 
AME    Apparent Mineralocorticoid Excess  
ASC   Adipose Stromal Cells 
AUC   Analytical Ultracentrifugation 
BCA   Bicinchoninic Acid 
BSA   Bovine Serum Albumin 
CBX   Carbenoxolone 
CRD   Cortisone Reductase Deficiency 
CVD   Cardiovascular Disease 
CYP   Cytochrome P450 Monooxygenase 
DNA   Deoxyribonucleic Acid 
DPMG   1,2-dimyristoyl-sn-glycero-3-phosphoglycerol 
E   Cortisone 
EDTA   Ethylenediaminetetraacetic Acid 
ER   Endoplasmic Reticulum 
F   Cortisol 
G6P   Glucose-6-phosphate 
G6PDH  Glucose-6-phosphate Dehydrogenase 
GC   Glucocorticoid 
GR   Glucocorticoid Receptor 
H6PDH  Hexose-6-phosphate Dehydrogenase 
HEK   Human Embryonic Kidney 
HPLC   High Performance Liquid Chromatography 
HSD    Hydroxysteroid Dehydrogenase 
IPTG   Isopropyl-β-D-thiogalactoside 
MOPS   3-(N-morpholino)propanesulfonic acid 
NAD(H)  Nicotinamide adenine dinucleotide 
NADP(H)  Nicotinamide adenine dinucleotide phosphate 
PAGE   Polyacrylamide Gel Electrophoresis 
PBS   Phosphate Buffered Saline 
PCR   Polymerase Chain Reaction 
pdb   Protein Data Bank 
SAT   Subcutaneous Adipose Tissue 
SDS   Sodium Dodecyl Sulphate 
SDR   Short Chain Dehydrogenase/Reductase 
THE   Tetrahydrocortisone 
THF   Tetrahydrocortisol 
UV   Ultraviolet 
VAT   Visceral Adipose Tissue
1 
Chapter 1. General introduction 
The inter-conversion between inactive glucocorticoids (cortisone in man and 11-
dehydrocorticosterone in rodents) and hormonally active glucocorticoids (cortisol and 
corticosterone), is performed by the two isoforms of the enzyme 11β-hydroxysteroid 
dehydrogenase (Figure 1.1). The type 1 enzyme (11β-HSD1) is predominantly expressed in 
the liver (Lakshmi and Monder, 1988), brain (Seckl, 1997), pancreatic islets (Davani et al., 
2000) and adipose tissue (Bujalska et al., 1997) with genome wide transcriptome analysis 
showing a small amount of 11β-HSD1 expression in most tissues (Shmueli et al., 2003). 11β-
HSD1 exhibits a predominant reductase activity in vivo, while the type 2 enzyme (11β-
HSD2), which is expressed mainly in the kidney, acts predominantly as a dehydrogenase 
(Krozowski et al., 1990). The two 11βHSD isoforms constitute an important ‘pre-receptor’ 
mechanism to regulate the physiological effects of active glucocorticoid (Draper and Stewart, 
2005). However, before the importance of the 11βHSD proteins can be understood, the 
physiological importance of cortisol (a steroid hormone) must be explained. 
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Figure 1.1. Inter-conversion of glucocorticoids in man (A) and rodents (B). In man, 11β-HSD1 converts 
inactive cortisone to active cortisol via reduction of the C-11 oxo-group. In rodents, 11β-HSD1 converts 11-
dehydrocorticosterone into corticosterone. The inactivation of glucocorticoid, via the oxidation of the C-11 
hydroxyl, is performed predominantly by the NAD+ dependent 11β-HSD2. Figure produced using ChemDraw Ultra 
7.0. 
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1.1. Hormones 
The word ‘hormone’ (coined from the Greek word meaning ‘urge’) was first used in 1905 by 
Bayliss and Starling to describe the gastrointestinal molecule secretin. Hormones can be 
classed as molecules which are able to act as a chemical ‘messengers’ which are carried in the 
blood from their source (classicaly an endocrine gland) to a target cell, in which the hormone 
will trigger a specific effect. Hormones can be classified into 3 major groups: protein and 
polypeptide hormones, steroid hormones and a third group in which molecules can contain 
both amino and steroid groups. There are five main classes of steroid hormones: 
glucocorticoids, androgens, progestogens, mineralocorticoids and oestrogens. These 
hormones are synthesized in various locations around the body including the ovaries/gonads 
(progestogens, androgens and oestrogens), adrenal cortices (glucocorticoids, 
mineralocorticoids and androgens) and the skin (vitamin D metabolites) (Laycock, 1996). 
Steroid hormones regulate a wide range of functions in organisms. Mineralocorticoids, such 
as aldosterone, increase blood volume and pressure by causing the distal tubules of the kidney 
to increase the reabsorption of Na+ and excretion of K+. The sex hormones, androgens in 
males (e.g. testosterone) and oestrogens in females (e.g. oestrone), are mainly responsible for 
the development of secondary sex characteristics. In females, the main progestogen, 
progesterone, is involved with preparing the lining of the uterus for implantation of an ovum 
as well as being essential for the maintenance of pregnancy (Laycock, 1996). The vitamins A 
and D are also important lipid soluble signalling molecules, with a signalling role for vitamin 
E now described in addition to its classical role as an antioxidant. Vitamin D (cholecalciferol) 
is activated first in the liver, and then in the kidney to form 1,25 dihydroxycholecalciferol 
(1,25(OH)2D3) whose primary function is to promote the correct mineralization, growth and 
remodeling of bone via the regulation of the concentration of calcium and phosphate in the 
bloodstream (Laycock 1996). Vitamin A is located either in the retina of the eye as retinal, a 
4 
light absorbing molecule essential for low light and colour vision, or as the hormone retinoic 
acid which activates transcription of target genes via the retinoic acid receptors (RARs) or the 
retinoid ‘X’ receptors (RXRs) to mediate growth and development in children (Stryer et al., 
2001). Alpha-tocopherol, the active form of vitamin E, has recently been shown to upregulate 
genes involved with blood coagulation (christmas factor) and  steroid metabolism (5α-steroid 
reductase type 1) implying a varied role for vitamin E as a hormone. (Rimbach et al., 2010). 
Finally, glucocorticoids have a wide range of functions but are primarily concerned with the 
regulation of blood glucose and inflammation. For example, cortisol will increase blood 
glucose concentration via increasing gluconeogenesis in liver and lipolysis in the adipose, 
while antagonizing the action of insulin in peripheral tissues. As this review is concerned with 
the interconversion of the major glucocorticoid cortisol and its inactive 11-keto form, 
cortisone, the rest of this section will mainly address the synthesis and function of 
glucocorticoids. However, due to the involvement of 11β-HSD2 in the condition ‘apparent 
mineralocorticoid excess’ (AME, discussed later), reference will also be made to the synthesis 
of the major mineralocorticoid, aldosterone.  
It is important to note that over the last 10 years, molecules which had no known signaling 
function have been shown to act as hormones. Bile acids, which have long been known to 
function as physiological detergents facilitating the absorption, transport and distribution of 
lipid soluble vitamins and dietry fats, have been shown to participate in a negative feedback 
pathway in which bile acid synthesis is inhibited when circulating levels are high (Chiang, 
2002). This is achieved by activation of the farnesoid X receptor (FXR) by bile acids, which 
induces expression of small heterodimer partner (SHP), which in turn suppresses cholesterol 7 
alpha-hydroxylase (CYP7A1, the enzyme responsible for the rate limiting step in bile acid 
synthesis) expression (Chiang, 2002). 
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1.1.1. Steroid hormone synthesis 
Glucocorticoids, mineralocorticoids and adrenal androgens, are produced in the adrenal cortex 
of the adrenal gland. Adult humans possess two adrenal glands weighing approximately 5 
grams with a size of around 30 x 50 x 10 mm. The adrenal gland is divided into three 
sections, the medulla, the cortex and the capsule (Figure 1.2). The medulla is composed 
primarily of chromaffin cells which are responsible for the production of the catecholamines 
such as adrenaline and noradrenalin (Ehrhart-Bornstein et al., 1998). The adrenal capsule is a 
layer of connective tissue surrounding the adrenal cortex, responsible for maintenance of the 
shape and structure of the adrenal gland (Figure 1.2). The adrenal cortex is the largest section 
of the adrenal gland and is divided into 3 sections, each a distinct band of cells, which are 
enzymatically and histologically distinct (Figure 1.2). Each section contains different 
cytochrome P450 monooxygenase enzymes, which together with two dehydrogenase 
enzymes, are responsible for steroid hormone synthesis (Figure 1.3). The outer zona 
glomerulosa consists of poorly defined clusters of small, narrow cells which contain the 
CYP11B2 enzyme (aldosterone synthase) (Ghayee and Auchus, 2007, Bureik et al., 2002, 
Ortiz de Montellano, 1995) and also lack the CYP17A1 (17-hydroxylase/17,20-lyase) enzyme 
responsible for 17α-hydroxylation of progesterone and pregnenolone (Ghayee and Auchus, 
2007). These cells are therefore responsible for synthesis of the major mineralocorticoid, 
aldosterone. The middle layer, the zona fasciculata, makes up 75% of the adrenal cortex and 
contains both the CYP17A1 and also the CYP11B1 (11-hydroxylase) and is therefore 
responsible for the synthesis of cortisol and also some androgen precursors (Ghayee and 
Auchus, 2007, Bureik et al., 2002). The innermost section of the adrenal gland is the zona 
reticularis and is responsible for the production of the adrenal androgens (Ghayee and 
Auchus, 2007).  
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Figure 1.2 Corticosteroids are synthesized in the adrenal cortex of the adrenal gland. The three sections 
are enzymatically and histologically distinct. The outer zona glomerulosa is responsible for synthesis of the major 
mineralocorticoid aldosterone, with the middle zona fasciculata and inner zona reticularis responsible for the 
synthesis of glucocorticoid and androgens respectively. Image taken from Gray et al. (2000) 
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Figure 1.3.  A - Common steroidogenic pathways and enzymes in humans. Also shown are the electron 
donor P450-oxidoreductase (POR) which is present in the ER, and mitochondrial steroidogenic acute regulatory 
protein (StAR). (Ghayee and Auchus, 2007). B - Synthesis of the major mineralocorticoid, aldosterone and major 
glucocorticoid, cortisol. For simplicity, only active hormones and the prohormone are shown. Pregnenolone is 
converted to progesterone by 3βHSD, with 3 subsequent hydroxylation reactions in the 17, 21 and 11 positions 
yielding cortisol. These reactions are carried out by CYP17A1, CYP21A2 and CYP11B1 respectively. 
Progesterone is converted to aldosterone by 2 subsequent hydroxylation reactions in the 21 and 11 positions, 
followed by an oxidation of the C-18 angular methyl group to an aldehyde.  These reactions are carried out by 
CYP21A2 and CYP11B2 respectively. Image adapted from Stryer et al. (2001). 
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All steroid hormones are produced from a common precursor, cholesterol (Figure 1.3 and 
Figure 1.4). In addition to its role in hormone biosynthesis, cholesterol is also involved in 
modulating membrane fluidity in animal cells and also in the production of bile salts. 
Cholesterol is present in most cells and can either be transported to the endocrine cell through 
the blood in complex with a lipoprotein or synthesized from acetyl CoA in a three stage 
process (Andersen and Dietschy, 1978). The structure of cholesterol is shown in Figure 1.4.   
 
 
Figure 1.4. Cholesterol is the precursor to all steroid hormones. The numbering scheme for carbon atoms in 
cholesterol and other steroids is shown, along with the lettering scheme for the steroid rings. Adapted from Stryer 
et al. (2001). 
 
Cholesterol is converted to the prohormone pregnenolone by the membrane bound 
mitochondrial CYP11A1, also known as P450scc. This rate limiting step in the production of 
steroid hormones (Chung et al., 1986) involves 3 reactions which all take place in one 
CYP11A1 active site (Miller, 1988). The reactions of all cytochrome P450 enzymes are 
similar and can be summarized by: 
 
R—H  +  O2  +  NADPH  +  H    R—OH  +  H2O  +  NADP+             (1) 
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In order for both the C-20 and C-22 positions of cholesterol to become hydroxylated, this 
reaction must occur twice (Stryer, 2002). Following the 20α- and 22-hydroxylation reactions, 
the cholesterol side chain is cleaved to yield pregnenolone and isocaproic acid (Strauss, 
1991).  
 
 
Figure 1.5. Pathway for the formation of the prohormone pregnenolone. Cholesterol is hydroxylated in both 
the C-20 and C-22 positions by the CYP11A1 enzyme (also known as cholesterol side-chain cleavage enzyme). 
The product, 20α, 22β-dihydroxycholesterol, is then cleaved to yield the prohormone pregnenolone and 
isocaproic acid. Image adapted from Stryer et al. (2001). 
 
All steroid hormones are then produced from pregnenolone (Figures 1.3). Depending on the 
hormone being produced, pregnenolone can either be converted to 17-hydroxypregnenolone 
or progesterone. Progesterone is formed via the oxidation of the 3-hydroxyl group of 
pregnenolone to a 3-keto group, with the subsequent isomerisation of the Δ5 double bond to a 
Δ4 double bond. Both the 3β-hydroxysteroid dehydrogenation and isomerisation reactions are 
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carried out by the ER bound enzyme 3β-hydroxysteroid dehydrogenase (3βHSD2) (Ghayee 
and Auchus, 2007, Strauss, 1991). Interestingly, since 3βHSD2 belongs to the short chain 
dehydrogenase/reductase (SDR) superfamily of enzymes, it is the only enzyme in the adrenal 
pathway for corticosteroid synthesis which is not a member of the P450 family. Both 
pregnenolone and progesterone can undergo a 17α-hydroxylation reaction to form 17-
hydroxypregnenolone or 17-hydroxyprogesterone respectively. This reaction is accomplished 
by the membrane bound, smooth ER enzyme CYP17A1 (Nakajin et al., 1984) (Figure 1.3). A 
subsequent C17,20 carbon bond cleavage on 17-hydroxypregnenolone or 17-
hydroxyprogesterone is also performed by CYP17A1. These give rise to 
dehydroepiandrosterone (DHEA) and androstenedione respectively.  The hydroxylase and 
lyase activities are under separate hormonal control and as such, represent a branch point in 
hormone synthesis. If neither activity is present, the progesterone will go onto form the 
mineralocorticoid aldosterone (Figure 1.3). If the hydroxylase activity is present but lyase 
activity is absent, 17-hydroxyprogesterone will form the major glucocorticoid, cortisol. If 
both activities are present, the sex steroids will be produced (Figure 1.3) (Strauss, 1991). Due 
to the location of CYP17A1 in the ER, the electron donor for the hydroxylation reactions is 
different from the adrenodoxin reductase which is present in the mitochondria. The membrane 
bound cytochrome P450-oxidoreductase (POR) donates electrons to both CYP17A1 and 
CYP21A2  without the need for an iron/sulphur protein (Tamburini and Gibson, 1983). 
The final common P450 involved in both glucocorticoid and mineralocorticoid synthesis is 
the CYP21A2. Located in the ER, CYP21A2 can use electrons donated by POR to 
hydroxylate both progesterone and 17-hydroxyprogesterone to yield deoxycorticosterone 
(DOC) and 11-deoxycortisol (Miller and Morel, 1989). In order for glucocorticoid production 
to proceed, CYP11B1 must be present. This membrane bound mitochondrial protein is 
expressed in high levels in the zona fasciculata of the adrenal cortex (Ghayee and Auchus, 
2007, Erdmann et al., 1995a, Erdmann et al., 1995b) and is involved with the 11β-
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hydroxylation of 11-deoxycortisol to yield the active glucocorticoid, cortisol (Figure 1.3). In 
contrast, expression of the CYP11B2 protein in the zona glomerulosa (Ghayee and Auchus, 
2007, Miller, 1995) will yield the mineralocorticoid, aldosterone (Figure 1.3). This is 
achieved by two hydroxylation reactions at positions C11 and C18, followed by an oxidation 
at C18. 11β-hydroxylase, 18-hydroxylase and 18-oxidase activities are all performed by the 
CYP11B2 protein which, like CYP11B1, is located in the membrane of the mitochondria and 
as such, utilizes adrenodoxin and adrenodoxin reductase for electron donation.  
 
1.1.2. Steroid hormone action 
Due to the relatively hydrophobic nature of the steroid hormones, and their almost planar 
structure, they are able to diffuse freely through cell membranes. Once in the blood, most 
steroid hormones are bound to plasma proteins. These proteins both protect the hormone from 
being inactivated in the blood as well as ensuring that when the hormone reaches its target 
tissue, it is readily available. These transport proteins are usually globulins and can either 
have a high affinity for certain classes of hormone (e.g. transcortin in transport of cortisol) or 
be present in such high concentrations in the blood to allow a high capacity but low affinity 
binding (e.g. albumin). Unbound cortisol exerts effects via either genomic or non-genomic 
pathways. For genomic signalling, the primary targets of the steroid hormones are 
intracellular, with receptors located either in the cytosol or nucleus. Like estrogens and 
xenoestrogens, cortisol is also able to exert effects via a non-genomic pathway, although 
genomic signalling is thought to predominate (Losel et al., 2003). Type 1 steroid receptors, 
which are responsible for the binding of sex hormones, glucocortoids and mineralocorticoids 
are situated in the cytosol and will move into the nucleus upon hormone binding (Jacobs and 
Lewis, 2002, Nicolaides et al., 2009). Type 2 receptors, which are responsible for the binding 
of thyroid hormones and both vitamins A and D, are located in the nucleus (Swift et al., 2008, 
Aranda et al., 2009). Although each steroid hormone has a specific receptor, the domain 
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structure of these receptor proteins are similar. Each possess A/B regions which contain the 
components which activate transcription, and a highly conserved C region which functions as 
a DNA binding domain. A hinge region (D) links to a highly conserved E region which 
functions to bind steroid, activating the steroid receptor (Laycock, 1996). The glucocorticoid 
receptor (GR) will be discussed in more detail in Section 1.3.                                                                                                                                                                                
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1.2. Cortisol 
As mentioned above, the corticosteroids are synthesized in the adrenal cortex from cholesterol 
utilizing four cytochrome P450 enzymes. Hence they have a common structure, the 
cyclopentanoperhydrophenanthrene nucleus. The corticosteroids can be separated into groups 
according to their primary effects: the mineralocorticoids (such as aldosterone) and the 
glucocorticoids (such as cortisol). Since the substrates of 11β-HSD1/11β-HSD2 system are 
the glucocorticoids, the rest of this section will concentrate on the release and subsequent 
activity of the major glucocorticoid in man, cortisol.  
1.2.1. Systemic regulation of cortisol 
The primary effect of cortisol, the major glucocorticoid in humans, is to regulate glucose 
metabolism and blood pressure in order to limit stress levels (Munck et al., 1984). As a 
response to physical or psychological stress, corticotrophin releasing hormone (CRH) is 
secreted by the paraventricular nucleus (PVN) in the hypothalamus (Vale et al., 1981). The 
CRH then acts synergistically with vasopressin (VP) in the anterior lobe of the pituitary gland 
to stimulate the production and subsequent secretion of the 39 amino acid adrenocorticotropic 
hormone (ACTH) (Millan et al., 1987, Chen et al., 1993, Guillemin and Rosenberg, 1955). 
Upon binding of ACTH to a G protein-coupled receptor on the adrenal cortex, an adenyl 
cyclase is activated causing a subsequent increase in cAMP levels. cAMP will then stimulate 
the conversion of cholesterol to pregnenolone, with subsequent production of cortisol (Holt 
and Hanley, 2007). Due to the wide array of physiological properties of cortisol (Table 1.1), 
the circulating levels of the glucocorticoid must be tightly controlled. Cortisol homeostasis is 
maintained by regulation of the hypothalamo-pituitary-adrenal (HPA) axis according to 
physical demands (Figure 1.6) (Cutler et al., 1978). Increased concentrations of cortisol in the 
plasma exerts a negative feedback effect on both the hypothalamus and pituitary gland with 
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subsequent reductions in both CRH and VP secretion while also inhibiting production of 
ACTH (Matteri, 1995) (Figure 1.6).  
 
 
Figure 1.6. The hypothalamic-pituitary-adrenal (HPA) axis is a system to control cortisol homeostasis. In 
this system, an increase in circulating cortisol concentrations will cause a negative feedback effect on both the 
hypothalamus and the pituitary gland. This negative feedback will cause reductions in both CRH and VP secretion 
while also inhibiting the production of ACTH. The specific actions of 11β-HSD types 1 and 2 in peripheral tissues 
will be discussed in sections 1.3.2 and 1.3.1 respectively. Adapted from Holt and Hanley 2007. 
 
1.2.2. Mechanism of action of cortisol 
Unbound cortisol exerts effects via either genomic or non-genomic pathways. Genomic 
signalling is thought to predominate over the rapid, seconds to minutes non-genomic 
signalling although much controversy remain about the precise mechanisms and roles of non 
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genomic signalling (Losel et al., 2003). Circulating cortisol is mostly bound (90%) to the 
cortisol binding globulin (CBG, also known as transcortin). However only the unbound 
cortisol is able to enter target cells via diffusion and exert an effect (Holt and Hanley, 2007). 
These effects are mediated by the 777 amino acid cytoplasmic glucocorticoid receptor (GR) 
(Hollenberg et al., 1985).  The human GR (hGR) is a member of the steroid/thyroid/retinoic 
acid nuclear receptor superfamily of transcription factor proteins, with alternative splicing of 
the hGR gene giving rise to two homologous isoforms, hGRα and hGRβ (Nicolaides et al., 
2009). While hGRα functions as a ligand-dependent transcription factor typical of steroid 
hormone receptors and will be discussed in more detail, hGRβ does not bind glucocorticoids 
(GC). Instead hGRβ has intrinsic,  hGRα-independent, gene transcriptional activity and also 
exerts a dominant negative effect on the transcriptional activity of hGRα (Nicolaides et al., 
2009, Zhou and Cidlowski, 2005). 
The domain structure of hGRα is typical of steroid hormone receptors, consisting of four 
distinct regions illustrated in Figure 1.7. The N-terminal domain (NTD, also known as the 
A/B region) contains the ligand-independent transactivation domain activation function (AF)-
1, which interacts with various molecules necessary for transcription such as coactivators, 
chromatin modulators and basal transcription factors (Figure 1.7A) (Nicolaides et al., 2009). 
The DNA binding domain (DBD) is the most conserved domain in the steroid receptor family 
and includes two zinc finger motifs, each containing a zinc atom tetrahedrally co-ordinated by 
four Cys residues. A small number of residues, known as the proximal (P)-box, in the first 
zinc finger are responsible for recognition of the glucocorticoid response elements (GRE) in 
the promoter region(s) of target genes. The second zinc finger contains a group of residues 
known as the distal (D)-box, which are responsible for the weak dimerisation interface of the 
DBD (Nicolaides et al., 2009). The structurally flexible hinge region (HR) allows a single 
receptor dimer to interact with multiple, potentially different, GREs. Finally, the ligand-
binding domain (LBD) binds glucocorticoid and also contains a second ligand-dependent 
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transactivation domain, AF-2. In addition, the LBD contains sequences for nuclear 
translocation, receptor dimerisation, heat shock protein association and interaction with 
cofactors (Nicolaides et al., 2009). 
When no glucocorticoid is present, hGRα resides in the cytoplasm as part of a hetero-
oligomeric complex consisting of heat shock proteins (HSPs) 90, 70 and 50, in addition to the 
immunophillin FKBP51 (Nicolaides et al., 2009, Pratt, 1993). HSP90 regulates both ligand 
binding and cytoplasmic retention by exposing the ligand binding site and masking the 
nuclear localization signals (NLS) 1 and 2 (Nicolaides et al., 2009). Binding of glucocorticoid 
causes hGRα to undergo a conformational change that first results in dislocation of hGRα 
from the multiprotein complex, before the receptor is translocated into the nucleus where it 
forms a homodimer (Dahlman-Wright et al., 1990, Dahlman-Wright et al., 1992, Dahlman-
Wright et al., 1991, Oakley et al., 1999). Once inside the nucleus, gene transcription is 
stimulated or suppressed by the dimerised GR interacting with a GRE on the target gene 
(Hayashi et al., 2004) (Figure 1.7B). Ligand activated hGRα can also modulate gene 
expression independently of binding to GRE via direct protein-protein interaction with other 
transcription factors such as activator protein 1 (AP1), nuclear factor-κB (NFκB), p53 and 
signal transducers and activators of transcription (STATs) (Figure 1.8B) (Nicolaides et al., 
2009).  
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Figure 1.7. Domain structure (A) and nucleocytoplasmic shuffling (B) of the hGRα. A – The domain 
structure of hGRα is typical of steroid hormone receptors, consisting of four distinct regions known as the N-
terminal domain (NTD), DNA binding domain (DBD), hinge region (HR) and the ligand-binding domain (LBD). B – 
In the absence of glucocorticoid, hGRα is present in the cytoplasm in complex with various heat shock proteins 
(HSPs). Upon ligand binding, hGRα is shuffled to the nucleus, dimerises and interacts with a GRE on the target 
gene. Alternatively, ligand activated hGRα can also modulate gene expression independently of binding to GRE 
via direct protein-protein interaction with other transcription factors (TF). GREs = glucocorticoid response 
elements, TFREs = transcription factor response elements. Image adapted from Nicolaides et al. (2009) 
 
1.2.3. Physiological effects of cortisol 
The primary effect of cortisol in humans is to regulate glucose metabolism and blood pressure 
in order to limit stress levels. A summary of some of the effects of cortisol are shown in Table 
1.1. In terms of intermediary metabolism, the overall effect of cortisol is to raise circulating 
glucose via promoting gluconeogenesis, raising hepatic glucose output and inhibiting glucose 
uptake by muscle and fat. Cortisol is also able to stimulate gluconeogenesis indirectly via 
increasing amino acid uptake in hepatic tissues and by stimulating lipolysis in adipose tissue 
with a subsequent increase in the mobilization of fatty acids. The catabolic effect of cortisol 
on protein in skin, muscle and bone also contribute to an increase in circulating glucose via an 
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increase of circulating amino acids which will stimulate gluconeogenesis in the liver. An 
excess of cortisol would therefore lead to unusually high levels of circulating glucose. This, 
coupled with the detrimental effect of excessive cortisol on the serum lipid profile (an 
increase in both triglyceride and total cholesterol with an accompanied decrease in HDL 
cholesterol) and the permissive effect of cortisol on glucagon and epinephrine can lead to an 
‘insulin resistant’ phenotype (Holt and Hanley, 2007). This is not true insulin resistance as 
although insulin is still able to exert its metabolic effect on the body, but greater insulin 
secretion is needed to achieve this effect. The metabolic complications of an excess of cortisol 
are discussed further in Section 1.4. 
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Effect Description 
Carbohydrate metabolism Stimulates gluconeogenesis. Notably, cortisol activates PEPCK, the enzyme 
responsible for the rate-limiting step of gluconeogenesis. 
Antagonizes peripheral action of insulin on glucose uptake. 
Protein metabolism Amino acid uptake and protein synthesis inhibited in peripheral tissues and 
stimulated in hepatic tissues. Increased amount of amino acids in liver stimulates 
gluconeogenesis.  
Protein catabolic agent in muscle, skin and bone. 
Lipid metabolism Stimulates lipolysis in adipose tissue with subsequent increased mobilization of 
fatty acids. This can then stimulate gluconeogenesis in liver. 
Apparent Mineralocorticoid 
Excess (AME) 
Lack of 11β-HSD2 activity leading to an increase of cortisol binding to and 
activating mineralocorticoid receptors (discussed later). 
Water metabolism A high level of cortisol can increase the glomerular filtration (GFR) rate, resulting 
in increased water retention. 
Cardiovascular Effect Increases vascular tone via potentiating the vasoconstrictor effects of vasoactive 
molecules. 
Growth Excessive amounts can lead to impaired growth via inhibiting somatotrophin 
release and insulin-like growth factor I (IGF-I) synthesis. 
Immune System Negative feedback via IL-1 stimulation of hypothalamic and pituitary production 
of CRH and ACTH to stop excessive responsiveness of lymphocytes. 
Stress response Factors such as haemorrhage, severe trauma, acute hypoglycaemia and 
emotional stimuli cause a large increase in the concentration of cortisol and 
corticotrophin in the blood. Role is probably to induce metabolic and 
cardiovascular effects listed above. 
Table 1.1.  List of physiological effects of cortisol. PEPCK = Phosphoenolpyruvate kinase. Information taken 
from Laycock 2006. 
 
1.2.4. Metabolism of cortisol 
After exerting its actions, cortisol must be metabolised to remove the active glucocorticoid 
from circulation. Reduction of the C4-5 double bond, with a subsequent hydroxylation on the 
3-oxo group by 5β- or 5α-reductase metabolises cortisol firstly to dihydrocortisol, then finally 
to 5β- or 5α-tetrahydrocortisol (5β- or 5α/allo-THF) where 5β-THF predominates in normal 
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physiology (Cope and Black, 1958). Cortisol can also be reduced on the 20-oxo group by 
20α- or 20β-HSD to produce α - or β -cortols (Szymanski and Furfine, 1977, Shackleton, 
1993). The THF and allo-THF can be conjugated to glucuronic acid and excreted in urine 
(Monder and Bradlow, 1980). It is worth noting here that cortisone is metabolised by the 
same pathways as cortisol. 
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1.3. 11β-hydroxysteroid dehydrogenase enzymes 
In addition to the negative feedback control of circulating cortisol discussed previously, the 
level of cortisol can be controlled locally in certain tissues by the enzymes 11β-HSD1 and 
11β-HSD2. These will be discussed in detail in the following sections. 
1.3.1. 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) 
11β-HSD2 is a microsomally located, NAD+-dependent dehydrogenase enzyme which 
belongs to the short chain dehydrogenase/reductase (SDR) superfamily of enzymes. In vivo, 
11β-HSD2 converts the active glucocorticoid cortisol to inactive cortisone (Brown et al., 
1993, Stewart et al., 1994) (Figure 1.8). However, when purified human kidney microsomes 
are incubated in vitro with an NADH regenerating system, some NADH-dependent 11-
oxoreduction can be observed for 11β-HSD2 with both cortisone and dexamethasone 
(Diederich et al., 1997, Obeyesekere et al., 1997).  
 
Figure 1.8. Diagrammatic representation of the 11β-HSD1 (left) and 11β-HSD2 (right) enzymes and their 
position in the cell. Note that 11β-HSD1 is expressed in liver, brain and adipose tissue, while 11β-HSD2 is 
expressed primarily in the kidney.  The steroid conversions shown are those which predominate in vivo. 
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Cloning of 11β-HSD2 from a number of species including rat (Zhou et al., 1995), rabbit 
(Naray-Fejes-Toth and Fejes-Toth, 1995), human (Albiston et al., 1994), mouse (Condon et 
al., 1997) and sheep (Agarwal et al., 1994) has shown all orthologues to be around 400 amino 
acids in length with high conservation of the first 382 residues (>90% identity) (Li et al., 
1996). Although no high-resolution structures exist for 11β-HSD2, sequence comparisons 
with similar microsomal proteins have suggested a structure consisting of a luminal-orientated 
N-terminal pentapeptide followed by 3 transmembrane helices with a cytosolic, catalytic C-
terminal domain (Obeyesekere et al., 1997) (Figure 1.9). However, analysis of the 11β-HSD2 
sequence using the TMHMM server (Krogh et al., 2001) indicates that the probability of any 
transmembrane domains being present in 11β-HSD2 is low (Figure 1.9). Indeed, N-terminal 
truncation studies revealed that removal of the three putative transmembrane domains does 
not move the protein to the soluble fraction upon expression in Chinese hamster ovary cells 
(CHOP-4), suggesting the retention of 11β-HSD2 in the membrane is not solely due to this 
region (Obeyesekere et al., 1997). This retention of protein in the insoluble fraction despite 
the removal of putative transmembrane domains has also been observed in the alcohol-
inducible Cytochrome P450IIE1 (Larson et al., 1991).  
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Figure 1.9. Analysis of the amino acid sequence of 11β-HSD2 indicates a potential membrane association. 
A – Hydrophobicity plot of 11β-HSD2. The three proposed transmembrane helices at the N-terminus can be 
clearly seen at the far left of the plot.  B – Membrane protein topology prediction for 11β-HSD2 using the TMHMM 
method. In TMHMM, transmembrane domains would be represented by red, ca 20-residue wide peaks with a high 
probability score. Therefore, unlike the hydrophobicity plot (A), the TMHMM results suggest a low probability of 
any transmembrane domains. C – Model of putative 11β-HSD2 topology in the ER membrane. A and C taken 
from Obeyesekere et al (1997), B was produced using TMHMM (Krogh et al., 2001). 
 
Expression of 11β-HSD2 has been shown in a variety tissues including the kidney (Agarwal 
et al., 1994, Albiston et al., 1994, Stewart et al., 1994) and colon (Whorwood et al., 1994), 
which are rich in mineralocorticoid receptor (MR), as well as skin (Kenouch et al., 1994), 
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ovary (Gomez-Sanchez et al., 2009), placenta (Brown et al., 1993, Lakshmi et al., 1993) and 
salivary epithelial cells (Roland and Funder, 1996).  The oligomerisation state of 11β-HSD2 
has been seen to vary between tissues. Monomeric, active 11β-HSD2 with a size of 
approximately 40-kDa seems to be expressed in kidney, colon, adrenal and submandibular 
gland (Obeyesekere et al., 1997, Smith et al., 1997), whereas a dimeric, inactive and latent 
11β-HSD2 with an approximate size of 80-kDa is expressed in the prostate and stomach 
(Smith et al., 1997, Obeyesekere et al., 1997). Both 40 and 80 kDa forms are expressed in the 
pancreas (Smith et al., 1997, Obeyesekere et al., 1997). Other groups have also shown 11β-
HSD2 to exist as an inactive dimer (Gomez-Sanchez et al., 2001), indicating that perhaps 
regulation of dimerisation could act as a mechanism for modulating enzyme activity. 
However, since the majority of SDRs are dimeric, with only the carbonyl reductases 1 & 3 
known to exist as monomers (Oppermann, 2007), active, monomeric 11β-HSD2 is unlikely. 
11β-HSD2 expression in MR-rich tissues is important as although the in vivo ligand for the 
MR is aldosterone, binding studies have shown that cortisol and corticosterone (the major 
rodent glucocorticoid) have a binding affinity for MR equal to that of aldosterone (0.5-1 nM) 
(Krozowski and Funder, 1983, Arriza et al., 1988). Therefore the function of 11β-HSD2 in 
these tissues is to protect the MR from activation via cortisol/corticosterone. The importance 
of 11β-HSD2 in this respect came from the understanding of a disease condition known as 
apparent mineralocorticoid excess (AME).  
AME is an autosomal recessive disease and is characterised by hypokalaemia and low-rennin, 
low-aldosterone hypertension. These symptoms have been attributed to a defective conversion 
of cortisol to cortisone in peripheral tissues caused by defective 11β-HSD2, resulting in illicit 
activation of the MR by cortisol (Stewart et al., 1988). Due to reduced cortisol metabolism, 
the normal negative feedback system discussed previously decreases the rate of cortisol 
secretion, maintaining a normal level of circulating cortisol. This means that patients do not 
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present with Cushingoid features, the classic symptom of glucocorticoid excess (Stewart et 
al., 1988).  
Around 100 cases of AME have been reported to date, with sequence analysis showing 
mutations in each of the 5 exons of the 6.2kb HSD11B2 gene, with most occurring on exons 3 
& 4 (reviewed in Draper and Stewart 2005). Mutations in AME patients can either be due to 
amino acid substitutions, which are predicted to have deleterious effects on 11β-HSD2 
structure, or be due to base changes which result in premature stop codons (Draper and 
Stewart, 2005).  
Interestingly, the high expression of 11β-HSD2 in the placenta is thought to be a mechanism 
of preventing the high level of circulating maternal glucocorticoids predisposing the foetus to 
hypertension in adulthood (Benediktsson et al., 1993). 
1.3.2. 11β-hydroxysteroid dehydrogenase type I (11β-HSD1) 
While 11β-HSD2 is expressed in mineralocorticoid target tissues (e.g. kidney), functioning to 
inactivate cortisol to cortisone, the isozyme 11β-HSD1 is expressed predominantly in 
glucocorticoid target tissues (e.g. liver and adipose) and converts the cortisone produced from 
the 11β-HSD2 reaction to active cortisol (Figure 1.8).  
1.3.3. Primary structure of 11β-HSD1 
11β-HSD1 is a microsomal (Ozols, 1995) 34 KDa integral membrane glycoprotein which is 
postulated to exist as a homodimer (Maser et al., 2002), although some studies have 
suggested it may exist as a homotetramer under some conditions (Hosfield et al., 2005). 
Although glycosylation has been postulated to be essential for structural stability (Filling et 
al., 2001), it has been shown that 11β-HSD1 is active in its non-glycosylated form (Ozols, 
1995, Blum et al., 2000, Walker et al., 2001b). 11β-HSD1 has an N-terminal membrane 
anchor (Mziaut et al., 1999, Odermatt et al., 1999), with a small portion of the extreme N-
terminus of the enzyme being cytosolic. The C-terminal catalytic domain lies in the lumen of 
26 
the endoplasmic reticulum (Odermatt et al., 1999, Walker et al., 2001a) (Figure 1.9). 11β-
HSD1 has been identified from a variety of species with primary sequences available for 
many of them. Species include human (Tannin et al., 1991) (Genbank protein accession code: 
NP_005516), mouse (Rajan et al., 1995, Oppermann et al., 1995, Hult et al., 2006) 
(NP_032314), guinea pig (Pu and Yang, 2000, Shafqat et al., 2003) (NP_001166328), 
chicken (XP_417988), squirrel monkey (Moore et al., 1993), pig (Klemcke et al., 2003) 
(NP_999413), cow (Tetsuka et al., 2003) (NP_001116504), sheep (Yang et al., 1992) 
(NP_001009395), rhesus monkey (Magness et al., 2005) (XP_001110531), rhesus macaque 
(Hult et al., 2006), cat (Schipper et al., 2004, Hult et al., 2006), dog (NP_001005756), 
African clawed frog (NP_001079807), rabbit (Hult et al., 2006), baboon (Pepe et al., 2001), 
chimpanzee (Clark et al., 2003) (XP_001168226) and rat (Nobel et al., 2002) (NP_058776). 
An alignment comparing the amino acid sequences of the enzymes from some of these 
species is shown in Figure 1.10. 
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Figure 1.10. Multiple sequence alignment of the available amino acid sequences of 11β-HSD1 across 11 species. Conserved residues are shaded black with similar residues 
shaded gray. Active site residues of 11β-HSD1 are shaded yellow. Transmembrane region is represented by a light blue box. Squirrel=squirrel monkey. Diagram produced using 
ClustalW and Boxshade.
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1.3.4. Kinetics and enzymology of 11β-HSD1 
It has been calculated that all HSD catalysed reactions should favour the reduction of 
ketosteroid due to the thermodynamically favourable oxidation of NAD(P)H (~-30 kcal/mol) 
and a low free energy difference between ketosteroid and the corresponding hydroxysteroid 
(~1kcal/mol) (Sherbet et al., 2007). It has been proven in a variety of studies that 11β-HSD1 
displays a predominant reductase activity in intact cells (Bujalska et al., 1997, Jamieson et 
al., 1995) while 11β-HSD2 functions as a dehydrogenase (Brown et al., 1993, Stewart et al., 
1994). This reductive activity in vivo of 11β-HSD1 can be partly attributed to the preference 
of 11β-HSD1 for the cofactor NADP(H) compared to 11β-HSD2, which utilizes NAD(H). 
Previous experiments using the analogous enzymes 17β-HSD1, which functions as a 
reductase, and 17β-HSD2, which function as a dehydrogenase, have shown that a single 
residue can alter the preference for cofactor, hence altering the reaction direction in vivo. 
Reductive HSDs contain a critical Arg residue (R38 in 17β-HSD1) which forms a salt bridge 
with the 2’-phosphate of NADP(H), distinguishing it from NAD(H) (Sherbet et al., 2007). 
However, NAD(H) dependent HSDs lack this residue and contain a Asp residue in the 
preceding position, conferring electrostatic repulsion to the 2’phosphate (Sherbet et al., 
2007). Mutation studies have confirmed these observations, showing that mutation of the 
residue preceding Arg38 (L37) to Asp in 17β-HSD1 is enough to change cofactor preference 
from NADP(H) to NAD(H) and subsequently reverse directional preference to favour the 
dehydrogenase reaction (Khan et al., 2004, Huang et al., 2001). The reverse is also true, with 
a double mutant of the oxidative 3β-HSD1 (D36A + L37R) enough to change cofactor 
preference from NAD(H) to NADP(H) (Thomas et al., 2003). The critical Arg residue seen in 
17β-HSD1 is also present in 11β-HSD1 (R66) and although no high-resolution data exists for 
11β-HSD2, one would expect an equivalent Asp residue to the one observed in 17β-HSD2 to 
be present. Therefore since large concentration gradients are present in cells due to 
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intermediary metabolism, with [NADPH] >> [NADP+] and [NAD+] >> [NADH] (Agarwal 
and Auchus, 2005), if each 11β-HSD isoform is restricted to one pair of cofactors, mass 
action will drive steroid flux for either hydroxysteroid oxidation (by NAD+) or ketosteroid 
reduction (by NADPH) .  
However, for 11β-HSD1 it appears that the factors governing directional preference are more 
complicated than in 17β-HSD1. 11β-HSD1 is present in the lumen of the ER, a relatively 
oxidative environment compared to the cytosol (Braakman et al., 1992) in which NADP+ 
might be expected to predominate over NADPH. It has frequently been observed that it is the 
dehydrogenase direction which predominates in purified preparations and cellular 
homogenates (Lakshmi and Monder, 1988). The apparent equilibrium constant (Kapp) at pH 
7.0 (shown by equation 2) for the NADPH-dependent conversion of cortisone to cortisol has 
been calculated to be 0.03 (Walker et al., 2001a), showing the reaction equilibrium to be to 
the cortisone/NADPH side and therefore potentially explaining the tendency for the 11β-
HSD1 reaction to proceed in the dehydrogenase direction in vitro (Figure 1.11).  
Keq[H+] = [NADP+][cortisol]/[NADPH][cortisone]                (2) 
However, if an NADPH-regenerating system is added to the in vitro assay (e.g. glucose-6-
phosphate dehydrogenase plus glucose-6-phosphate), 11β-HSD1 is able to reduce cortisone 
to cortisol (Walker et al., 2001a). It would therefore appear that the in vivo reductive activity 
of 11β-HSD1 requires a high NADPH/NADP+ ratio for effective activity. This high luminal 
ratio of NADPH/NADP+ is now known to be controlled by the microsomal enzyme hexose-
6-phosphate dehydrogenase (H6PDH). This system is discussed in detail in Section 1.5.  
 
30 
 
Figure 1.11. Diagrammatic representation of the apparent equilibrium constant, Kapp (equivalent to 
Keq[H+]) of 11β-HSD1 at pH 7.0. Kapp is expressed as [NADP][cortisol]/[NADPH][cortisone] at equilibrium. Taken 
from Hewitt et al. 2005. 
 
The 11β-HSD1 reaction follows a compulsory ordered ternary complex bi-bi mechanism 
(Castro et al., 2007) using a catalytic tetrad of N-Y-S-K typical of SDRs (described in more 
detail in Section 1.7). In this ordered reaction, NADPH binds first at the active site, followed 
by cortisone. Cortisone is reduced to cortisol which leaves the active site followed by NADP+ 
(Castro et al., 2007). Interestingly, published Michaelis constants for 11β-HSD1 vary 
dramatically depending on method, species, substrate and authors. Some apparent Km values 
for the steroid substrates of the human and rat enzymes are listed in Table 1.2. In terms of 
human 11β-HSD1, the discrepancies between Maser et al. (2002), Arampatzis et al. (2005) 
and the three groups which used bacterially produced recombinant protein can potentially be 
explained by the difference in how the protein was produced and subsequently assayed. 
Maser et al. (2002) utilized native protein purified from human liver and as such, the 
relatively high apparent Km values, especially for cortisol, could perhaps reflect the 
purification procedure used to obtain 11β-HSD1. This could also potentially explain the 
observation of enzyme cooperativity which has not been observed elsewhere. The apparent 
Kapp	  =	  0.03	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Km values reported by Arampatzis et al. (2005) were assayed using lysed human embryonic 
kidney (HEK)-293 cells overexpressing 11β-HSD1. Using this system, the full length 11β-
HSD1 protein should still be embedded in the microsomal membrane, with the lower 
apparent Km values perhaps reflecting improved folding/stability of the protein in this 
environment (Table 1.2). An obvious disadvantage of this method is the impurity of the 
protein makes accurate estimation of protein amount, hence specific 11β-HSD1 activity, 
difficult.  
However, the large differences between the three groups who used bacterially produced 
recombinant protein are harder to explain (Table 1.2). All the groups used the same E.coli 
system, BL21(DE3), expressing N-terminally truncated 11β-HSD1 containing residues 24–
292 in a pET28 plasmid, with the resulting protein purified in a similar way (Castro et al., 
2007, Shafqat et al., 2003, Walker et al., 2001a). The only major difference in enzyme 
preparation is the removal of the His6-tag by Castro et al., which could potentially explain the 
low nanomolar apparent Km values reported (Table 1.2). However, studies using heat shock 
protein HSC70, have shown that removal of His6-tag does not effect enzyme activity (Amor-
Mahjoub et al., 2006) indicating that this is unlikely. The only other reported difference 
between these groups is the method of assay. Castro et al. (2007) include detergent and 
reducing agent in their assay, with steroid separation performed by high throughput liquid 
chromatography (HTLC). Walker et al. (2001) and Shafqat et al. (2003) do not include these 
additives with steroid separation performed by thin layer chromatography (TLC) and high 
performance liquid chromatography (HPLC) respectively. However, it seems unlikely that 
method of assay and steroid separation would cause such a large difference in apparent Km 
values indicating that more studies are required to fully elucidate the accurate Michaelis 
constants for 11β-HSD1 produced using this recombinant system.  
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Species Km (µM) kcat (min-1) Substrate Assay method Reference 
Human 0.52 +/- 0.07 - Cortisone In cell (Lysed 
kidney cells) 
(Arampatzis 
et al., 2005) 
Human 
(recombinant) 
0.80 +/- 0.20 
2.90 +/- 0.40 
1.60 +/- 0.70 
11.1 +/- 2.80 
Cortisone 
Cortisol 
In vitro (HIS-
tagged) 
(Shafqat et 
al., 2003) 
Human 13.9 +/- NA 
41.3 +/- NA 
- 
- 
Cortisone 
Cortisol 
In vitro (Purified 
from liver) 
(Maser et 
al., 2002) 
Human 
(recombinant) 
0.04 +/- 2.90 0.27 +/- 0.01 Cortisone In vitro (HIS-tag 
removed) 
(Castro et 
al., 2007) 
Human 
(recombinant) 
9.50 +/- 0.90 
1.40 +/- 0.60 
- 
- 
Cortisone 
Cortisol 
In vitro (HIS-
tagged) 
(Walker et 
al., 2001a) 
Rat 1.83 +/- 0.06 
17.3 +/- 2.24 
- 
- 
Corticosterone 
Cortisol 
Purified from 
microsomes 
(Lakshmi 
and Monder, 
1988) 
Rat 0.85 +/- 0.12 - 11-
dehydrocorticosterone 
In cell (Lysed 
kidney cells) 
(Arampatzis 
et al., 2005) 
Human 
(recombinant) 
14.4 +/- 1.70 0.21 +/- 0.01 NADPH In vitro (HIS-tag 
removed) 
(Castro et 
al., 2007) 
Table 1.2. Apparent Km and kcat values for steroid substrate calculated for 11β-HSD1 from rat and human. 
The equilibrium dissociation constant, Kia, for the human enzyme was calculated to 147.5 (Castro et al., 2007). 
Note particularly the large differences for the Km values for the human protein. In vitro kinetic measurements of 
11β-HSD1 with steroid were obtained using an excess of cofactor (i.e. >200µM) over enzyme. 
 
It must be noted here that the glucocorticoid hormones are not the only substrate for 11β-
HSD1. It has been shown that 11β-HSD1 can act as 7β-hydroxycholesterol dehydrogenase, or 
7-keto-cholesterol reductase, inter-converting 7β-hydroxycholesterol and 7-ketocholesterol 
(Figure 1.12) (Schweizer et al., 2004, Hult et al., 2004). It has also been shown that 11β-
HSD1 is able to interconvert 7α /7β-hydroxy-dehydroepiandrosterone (7α/7β-DHEA) and 7-
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keto-dehydroepiandrosterone (7-keto-DHEA) (Figure 1.12) (Muller et al., 2006). 
Furthermore, 11β-HSD1 is able to catalyse the epimerisation of the 5α-reduced 7-
hydroxysteroids, 7α-hydroxy-epiandrosterone and 5α-androstane-3β,7α,17β–triol, to their 7β-
hydroxy derivatives with the active site Ser-170 thought to produce a hemi-ketal species 
which allows reduction by NADPH (Hennebert et al., 2009). 
 
 
Figure 1.12. Alternative reactions catalyzed by 11β-HSD1.11β-HSD1 is able to convert the 7-keto forms of 
both dehydroepiandrosterone (7-keto-DHEA) and cholesterol (7-keto-cholesterol) to their respective 7α and 7β-
hydroxylated metabolites. In both cases, there is a preference for the formation of 7β-hydroxylated metabolites 
over the 7α-hydroxylated species. 
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Interestingly, there seems to be a preference for the formation of 7β-metabolites from 7-keto 
substrates by 11β-HSD1. Modelling studies have suggested that 7β–hydroxy-DHEA and 7-
keto-DHEA are able to bind to 11β-HSD1 in two conformations favourable to interact with 
nicotinamide ring and the catalytic tyrosine. One conformation has the D ring of the steroid 
oriented towards the centre of the protein (Figure 1.13A), while in the other conformation the 
steroid is essentially flipped, with the A ring oriented towards the centre of the protein 
(Figure 1.13B) (Nashev et al., 2007).  It can be seen in Figure 1.13B that this second 
conformation is not favoured for 7α–hydroxy-DHEA, perhaps explaining the preference for 
the formation of 7β-metabolites  (Nashev et al., 2007). 
 
 
Figure 1.13. Modelling studies showing the theory to explain the preference for the formation of 7β-
metabolites from 7-keto substrates by 11β-HSD1. A – The D ring of the steroid substrate is oriented towards 
the centre of the protein. B – The A ring of the steroid substrate is oriented towards the centre of the protein. The 
conformation of steroid in B is not sterically favoured for 7α–hydroxy-DHEA, perhaps explaining the preference 
for the formation of 7β-metabolites. Taken from Nashev et al. (2007).
35 
 
1.4. 11β-HSD1 and the Metabolic Syndrome 
Due to the wide array of physiological and cellular effects of cortisol (Table 1.1), variations 
in levels of the glucocorticoid can have profound effects on the health of an organism. There 
has been considerable interest recently in the possibility that glucocorticoid levels could have 
a pronounced influence on the ‘metabolic syndrome’, also referred to as syndrome X 
(Reaven, 1988) or insulin resistance syndrome.  The metabolic syndrome refers to the 
tendency of certain risk factors for cardiovascular disease (CVD) to group together. These 
risk factors include insulin resistance, abnormal lipid and glucose metabolism, hypertension 
and central obesity (Draper and Stewart, 2005). Although some doubt has been expressed on 
the validity of this syndrome (Unwin, 2006), the epidemic increase in obesity accompanied 
by an equal rise in the metabolic complications of obesity would suggest the metabolic 
syndrome has considerable medical relevance (Eckel et al., 2005).  It also represents a useful 
reminder of the risk factors associated with a lack of physical activity and obesity. 
The idea that an excess of cortisol could lead to the metabolic syndrome first came from 
studying sufferers of the hormonal disorder, Cushing’s syndrome (Arnaldi et al., 2003, Peeke 
and Chrousos, 1995). Nearly all patients who suffer from Cushing’s syndrome are 
hypertensive with most showing some form of visceral obesity and up to 50% developing 
diabetes mellitus (Stewart, 2005). This is accompanied by the characteristic ‘moon face’ and 
fragile skin associated with the condition. The molecular pathogenesis of Cushing’s 
syndrome, sometimes referred to as hypercortisolism, includes an increase in the level of 
circulating cortisol. This increase can come from a variety of sources. Firstly, glucocorticoids 
used as effective treatments for inflammatory diseases such as asthma, rheumatoid arthritis 
and lupus; or as immunosuppressive agents following transplant operations, can increase the 
level of circulating cortisol, leading to Cushing’s syndrome (Whitworth et al., 2005). 
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Alternatively, hypercortisolism can arise as a result of pituitary adenomas, adrenocortical 
carcinomas or small cell lung cancers which can increase the levels of glucocorticoid either 
by directly secreting the hormone or indirectly via ACTH secretion (Whitworth et al., 2005).  
However, Cushing’s syndrome is a rare condition with an annual incidence rate of 
approximately 1-2 cases per million (Stewart, 2005). This together with the observations that 
circulating cortisol is often normal, if not reduced, in obesity indicates that a simple increase 
in circulating cortisol cannot explain obesity (Hautanen and Adlercreutz, 1993, Glass et al., 
1981, Dunkelman et al., 1964, Migeon et al., 1963, Streeten, 1993).  
Since obesity could not be linked to a systemic increase in cortisol levels, investigation was 
directed at the regulation of cortisol at a tissue level. The first indication that a local excess of 
cortisol could cause deleterious effects on health came from the condition AME discussed 
previously. This condition is effectively caused by an excess of cortisol due to inactivity of 
the 11β-HSD2 enzyme, prompting some to call AME “Cushing’s disease of the kidney” 
(Stewart, 2005). This led to the current idea that abnormal metabolism of cortisol by 11β-
HSD1 in adipose and liver tissue could cause symptoms of the metabolic syndrome. This is 
illustrated in Figure 1.14. Interestingly, it has recently been shown that circulating 11β-HSD1 
mRNA is decreased in obese patients, supporting the idea of tissue specific disregulation of 
11β-HSD1 in obesity (Al Bakir et al., 2008). 
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Figure 1.14. The possible detrimental effects of production of cortisol by 11β-HSD1. Evidence suggests 
that patients who present with obesity have down-regulated 11β-HSD1 in an attempt to control the deleterious 
effects of cortisol. It has also been shown that patients who present with type II diabetes are unable to down 
regulate 11β-HSD1. Red arrows represent the normal physiological reactions taking place in the liver and 
adipose tissue. A green arrow shows the NADP+-dependent dehydrogenase reaction seen in some tissues.  
Adapted from Tomlinson & Stewart (2005). 
 
In humans, adipose tissue is characterized as a specialized type of connective tissue 
consisting of lipid-laden cells known as adipocytes.  Adipocytes are surrounded by 
connective tissue cells, known as adipose stromal cells (ASC), which consists of mainly 
macrophages, fibroblasts, pericytes and blood cells (Cryer, 1985). Mature adipocytes are 
known to develop from a specific line of connective tissue cells resembling fibroblasts known 
as preadipocytes (Cryer, 1985) which are present in the stromal-vascular fraction together 
with ASC. Due to the collagenase digestion method used to separate mature adipocytes from 
preadipocytes, it is not possible to separate the preadipocytes from the rest of the ASC, hence 
preadipocytes are also known as ASC. Adipose tissue can be stored in numerous locations 
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around the body and can be categorized by the location found; subcutaneous, perivascular, 
intermuscular, peritoneal (mesenteries and omentum), retro-peritoneal, synovial, mediastinal, 
retro-orbital, intraspinal and medullary (bone marrow) (Cryer, 1985). Despite the numerous 
locations in which adipose tissue is found, it is clear that symptoms of the metabolic 
syndrome correlate strongly with the amount of omental fat independently from total 
adiposity and the amount of subcutaneous abdominal fat (Despres et al., 1989, Fujioka et al., 
1987). 
At a cellular level, obesity is thought to be caused by a combination of preadipocyte 
differentiation and proliferation, and also hypertrophy of existing adipocytes (Yau et al., 
1995, Tomlinson and Stewart, 2001).  Preadipocyte differentiation can be caused by cortisol 
(Hauner et al., 1987). Furthermore, cortisone addition to omental preadipocytes expressing 
11β-HSD1 has been shown cause differentiation to adipocytes (Bujalska et al., 1999a) with 
subsequent studies showing that inhibition of 11β-HSD1 activity via depletion of luminal 
NADPH can block preadipocyte differentiation (Marcolongo et al., 2008). Although 11β-
HSD1 expression is low in preadipocytes, expression is greatly increased in the late stages of 
differentiation when induced by glucocorticoid (Bujalska et al., 1999a). However, if 11β-
HSD1 expression is blocked, glucocorticoid induced differentiation is inhibited, indicating 
the involvement of 11β-HSD1 in a positive feedback mechanism in which active 
glucocorticoid can induce 11β-HSD1 expression, which in turn leads to generation of more 
active glucocorticoid (Bujalska et al., 1999a). The effect of cortisol on adipose tissue is not 
straightforward, as it has been shown that the glucocorticoid, modulated by 11β-HSD1, is 
able to inhibit human omental preadipocyte proliferation (Draper and Stewart, 2005). This is 
perhaps not unusual as it is known that cellular proliferation is generally inhibited by 
glucocorticoids (Laycock, 1996). It seems therefore that cortisol would have a twofold effect 
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on adipose tissue, both stimulating differentiation of preadipocytes while inhibiting 
proliferation.  
An array of knockout, transgene and inhibitor studies on mice have gone some way to 
elucidate the role of 11β-HSD1 in the metabolic syndrome. Perhaps most importantly, it was 
found that 11β-HSD1 KO mice on a high fat diet were able to resist obesity (Masuzaki et al., 
2001) with other studies on the same mice showing improved insulin tolerance in the liver, 
glucose tolerance and improved lipid and lipoprotein profiles (Morton et al., 2001). Further 
support of the role of 11β-HSD1 in obesity comes from transgenic experiments in which an 
11β-HSD1 transgene, targeted to adipose tissue under the AP2 promoter enhancer, led to a 
sevenfold increase in 11β-HSD1 expression, a 15-30% increase in local active glucocorticoid 
and an obese phenotype (Masuzaki et al., 2001). This was accompanied by marked 
hyperlipidemia, hyperglycaemia, hypertension and hyperinsulinaemia (Masuzaki et al., 2003, 
Masuzaki et al., 2001). No change in plasma cortisol levels was observed, due to a 
compensatory decrease in ACTH secretion. Similar experiments with another 11β-HSD1 
transgene, this time targeted to the liver under the ApoE promoter, showed hepatic 11β-
HSD1 overexpression gave marked insulin resistance, dyslipidaemia, hypertension and fat 
accumulation in the liver, but without an obese phenotype (Paterson et al., 2004). 
Experiments on obese rodent models such as Zucker rats (Livingstone et al., 2000) and ob/ob 
mice (Liu et al., 2003), have shown disregulation of 11β-HSD1 at the tissue level, with 
expression reduced in the liver, but increased in adipose tissue. A study in which obese, 
hyperlipidaemic mice were able to reduce both weight gain and fasting insulin after 
administration of the 11β-HSD1 inhibitor carbenoxolone, via subcutaneous injection, 
supports the concept of 11β-HSD1 over-expression in obesity (Nuotio-Antar et al., 2007).  
In contrast somewhat to the studies on rodents, the involvement of 11β-HSD1 in obesity and 
type II diabetes in humans is not clear-cut. Many groups using the conventional method of 
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measuring 11β-HSD1 activity in vivo, via measuring the ratio of urinary metabolites of 
cortisol and cortisone (Figure 1.15, described in section 1.2.3), have seen inconsistent 
changes in 11β-HSD1 activity in both obese (Andrew et al., 1998, Fraser et al., 1999, Stewart 
et al., 1999, Rask et al., 2002, Klemcke et al., 2003, Westerbacka et al., 2003) and diabetic 
(Valsamakis et al., 2004, Kerstens et al., 2000, Andrews et al., 2002) subjects. This is 
perhaps not surprising, as this ratio may be altered by the expression and activities of other 
enzymes, such as 11β-HSD2 and the 5α- and 5β-reductases that have been shown to differ in 
obesity (Sandeep et al., 2005, Mussig et al., 2008). The method is also insensitive to tissue 
specific changes in 11β-HSD1 expression and activity which could occur. This, however, has 
not stopped the technique being used, with a recent study showing 11β-HSD1 activity being 
reduced in obese boys (Wiegand et al., 2007).  
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Figure 1.15. In vivo activity of 11β-HSD1 is conventionally measured by the ratio of urinary E to F 
metabolites. The metabolites of cortisone and cortisol generated by reactions catalysed by the 5α- and 5β- 
reductases and 20α- and 20β-HSD enzymes can be detected in the urine and serve as biomarkers of 11β-HSD1 
activity. Impaired conversion of cortisone to cortisol is offset by changes to cortisol secretion by the HPA axis. 
THE = tetrahydrocortisone, THF = tetrahydrocortisol, allo-THF = allo-tetrahydrocortisol, HPA = hypothalamic-
pituitary-adrenal. Adapted from Lavery et al. 2008. 
 
In order to separate the tissue specific activities of 11β-HSD1, more exact methods must be 
used to elucidate the involvement of hepatic and adipose 11β-HSD1 in glucocorticoid 
regeneration and health. Studies to assess the activity of hepatic 11β-HSD1 using the 
measurement of cortisol in peripheral plasma following an oral dose of cortisone have found 
11β-HSD1 activity in the liver to be reduced in obesity (Stewart et al., 1999, Rask et al., 
2001, Valsamakis et al., 2004, Westerbacka et al., 2003). They also observed that this 
downregulation is not present in patients who also present with type II diabetes (Tomlinson 
and Stewart, 2005, Valsamakis et al., 2004, Andrews et al., 2002). It has been suggested that 
the decreased hepatic 11β-HSD1 activity represents a mechanism to protect the body from 
the deleterious effects of obesity by attempting to increase insulin sensitivity and decrease 
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hepatic glucose output. The inability of type II diabetes sufferers to downregulate hepatic 
11β-HSD1 activity would lead hyperglycaemia, a potential increase in adiposity and 
decreased insulin sensitivity (Tomlinson and Stewart, 2005). It is also worth noting that the 
association between hepatic fat accumulation and hepatic overexpression of 11β-HSD1 
which was seen in the transgenic mice was not observed in human subjects who presented 
with the most severe form of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis 
(NASH) (Paterson et al., 2004, Konopelska et al., 2009).  
The specific activity and expression of 11β-HSD1 has been investigated in both subcutaneous 
(SAT) and visceral (VAT) adipose tissue. This is an important distinction to make, as VAT 
releases large amounts of free fatty acids to the liver via the portal system and has long been 
regarded as having a greater number of glucocorticoid receptors (GR) than SAT (Bronnegard 
et al., 1990). Therefore, an increased 11β-HSD1 activity in VAT could potentially have more 
deleterious effects on health than a similar increase in SAT would. However, recent work has 
suggested that VAT and SAT express a similar number of GR (Bujalska et al., 2006). Many 
investigators have, using in vitro biopsies, shown marked increases in 11β-HSD1 mRNA and 
activity in the SAT of obese subjects when compared to lean (Rask et al., 2002, Paulmyer-
Lacroix et al., 2002, Lindsay et al., 2003, Wake et al., 2003, Engeli et al., 2004, Kannisto et 
al., 2004). These increases are comparable to the increases seen in the transgenic mouse 
model (Masuzaki et al., 2001). One group did not see any such increase (Tomlinson et al., 
2002), perhaps due to the method used to obtain the biopsies (Sandeep et al., 2005).  
A study by Sandeep et al. (2005) using an in vivo microdialysis technique, together with a 
9,11,12,12-[2H4]cortisol tracer, showed increased 11β-HSD1 activity in SAT together with 
the previously documented decrease in 11β-HSD1 activity in the liver. This, together with the 
findings that the non-specific 11β-HSD1 inhibitor carbenoxolone will increase insulin 
sensitivity in both lean healthy (Walker et al., 1995) and diabetic (Andrews et al., 2003) men, 
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but not obese subjects (Sandeep et al., 2005), supports the concept that a decrease in hepatic 
11β-HSD1 may occur in obesity (Tomlinson and Stewart, 2005).  
A more recent study (Desbriere et al., 2006) has found elevated 11β-HSD1 mRNA in obese 
women in both VAT and SAT. This study was important as it was the first time in which 
elevated 11β-HSD1 mRNA was observed in VAT, with the amount of VAT in a patient 
being one of the major indicators of type II diabetes and obesity (Despres et al., 1989, 
Fujioka et al., 1987). This was followed by a study investigating the expression of 11β-HSD1 
in VAT and SAT in both male and female patients presenting with obesity (Paulsen et al., 
2007). This study found that 11β-HSD1 mRNA expression, in both male and female obese 
patients, was increased in SAT compared to lean patients. However, expression of 11β-HSD1 
was only increased in the VAT of obese women. This is interesting as when the level of 11β-
HSD1 in lean men and women is compared in SAT, it can be seen that women have 
considerably less 11β-HSD1 expression than men. In obese subjects, the level of 11β-HSD1 
expression is similar in both men and women. This sex specific difference, coupled with 
studies which show that increased levels of 11β-HSD1 in SAT correlate with metabolic 
disorders (Alberti et al., 2007, Goedecke et al., 2006), could potentially show that the 
upregulation of 11β-HSD1 in obesity may have a greater effect on women than men. This 
could go some way to explaining higher risk of CVD in women suffering from the metabolic 
syndrome (Paulsen et al., 2007).  
Interestingly, there is some evidence to suggest that 11β-HSD2 expression is increased in 
both the kidney and SAT in obese rodent models. A recent study (Mussig et al., 2008), has 
shown 11β-HSD2 activity to be increased in the kidneys of 72 extremely obese human 
subjects. Although some groups have found no change in 11β-HSD2 activity (Stewart et al., 
1999), Mussig et al. (2008) argue that due to the high free plasma concentrations of cortisone, 
the inactive hormone can function as a rapidly available glucocorticoid which is activated to 
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cortisol in specific tissues such as the liver and adipose. Therefore, an increase in circulating 
free cortisone as a result of increased 11β-HSD2 activity, could indirectly lead to increased 
active hormone in adipose tissue, thereby enhancing that effect of increased 11β-HSD1 
activity in the adipose tissue of obese subjects (Mussig et al., 2008).  
As has been mentioned previously in this text, in addition to hepatic and adipose expression, 
11β-HSD1 is also expressed in pancreatic islet cells (Davani et al., 2000). The beta cells of 
the pancreatic islets, which make up around 80% of islet cells, are responsible for the 
production of insulin, with glucocorticoids known to inhibit insulin secretion (Billaudel and 
Sutter, 1979, Pierluissi et al., 1986, Lambillotte et al., 1997). Interestingly, a recent report has 
shown that short term GC treatment will actually increase insulin section from islets, possibly 
priming the cells for a switch in GC response eventually resulting in glucose insensitivity and 
a decrease in insulin secretion (Hult et al., 2009). In rodent models, glucose-stimulated 
insulin release (GSIR) was decreased in a dose dependent manner, when they were incubated 
with 11-dehydrocorticosterone, with the decrease reversed by addition of the 11β-HSD1 
inhibitors carbenoxolone and BVT.2733 (Ortsater et al., 2005, Davani et al., 2000). This led 
to the idea that 11β-HSD1 was expressed in the insulin producing beta cells of the pancreatic 
islets. However, a recent study has shown via immunohistochemistry and 
immunofluorescence, that 11β-HSD1 co-localises with glucagon in the periphery of both 
human and murine islets (Swali et al., 2008). This, coupled with the fact that no 11β-HSD1 
co-localised with insulin, shows that 11β-HSD1 is localised exclusively in the alpha cells of 
pancreatic islets (Swali et al., 2008). This implies that the relationship between generation of 
active glucocorticoid by 11β-HSD1 in islet cells and the decrease in GSIR may be more 
complicated than previously thought. Functional glucagon receptors can be found in human 
beta cells which are able to generate signals for GSIR. A recent study has shown the potent 
negative effect of glucocorticoids on both GSIR and glucagon secretion (Swali et al., 2008). 
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The same study has also shown that the inhibitory properties of 11-dehydrocorticosterone on 
GSIR and glucagon secretion is dependent on 11β-HSD1 activating the inactive 
glucocorticoid to corticosterone (Swali et al., 2008). Insulin secretion in beta cells can be 
stimulated by glucagon using both cAMP and protein kinase A dependent mechanisms 
(Gromada et al., 1997), with glucagon receptor knockout mice having reduced GSIR when 
compared to WT mice (Sorensen et al., 2006). This suggests that the generation of active 
glucocorticoid by 11β-HSD1 in alpha cells could impact on insulin secretion from beta cells 
by decreasing the secretion of glucagon, which would in turn decrease insulin secretion via 
the effects on the glucagon receptors on beta cells (Swali et al., 2008).  
1.4.1. Function and expression of 11β-HSD1 in other tissues 
Recent research has indicated the involvement of 11β-HSD1 and 11β-HSD2 in the regulation 
of endothelial nitric oxide synthase (eNOS) expression and hence, a possible involvement of 
these enzymes in vascular function (Liu et al., 2009). This was shown by the discovery of a 
previously unknown glucocorticoid response element (GRE) on the eNOS promoter region 
which, when in complex with cortisol bound to GR, serves to downregulate eNOS expression 
(Liu et al., 2009). This is interesting as it is suggestive that suppression of eNOS may be 
involved with the pathology associated with the possible 11β-HSD1 overexpression in the 
metabolic syndrome or the 11β-HSD2 deficiency in AME. 
Glucocorticoids play an important role in the function of the central nervous system (CNS) 
with known involvement in neurotransmission, neuronal division, cellular metabolism and 
survival (Woolley et al., 1990, Swaab et al., 2005, Landfield et al., 1978). There is increasing 
evidence to suggest that an increase in GC can cause an impairment in cognitive function. 
Firstly, patients who suffer from Cushing’s syndrome, in addition to the metabolic 
complications discussed earlier, can display cognitive and psychotic disorders (Swaab et al., 
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2005).  Secondly, the cognitive impairment due to ageing is associated with an increase in 
GC in rodents and humans (Meaney et al., 1995). Finally, processes which maintain a lower 
level of GC through life, such as neonatal programming of tighter HPA control or 
adrenalectomy with low-dose GC replacement, have been shown to prevent the emergence of 
cognitive deficits which commonly occur with age (Meaney et al., 1988, Landfield et al., 
1981). As previously mentioned, 11β-HSD1 is widely expressed in the brain, most notably in 
the cerebellum, hippocampus and neocortex, indicating involvement of the enzyme in 
memory and learning (Moisan et al., 1990). Indeed, in situ hybridisation studies in the post 
mortem brain have confirmed the presence of 11β-HSD1 in these areas with 11β-HSD2 
notably absent (Sandeep et al., 2004). The presence of 11β-HSD1 in neuronal tissues leads to 
the question as to whether inhibition can be therapeutic in the treatment of cognitive 
impairment. The action of 11β-HSD1 to produce active GC, which are known to amplify the 
neuro-endangering process of excitory amino acid induced toxicity (Rajan et al., 1996, 
Ajilore and Sapolsky, 1999) and the observation that aged 11β-HSD1-/- mice are able to resist 
the cognitive impairments seen in WT aged mice (Yau et al., 2001) would suggest that 11β-
HSD1 inhibition would be beneficial. In addition, a recent study has shown aging mice (18 
months) overexpressing 11β-HSD1 in the forebrain display premature age associated 
cognitive decline in the absence of a increase in circulating cortisol (Holmes et al., 2010). 
Studies have now shown that the non-specific 11βHSD inhibitor carbenoxolone is able to 
improve verbal fluency in healthy elderly men and verbal memory in patients with type 2 
diabetes (Sandeep et al., 2004). Improvements in cognitive function with 11β-HSD1 
inhibition have also been shown in rodents (Dhingra et al., 2004). However, due to the non-
specific nature of inhibitor and KO studies, it is not currently known if the neuroprotective 
effects of 11β-HSD1 inhibition are secondary to the more well characterized metabolic and 
vascular effects of 11β-HSD1 inhibition (Wamil and Seckl, 2007).  
47 
In addition to a role for 11β-HSD1 in the pathogenesis of type II diabetes and obesity, it has 
been postulated that inhibition of 11β-HSD1 in the eye could lead to a novel therapeutic 
strategy against glaucoma. This can be explained by 11β-HSD1 expression in the rat (Stokes 
et al., 2000), human (Stokes et al., 2000, Rauz et al., 2001) and rabbit eye (Onyimba et al., 
2006). A high amount of cortisol in this area can have profound effects on increasing intra-
ocular pressure (Rauz et al., 2001). Studies using the 11β-HSD1 inhibitor carbenoxolone 
have shown some success in reducing intraocular pressure in glaucoma sufferers (Rauz et al., 
2003, Rauz et al., 2001). 
1.4.2. Inhibitors of 11β-HSD1 activity 
Although more research needs to be done to fully elucidate the role of 11β-HSD1 in obesity, 
it would seem that there is a clear relationship between an increase in 11β-HSD1 expression 
in adipose tissue, and obesity. It is also clear that there is a relationship between production of 
glucocorticoids by 11β-HSD1 and a decrease GSIR. Inhibitors which are selective for 11β-
HSD1 could therefore be therapeutic for the treatment of both insulin resistance and obesity, 
with some success reported for various sulphonamides (Barf et al., 2002, Alberts et al., 2002, 
Alberts et al., 2003, Neelamkavil et al., 2009, Siu et al., 2009, Sun et al., 2009, Zhang et al., 
2009a, Xiang et al., 2008, Tu et al., 2008, Moreno-Diaz et al., 2008), triazoles (Olson et al., 
2005, Tu et al., 2008, Zhu et al., 2008a, Zhu et al., 2008b), spiro-carboxamides (Lepifre et 
al., 2009), colletoic acid (Aoyagi et al., 2008), sterenins (Ito-Kobayashi et al., 2008), 
benzamides (Julian et al., 2008), adamantanes (Rohde et al., 2007, Su et al., 2009) and 
thiazolones (Jean et al., 2007, Caille et al., 2009, Fotsch et al., 2008). A selection of these 
inhibitors is shown in Figure 1.16. Various docking and crystallization studies suggest the 
above inhibitors function through binding to the 11β-HSD1 active site, although for most of 
the above the exact mode of inhibition is not known. Tu et al. (2008) have shown that while 
their sulphonamide compound (known as compound 1) shows simple substrate competitive 
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inhibition, their triazole inhibitor (compound 2) functions as a mixed inhibitor. Finally, a 
recent study has shown a stereo specific difference between the inhibitory properties of the 
two glycyrrhizin metabolites, 18α-glycyrrhetinic and 18β- glycyrrhetinic acid (18α-GA and 
18β-GA) (Classen-Houben et al., 2009). While both isomers were able to inhibit 11β-HSD1, 
only 18β-GA was able to inhibit 11β-HSD2, indicating that the olean scaffold, specifically 
structures similar to 18α-GA, may used in the development of selective 11β-HSD1 inhibitors 
(Classen-Houben et al., 2009). 
 
 
Figure 1.16. Some examples of the types of 11β-HSD1 inhibitors proposed for the treatment of the 
metabolic syndrome. Shown are the naturally occuring non-specific 11β-HSD1 inhibitor glycyrrhetinic acid (A) 
and its derivative, carbenoxolone (B). Also shown are the more specific, non-steroidal inhibitors such as an 
arylsulfonylpiperazine (C), an adamantane amide (D) and compound 2922 (a thiazolone, E).  
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Interestingly, the search for selective 11β-HSD1 inhibitors has not been purely via high 
throughput screens and structure based design. A recent study has shown that traditional 
antidiabetic medicines, such as extracts from Eriobotrya japonica (Rosaceae) and roasted 
Coffea arabica (coffee) beans, were able to selectively inhibit 11β-HSD1 activity in HEK-
293 cells (Atanasov et al., 2006, Gumy et al., 2009). 
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1.5. Regulation of 11β-HSD1 activity via hexose-6-phosphate 
dehydrogenase 
As mentioned previously, although 11β-HSD1 is known to display a predominant reductase 
activity in intact cells, it is the dehydrogenase direction which predominates in purified 
preparations and cellular homogenates. The equilibrium constant (at pH 7.0) for the 
conversion of cortisone to cortisol was calculated to be 0.03 (Walker et al., 2001b), showing 
the reaction to favour cortisone and NADPH at equilibrium (Figure 1.11) and hence the 
tendency for the 11β-HSD1 reaction to proceed in the dehydrogenase direction in vitro.  
Since 11β-HSD1 acts as an ketoreductase in vivo, certain factors must be pushing the 
equilibrium towards cortisol and NADP+. One of these factors appears to be the lumenal 
concentration of NADPH, or more specifically the ratio of NADPH to NADP+, which is 
controlled by microsomal enzyme hexose-6-phosphate dehydrogenase (H6PDH).  
The interest in the luminal ratio of NADPH/NADP+ in relation to 11β-HSD1 was started by 
Agarwal et al. (1990), whose kinetic studies on purified, recombinant 11β-HSD1 from rat 
cDNA expressed in Vaccinia virus suggested that an important regulator of the reaction 
direction of 11β-HSD1 was the availability of cofactor (Agarwal et al., 1990). In this system, 
addition of the cytosolic enzyme glucose-6-phosphate dehydrogenase (G6PDH), which 
converts NADP+ to NADPH, increased reductase activity significantly. The potent effects of 
NADPH regeneration by G6PDH in vitro have since been demonstrated elsewhere (Bujalska 
et al., 1999a) with in vivo studies also providing evidence that cofactor levels are an 
important regulator of 11β-HSD1 reaction direction (Ge et al., 1997, Ferguson et al., 1999, 
Bujalska et al., 2002). However, due to the cytosolic location of G6PDH and the fact that 
pyridine nucleotides are generally believed not to cross cellular membranes, G6PDH is 
unlikely to perform this function in vivo. However a microsomal glucose dehydrogenase 
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exists (H6PDH) which is distinct from the cytosolic G6PDH (Beutler and Morrison, 1967). 
H6PDH is the first enzyme in the microsomal pentose phosphate pathway and has a broader 
substrate specificity than G6PDH, reducing not only the hexose-6-phosphates glucose-6-
phosphate and galactose-6-phosphate, but also 2-deoxyglucose-6-phosphate and sugars such 
as glucose (Beutler and Morrison, 1967, Romanelli et al., 1994). However, the physiological 
substrates are believed to be glucose-6-phosphate and NADP+  (Kulkarni and Hodgson, 
1982).  
1.5.1. Structure and localization of H6PDH 
The amino acid sequence for H6PDH was obtained for enzyme purified from rabbit liver 
microsomes (Ozols, 1993) and this allowed subsequent cloning and identification of the 
human and murine H6PDH cDNAs and genes (Mason et al., 1999). Rabbit H6PDH is a 90-
kDa protein, 763 amino acids in length with carbohydrate attached to both Asn-138 and Asn-
263 (Ozols, 1993, Brands et al., 1985). Although no transmembrane domain could be found, 
analysis of the amino acid sequence using SignalP clearly shows a the presence of a signal 
peptide, explaining the localization of H6PDH in the ER (Bendtsen et al., 2004).  Subsequent 
sequence comparisons between H6PDH and the enzymes of the cytosolic pentose phosphate 
pathway indicated that H6PDH had a high level of sequence similarity with not only G6PDH, 
but also with 6-phosphogluconolactonase (Hewitt et al., 2005, Collard et al., 1999). This 
suggested that H6PDH not only catalyzed the oxidation of glucose-6-phosphate but also the 
subsequent hydrolysis of 6-phosphogluconolactone (Figure 1.17). The bi-functional nature of 
H6PDH has subsequently been confirmed using purified native murine H6PDH (Mason et 
al., 1999, Clarke and Mason, 2003). Although the bi-functional nature has not been proven 
for the human enzyme, a high level of sequence similarity between this enzyme and the 
murine form suggests that this is the case (Hewitt et al., 2005).  
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Figure 1.17. The oxidative stage of the pentose phosphate pathway in the cytosol. Also shown is the bi-
functional nature of H6PDH in the ER. H6PDH can catalyze the first two steps of the microsomal pentose 
phosphate pathway. The N terminal domain oxidizes glucose-6-phosphate to 6-phosphogluconolactone, while 
the C terminal domain hydrolyses this product to 6-phosphogluconate. 
 
Evidence for the role of H6PDH in NADPH regeneration, and therefore its role in promoting 
the reductase activity of 11β-HSD1, comes from a variety of in vitro and in vivo experiments. 
Firstly, a study by Atanasov et al. (2005) showed that expression of 11β-HSD1 in the ER 
lumen of human embryonic kidney (HEK)-293 or Chinese hamster ovary (Cho) cells showed 
it to have bidirectional activity, with a preference for the dehydrogenase direction (Atanasov 
et al., 2004). However, a 5-fold increase in 11β-HSD1 reductase activity was seen when 11β-
HSD1 was co-expressed with H6PDH. Co-expression also caused a 6-fold decrease in 11β-
HSD1 dehydrogenase activity (Atanasov et al., 2004). A second study by Bujalska et al. 
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(2005) supported these findings and showed in addition that the reductase activity of 11β-
HSD1 was not affected by expression of the cytosolic G6PDH (Bujalska et al., 2005). 
Finally, an in vivo study in mice demonstrated the potent activation of 11β-HSD1 reductase 
activity in intact hepatic microsomes by addition of the substrate for H6PDH, glucose-6-
phosphate (Lavery et al., 2006b). In the same study, it was shown that addition of glucose-6-
phosphate to intact hepatic microsomes from a H6PDH KO mouse was unable to stimulate 
11β-HSD1 reductase activity (Lavery et al., 2006b), showing the requirement of H6PDH for 
11β-HSD1 reductase activity. The potent effect of H6PDH on 11β-HSD1 activity is not just 
limited to the conversion of cortisone to cortisol, with 11β-HSD1 conversion of 7-keto-
DHEA and 7-ketopregnenolone to their 7β-metabolites also dependent on the presence of 
H6PDH (Nashev et al., 2007).  
1.5.2. Direct interaction of H6PDH and 11β-HSD1 
If estimates are to be believed, the ER lumen is an oxidative environment with a ratio of 
oxidized glutathione (GSSG) to reduced glutathione (GSH) of between 1 and 3 (Braakman et 
al., 1992). Therefore, since it has been shown that efficient 11β-HSD1 reductase activity 
requires a 10-fold excess of NADPH over NADP+ the ER lumen is either more reductive than 
thought or H6PDH and 11β-HSD1 interact in close proximity facilitating efficient 11β-HSD1 
reductase activity (Dzyakanchuk et al., 2009). A recent study has now shown via a 
combination of co-immunoprecipitation, Far-Western blotting and fluorescence resonance 
energy transfer (FRET) that 11β-HSD1 and H6PDH do interact directly in the ER lumen 
(Atanasov et al., 2008). It was also shown that the 39 N-terminal amino acids of 11β-HSD1 
were responsible for the direct interaction with H6PDH (Atanasov et al., 2008). A further 
study using co-immunoprecipitation and purified recombinant protein has also demonstrated 
the direct interaction of H6PDH and 11β-HSD1 in vitro (Zhang et al., 2009b). This protein-
protein interaction between 11β-HSD1 and H6PDH is perhaps not surprising, as it provides a 
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direct coupling of intracellular glucose status, via glucose-6-phosphate, to glucose regulating 
hormones, such as cortisol. Due to the importance of H6PDH in conferring reductase activity 
to 11β-HSD1, it has been postulated that H6PDH could be a potential target of therapeutics 
aimed to decrease 11β-HSD1 activity (Atanasov et al., 2008). This view has been given 
credence by studies which have demonstrated an adipose tissue specific increase in 11β-
HSD1 and H6PDH expression both in obese rats (London et al., 2007), and human patients 
who present with type 2 diabetes (Uckaya et al., 2008).  
1.5.3. Regulation of H6PDH activity 
Just as levels of NADPH and cortisone regulate the activity of 11β-HSD1, the function of 
H6PDH is controlled via levels of its substrates, glucose-6-phosphate and NADP+. Glucose-
6-phosphate (G6P) is able to enter the ER via the glucose-6-phosphate transporter (G6PT) 
which transfers G6P from the cytosol to the lumen of the ER (Arion et al., 1980a, Arion et 
al., 1980b, Lange et al., 1980) (Figure 1.19). It should be noted that another membrane bound 
enzyme, the glucose-6-phosphatase (G6Pase), competes with H6PDH for the G6P transferred 
into the ER (Foster et al., 1997). It also interesting to note that both G6PT and G6Pase have 
been proposed as potential targets for the treatment of type II diabetes (Foster et al., 1997). 
Interestingly, patients who present with glycogen storage disease type 1b, as a result of a 
deficiency in G6PT, display decreased 11β-HSD1 reductase activity, while those who present 
with glycogen storage disease type 1a with deficient G6Pase show increased 11β-HSD1 
reductase activity (Walker et al., 2007). Patients who present with glycogen storage disease 
type 1b are still able to reduce cortisone to cortisol to some extent, suggesting an alternative 
source for NADPH generation in the ER with some groups postulating that perhaps isocitrate 
dehydrogenase may carry out this role (Margittai and Banhegyi, 2008). However, the lack of 
signal peptide or a retention sequence makes in unclear how isocitrate dehydrogenase would 
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appear in the ER (Dzyakanchuk et al., 2009). The microsomal G6PT-H6PDH-11β-HSD1 
system is shown in Figure 1.18.  
 
 
Figure 1.18. The G6PT-H6PDH-11β-HSD1 system in liver and adipose tissue. G6P enters the ER lumen via 
the specific G6PT and is converted to 6PGL via H6PDH, generating NADPH allowing 11β-HSD1 to convert 
cortisone to cortisol. 6PGL is further oxidized to 6-phosphogluconate by H6PDH. Also shown is the G6Pase, 
which competes for the G6P substrate. GP6 = glucose-6-phosphate, 6PGL = 6-phosphogluconolactone, G6PT = 
glucose-6-phosphate transporter, G = glucose, G6Pase = glucose-6-phosphatase. Adapted from Lavery et al. 
2008. 
 
56 
 
1.6. 11β-HSD1, H6PDH and Cortisone Reductase Deficiency 
In addition to the metabolic syndrome, diabetes and associated CVD, unusual activity of 11β-
HSD1 is thought to be involved in a condition known as cortisone reductase deficiency 
(CRD). CRD is a disorder in which there is a failure to regenerate the active glucocorticoid 
cortisol (F) from cortisone (E) via 11β-HSD1 (Tomlinson et al., 2004). A lack of cortisol 
regeneration stimulates ACTH-mediated adrenal hyperandrogenism (Figure 1.19), with males 
manifesting in adolescence with precocious pseudopuberty and females presenting in midlife 
with hirsuitism, oligoamenorrhoea, and infertility. Biochemically, CRD has been diagnosed 
through the assessment of urinary cortisol and cortisone metabolites, such as measuring the 
ratio of tetrahydrocortisol (THF) plus 5α-THF to tetrahydrocortisone (THE) (Figure 1.15). In 
CRD patients the ratio is typically lower than 0.1 (reference range 0.7–1.2) (Tomlinson et al., 
2004). 
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Figure 1.19. The possible involvement of 11β-HSD1 in the pathogenesis of CRD. A – Normal function of11β-
HSD1 in the HPA axis. Cortisol is regenerated from cortisone in liver  and peripheral tissues which contributes to 
the total amount of cortisol in circulation. B - Defective 11β-HSD1 activity would lead to a decrease in peripheral 
cortisol regeneration. Increased synthesis of ACTH ensures the maintenance of circulating cortisol via increased 
cortisol synthesis by the adrenal gland. This is at the expense of androgen excess. Taken from Cooper et al. 
2009. 
 
CRD was first described nearly 30 years ago (Taylor et al., 1984) with patients unable to 
convert cortisone to cortisol due to a deficient 11βHSD activity. Until 2008, eleven 
individuals have been described (Taylor et al., 1984, Savage, 1991, Nikkila et al., 1993, 
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Phillipov et al., 1996, Jamieson et al., 1999, Nordenstrom et al., 1999), with the HSD11B1 
gene of seven of the CRD kindreds analyzed. Although no functional mutations were found 
on the HSD11B1 gene, analysis revealed an A insertion and a T-G substitution in intron 3 in 
some patients. This 83557A/83597T-G haplotype was seen to be associated with a 28-fold 
reduction in 11β-HSD1 mRNA in adipose tissue with complete loss of reductase activity 
indicating a potential biomarker for CRD.  However, due to the heterozygous presence of this 
locus in 25% of normals and homozygous presence in 3% of normals, these mutations cannot 
account for the CRD phenotype (Draper and Stewart, 2005). It was also proposed that the A 
insertion in the HSD11B1 gene, may act together with a R453Q mutation in the H6PD gene 
and that this might be a cause of CRD (Draper et al., 2003). However, this theory has also 
been disproven (Smit et al., 2006, Draper et al., 2006, San Millan et al., 2005, Lavery et al., 
2008). A more recent study has now revealed four novel homozygous mutations in the H6PD 
gene associated with defective 11β-HSD1 activity, all without mutations in the HSD11B1 
gene (Lavery et al., 2008). The first of these (Case A in Figure 1.20) was a homozygous 
c.325delC mutation (i.e. the C at position 325 was deleted) on exon 2 which resulted in a 
frame shift, truncating H6PDH by 781 amino acids (Figure 1.20). The second (Case B in 
Figure 1.20) was a homozygous c.948C>G mutation in exon 4, which caused H6PDH to be 
truncated by 575 amino acids due to the introduction of a stop codon (Y316X) (Figure 1.20). 
Third, a homozygous c.1076G>A mutation in exon 5, resulting in G359 missense mutation 
(Case C in Figure 1.20). Finally, Case D was compound heterozygous for a maternally 
inherited c.1860ins29bp insertion mutation in exon 5 and a paternally inherited c960G>A 
mutation in exon 4. The c.1860ins29bp insertion mutation would generate both a frame shift 
and an in-frame stop codon, with the resulting H6PDH protein truncated by 268 amino acids 
(D620fsX3). The generation of a strong donor splice site consensus sequence from the 
c960G>A mutation results in two products. One in which mRNA is truncated by 54-
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nucleotides with the resultant protein missing 18 amino acids, and another in which intron 4 
is retained. (Figure 1.20). When expressed in HEK-293 cells, all mutant H6PDH proteins 
were inactive with a subsequent loss of 11β-HSD1 reductase activity within the cells (Lavery 
et al., 2008). These mutations therefore result in apparent cortisol reductase deficiency 
(ACRD) as 11β-HSD1 reductase activity has been affected indirectly. Since it has been 
shown that H6PDH KO mice not only lose 11β-HSD1 reductase activity (Lavery et al., 
2006b), but show an increase in dehydrogenase activity, it has been postulated that ACRD 
patients (with defective H6PDH) would have a more severe biochemical phenotype than 
those with simple CRD (defective in 11β-HSD1). The mutations involved in CRD/ACRD are 
summarised in Table 1.3. 
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Figure 1.20. H6PD gene mutations which give rise to ACRD. Family pedigree and the alteration in both 
nucleotide and protein are shown. Mutations to the H6PD gene in cases A and B results in a severely truncated 
protein, while mutation to the H6PD gene in Case C causes a G359D missense mutation. Case 4 had a H6PDH 
protein which was truncated by 268 amino acids (D620fsX3) as a result of being heterozygous for a maternally 
inherited c.1860ins29bp mutation in exon 5 and a paternally inherited c.960GA mutation in exon 4. All mutants, 
when expressed in HEK-293 cells, were inactive. Taken from Lavery et al. (2008a). 
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Mutation 
 
Gene 
 
Coding 
Effect on 
Activity 
Significant in 
CRD/ACRD? 
Reference 
83557A 
HSD11B1 No None No (Draper and Stewart, 
2005) 
83597T-G 
HSD11B1 No None No (Draper and Stewart, 
2005) 
Y316X 
H6PD Yes Null Yes (Lavery et al., 2008) 
R109AfsX3 
H6PD Yes Null Yes (Lavery et al., 2008) 
G359D 
H6PD Yes Null Yes (Lavery et al., 2008) 
D620fsX3 
H6PD Yes Null Yes (Lavery et al., 2008) 
R453Q 
H6PD Yes None No (Mason et al., 1999) 
Table 1.3. Mutations which have been postulated to be involved with CRD and ACRD. 
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1.7. Short Chain Dehydrogenase/Reductases 
The 11β-HSD1/11β-HSD2 enzymes are both members of the short chain 
dehydrogenase/reductase family of enzymes (SDRs). This class of enzymes was first 
discovered when functional differences were noted between sect-type and liver-type alcohol 
dehydrogenases, which correspond to the SDR and medium chain dehydrogenase/reductases 
(MDRs) families respectively (Jornvall et al., 1981). One such difference was the binding of 
dinucleotide cofactor which, in contrast to pro-R’ hydride transfer observed in MDRs, binds 
in an extended conformation which allowes pro-S’ hydride transfer (Kavanagh et al., 2008). 
While SDRs primarily interconvert hydroxyl and carbonyl groups, SDR enzymes are also 
able to mediate dehydratase, isomerase, decarboxylation and sulphotransferase reactions and 
also catalyze the reduction of C=C and C=N double bonds (Figure 1.21) (Oppermann et al., 
2003). There are over 20,000 SDR depositions in sequence databases, with 71 distinct SDR 
enzymes reported in humans (Kavanagh et al., 2008).  The number of human SDRs doubles 
if variant enzymes are included due to differential splicing and related isoforms (Kavanagh et 
al., 2008). 
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Figure 1.21. The various reactions catalyzed by SDR enzymes. Taken from Kavanagh et al. (2008). 
 
The family of SDR enzymes are often not that closely related, with an amino acid homology 
of typically around 15-30%. However, all solved structures possess a Rossmann fold which 
consists of a central β -sheet flanked by α -helices which is common in the oxidoreductase 
class of enzyme (Jornvall et al., 1995, Oppermann et al., 2003) (Figure 1.22). The amino and 
carboxy termini of the SDRs are typically important for function with signal peptides or 
transmembrane domains sometimes associated with them (Jornvall et al., 1995, Oppermann 
et al., 2003). 
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Figure 1.22. Ribbon diagram displaying the Rossmann fold of a monomer of 3α/17βHSD (PDB code 1xhx). 
All solved structures of the SDR family possess the Rossmann fold, which consists of a central β-sheet (blue) 
flanked by α-helices (red). N = N-terminus, C = C-terminus. Image produced using UCSF Chimera. 
 
As with any protein family, SDRs have a number of sequence motifs which are conserved to 
different degrees. A well conserved N-terminal T-G-X-X-X-G-X-G motif constitutes the 
majority of the nucleotide binding region by forming a cleft in which the cofactor can bind 
(Figure 1.23) (Oppermann et al., 2003). The motif is also involved with the maintenance of 
the central β -sheet (Oppermann et al., 1997, Filling et al., 2002). Another well conserved 
motif is the N-N-A-G motif which is also involved with maintenance of the central β-sheet 
(Oppermann et al., 1997, Filling et al., 2002). A P-G motif can also be involved in co-factor 
binding (Filling et al., 2002). In addition, a relatively well conserved T residue is also 
involved in hydrogen bonding to the carboxamide of the nicotinamide ring of cofactor 
(Oppermann et al., 1997). 
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Figure 1.23. The N-terminal T-G-X-X-X-G-X-G motif involved with binding cofactor, in this case NAD+, in 
the SDR family member 3α /20β-HSD (PDB code 2HSD). This motif is highly conserved across the SDR 
superfamily of proteins and is also involved with maintenance of the central β-sheet. Hydrogen bonds are 
indicated by the blue lines. Image produced using UCSF Chimera. 
 
However, the most conserved of these motifs is the N-S-Y-K catalytic tetrad. It was 
originally thought that the catalytic mechanism of SDRs involved a catalytic triad of S-Y-K 
with the tyrosine working as the catalytic base, the serine stabilizing the substrate and lysine 
interacting with the nicotinamide ring of the ribose and lowering the pKa of the Tyr-OH, 
promoting proton transfer (Jornvall et al., 1995). This was similar to the mechanism observed 
in horse liver dehydrogenase (Liao et al., 2001, Eklund et al., 1982). However, inspection of 
the related Drosophila alcohol dehydrogenase structure suggested that an additional 
interaction existed between a conserved Asn residue, via a water molecule, with the active 
site Lys (Benach et al., 1998). This was then subsequently shown in the 3β/17β-HSD 
structure and other SDR structures, which suggests this critical Asn has an analologous role 
in positioning the conserved water molecule in SDR catalysis (Figure 1.24) (Filling et al., 
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2002). It is important to note here that some SDRs, instead of the critical Asn, have a Ser 
residue which acts in a similar way (Filling et al., 2002). The completion of this proton relay 
system is critical in maintaining the position of the active site Lys.  
 
Figure 1.24. The catalytic mechanism of 11β-HSD1 and other “classical” SDRs. Catalysis is started by the 
transfer of a proton from Tyr-183 hydroxyl to the C-11 carbonyl group of cortisone. This is followed by hydride 
transfer to the C-11 of cortisone. A proton relay system involving the Tyr-183, 2’-OH of the nicotinamide ribose, a 
conserved Lys and a conserved water molecule is then formed. This conserved water molecule is positioned by 
the critical Asn residue. Residue numbering refers to the guinea pig enzyme. ARPP, the adenosine ribose 
pyrophosphate moiety. Adapted from Filling et al. (2003). 
 
SDRs can vary in size, function and also in the motifs present. Using these differences, SDRs 
can be classified into five families ‘classical’, ‘extended’, ‘intermediate’, ‘divergent’ and 
‘complex’ (Persson et al., 2003). The motifs discussed above all refer to the ‘classical’ SDR 
family, to which 11β-HSD1 belongs. The ‘classical’ and ‘extended’ SDRs include similar 
motifs but differ in function and size, acting as either a ca 250 residue dehydrogenase or 
reductase (‘classical’) or a ca 350 residue isomerase, epimerase, dehydratase or lyase 
Cortisone 
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(‘extended’) (Persson et al., 2003). The unusual activities of ‘extended’ SDRs are explained 
by the coupling of thsese activites to an initial reductive step on specific substrates. The 
NAD(P)(H) nucleotide cofactor dependence and conservation of active site residues when 
compared to ‘classical’ SDRs further emphasize the absence of any additional enzymatic 
steps in ‘extended’ SDRs. Examples of ‘extended’ SDRs include UDP-galactose epimerase, 
3β-hydroxy-5ene-steroid isomerase and GDP-mannose dehydratase. The ‘intermediate’ 
family of SDRs are closely related in sequence to the ‘classical’ SDRs with the exception of a 
G/AxxGxxG/A nucleotide binding motif similar to that seen in extended SDRs (Table 1.4) 
(Persson et al., 2003). Interestingly, in addition to changes to nucleotide binding regions, both 
‘divergent’ and ‘complex’ SDRs have different active site motifs to the more common 
YxxxK observed in most SDRs i.e. YxxMxxxK in divergent SDRs and YxxxN in complex 
SDRs (Table 1.4) (Persson et al., 2003). Despite this change, the Y and K side chains in 
‘divergent’ enzymes are close in space and similarly spaced to those in ‘classical’ SDRs. 
However, due to the function of this class of enzymes (enoyl-thioester reductases involved in 
fatty acid metabolism) and the fact that proton is donated directly from solvent, not from the 
active site tyrosine residue, implies that different catalytic mechanisms are present in this 
class of SDRs. In contrast to the ‘divergent’ enzymes, if the three-dimensional structures of 
‘complex’ SDRs are examined (e.g. the ACP-ketoacyl reductase domain of Streptomyces 
erythromycin synthase) all of the catalytic machinery i.e. the N, S, Y and K residues, while 
not close in sequence, are similarly spaced to those in ‘classical’ SDRs, implying they may 
function in a similar manner. 
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Subfamily Cofactor binding Active site 
‘classical’ TGxxx[AG]xG YxxxK 
‘extended’ [ST]GxxGxxG YxxxK 
‘intermediate’ [GA]xxGxx[GA] YxxxK 
‘divergent’ GxxxxxSxA YxxMxxxK 
‘complex’ GGxGxxG YxxxN 
Table 1.4. Active site and cofactor binding site sequence motifs for the five SDR families. Takem from Kavanagh 
et al, (2008). 
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1.8. Structural studies of 11β-HSD1 
For a protein whose substrate has such wide-reaching applications in medicine, only 
suprisingly recently have high resolution structures of 11β-HSD1 become available. This is 
primarily due to the fact that, in contrast to most other members of the SDR family, 11β-
HSD1 is a glycosylated, membrane-bound protein making isolation of full length protein a 
difficult, although not impossible, task (Hult et al., 2001, Nobel et al., 2002). Since the 
crystallization of membrane-bound proteins has a low success rate (Newman, 1996), 
recombinant human 11β-HSD1 which has the N-terminal transmembrane domain removed 
has been engineered (Walker et al., 2001a). Following expression of this construct in 
bacteria, 11β-HSD1 can be purified to a relatively high level of homogeneity and 
monodispersity, essential factors for crystallography (Walker et al., 2001a). At the time of 
writing, 23 structures of recombinant N-terminally truncated 11β-HSD1 have been deposited 
in the PDB. The key features of these structures are listed in Table 1.5. A comparison of the 
guinea pig (1XSE), mouse (1Y5M) and human (2BEL) enzyme structures is shown in Figure 
1.25. It can clearly be seen (Figure 1.25) that the mouse, guinea pig and human (2BEL) 
enzyme structures are very similar. Therefore, although the following description is for the 
human (1XU9) structure, solved to 1.55Å, most elements may be applied to the guinea pig 
and murine structures. 
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PDB 
Code 
Species Resolution (Å) R Rfree Ligand Reference 
2BEL Human 2.11 0.190 0.246 CBX, NADP+ (Wu et al., 2007) 
1XU7 Human 1.80 0.198 0.217 CPS, NADP+ (Hosfield et al., 2005) 
1XU9 Human 1.55 0.158 0.181 CPS, NADP+ (Hosfield et al., 2005) 
3CZR Human 2.35 0.221 0.247 CPS, 3CZ 
NADP+ 
(Sun et al., 2008) 
3BZU Human 2.25 0.204 0.263 A21, NADP+ (Hale et al., 2008) 
2ILT Human 2.30 0.212 0.275 NN1, NADP+ (Sorensen et al., 2007) 
2RBE Human 1.90 0.219 0.264 ZMG, NADP+ (Yuan et al., 2007) 
3BYZ Human 2.69 0.222 0.293 H11, NADP+ Johansson et al, to be 
published 
3CH6 Human 2.35 0.188 0.230 311, NADP+ (Wang et al., 2008) 
2IRW Human 3.10 0.239 0.278 NN4, NADP+ (Patel et al., 2007) 
3D5Q Human 2.55 0.232 0.265 T30, NADP+ (Tu et al., 2008) 
3D4N Human 2.50 0.228 0.259 D4N, NADP+ (Julian et al., 2008) 
3D3E Human 2.60 0.230 0.283 D3E, NADP+ (Julian et al., 2008) 
3FCO Human 2.65 0.224 0.254 IIG, NADP+ (McMinn et al., 2009) 
3H6K Human 2.19 0.194 0.275 33T, NADP+ (Wan et al., 2009) 
3HFG Human 2.30 0.234 0.285 17R, NADP+ (Wan et al., 2009) 
3FRJ Human 2.30 0.210 0.243 A49,NADP+ (Rew et al., 2009) 
3EY4 Human 3.00 0.219 0.319 352, NADP+ Christopher et al, to be 
published 
1Y5R Mouse 3.00 0.210 0.247 Corticosterone 
NADP+ 
(Zhang et al., 2005) 
1Y5M Mouse 2.30 0.219 0.250 NADP+ (Zhang et al., 2005) 
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1XSE Guinea Pig 2.50 0.196 0.267 NADP+ (Ogg et al., 2005) 
3G49 Guinea Pig 2.50 0.191 0.225 3G4, NADP+ (Siu et al., 2009) 
3DWF Guinea Pig 2.20 0.200 0.255 NADP+ (Lawson et al., 2009) 
Table 1.5. Comparison of the 23 11β-HSD1 structures in the pdb database. CBX = Carbenoxolone; CPS = 3-
[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (a steroidal detergent); NN1 = adamantane sulfone 
inhibitor; 3CZ, 17R, 3G4 = arylsulphonyl-piperazine inhibitors; H11, ZMG = 2-anilinothiazolone inhibitors; A21 = 
thiazolone inhibitor; 311 = pyridine amide inhibitor; T30 = triazole inhibitor; 352 = thialozone inhibitor; D4N = 
sulfonamide inhibitor; D3E, IIG, 33T, A49 = benzamide inhibitors. 
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Figure 1.25. A comparison of the crystal structures of 11β-HSD1 from different species.  a – Ribbon 
representation of human (2BEL), guinea pig (1XSE) and mouse (1Y5M) 11β-HSD1 dimers. b – Superimposition 
of human (red), guinea pig (blue) and mouse (yellow) monomers. c – The superimposition in b rotated 90o. Note 
the varying lengths of the C-terminal helix in c, with the guinea pig helix longer than both the mouse and human. 
This extension (α2 & α3) is specific to 11β-HSD1 when compared to other SDRs. The dimerisation domain is 
made up of helices αE, αF, α2 and α3. N = N-terminus, C = C-terminus. Images produced using the UCSF 
Chimera package (Pettersen et al., 2004). 
73 
 
The crystal structure of 11β-HSD1 confirmed that the protein existed as a homodimer with 
each monomer possessing a Rossmann fold, with the monomer described below. The central 
β- sheet which makes up the Rossmann fold, is made up from 7 β-strands (βA – βG) with 3 
helices on each side (αB, αC, αG on one side and αD, αE, αF on the other) completing the 
fold (Figure 1.26). In addition, a double turn α-helix designated α-1, exists between βF and 
αG and forms a ‘lid’ over the substrate-binding pocket. Unsurprisingly, this central scaffold is 
highly similar (about 2Å RMSD) to most other SDRs such as porcine carbonyl reductase 
(1DOH), human estradiol 17β-hydroxysteroid dehydrogenase type I (1BHS) and E.coli 7α-
hydroxysteroid dehydrogenase (1AHI). A topology diagram of the human 11β-HSD1 
structure is shown in Figure 1.26. The annotated amino acid sequence is shown in Figure 
1.27. 
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Figure 1.26. A topology diagram of human 11β-HSD1 (1XU9) coloured according to secondary structure. 
Dark blue cylinders = α helix, light blue arrows = β strand. The red cylinders represent helices from the 
corresponding monomer which make up the dimerisation domain. Image produced using PDBsum. 
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Figure 1.27. The amino acid sequence of human 11β-HSD1 aligned with secondary structure. α -helices 
are shown by the dark blue helical structure with β-strands shown by the light blue arrows. Catalytic residues are 
highlighted by a yellow box with residues which interact with co-factor shown by the green arrows and red dots. 
Image produced using PDBsum. 
 
If the position of bound steroid and cofactor in the structure of human 11β-HSD1 is analysed 
(1XU9), it is clear that cofactor binds to residues towards the N-terminus (i.e. the ‘top’ of 
11β-HSD1) while steroid will bind to the residues towards the C-terminus (i.e. the ‘bottom’ 
of 11β-HSD1) (Figure 1.28). The positioning of these binding sites could be important due to 
the position of 11β-HSD1 with respect to the ER membrane (discussed later). The central 
fold of 11β-HSD1 also contains many motifs and features associated with SDRs. The 
structure confirmed the presence of the N-S-Y-K catalytic tetrad (Figure 1.29), T-G-X-X-X-
G-X-G motif (residues 40-45), an equivalent P-G motif (L-G, residues 215 & 216 in 11β-
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HSD1) involved in cofactor binding and a N-K-V-N motif which is equivalent to the I-R-V-N 
motifs seen in other SDRs (Filling et al., 2002, Ogg et al., 2005).  
 
Figure 1.28. Ribbon representation of a monomer of human 11β-HSD1 (1XU9) using a colour gradient 
from blue (residues near the N-terminus) to red (residues near the C-terminus).The cofactor, NADP+, is 
coloured blue while the steroidal detergent, CHAPS, which is located in the active site in place of substrate, is 
coloured red. It can be seen that the cofactor and steroid are surrounded by blue/green and red/yellow residues 
respectively,  illustrating the N-terminal location of the cofactor binding region and the C-terminal location of the 
substrate binding region. Image produced using UCSF Chimera. 
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Figure 1.29. The N-S-Y-K active site of 11β-HSD1 (1XU9). The mechanism is a proton relay system involving 
the Tyr-OH, the 2’-OH of the nicotinamide ribose, a conserved Lys (K187) and a conserved water molecule. This 
conserved water molecule (HOH1511) is positioned by the critical Asn (N143) residue. Structure shows bound 
NADP+ and the steroidal detergent, CHAPS. Image produced using UCSF Chimera. 
 
However, 11β-HSD1 does show a striking difference to other SDR structures at the C-
terminus. The last 2 helices (α2 and α3) protrude and form a long structure which packs 
against the C-terminus of the other subunit in an antiparallel conformation, extending the 
dimerization interface formed by helices αE and αF (Figure 1.30). This results in a total 
dimer interface of 2502.7 Å2. This is unusual, as although some cases exist (Blankenfeldt et 
al., 2002), most dimeric SDRs have a dimerization interface that involves only helices E and 
F (Powell et al., 2000, Hoque et al., 2008, Ghosh et al., 1991, Tanaka et al., 1996). 
Interestingly, a R137 residue, which is conserved across 11β-HSD1 proteins from different 
species, is present on helix αE of one subunit (A), positioned at the edge of the dimer 
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interface and forms a salt bridge with the highly conserved residue E141 on the other subunit 
(B). A corresponding interaction between R137 on the B subunit and E141 on the A subunit 
forms a second bridge.  Salt bridges, particularly those involving arginine are known to have 
a prominent role in inter-subunit interactions in proteins (Musafia et al., 1995) promoting 
correct orientation of the subunits during dimer formation in addition to stabilizing the final 
assembly (Vijayakumar et al., 1998, Gabdoulline and Wade, 2001). The importance of this 
salt bridge is discussed in more detail in Chapter 3.  
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Figure 1.30. Ribbon representation of the dimerisation domain of human 11β-HSD1 (1XU9). A – side view 
of the 11β-HSD1  dimer. B – View of the 11β-HSD1 dimer from the top of the orientation shown in A. Helices 
which from the dimer interface (αE, αF, α1 & α2) are coloured red from one subunit and blue from the other.  
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In addition to the role in dimerization, the last helix in the C-terminus, α3, and the preceding 
loop of one subunit interact with the substrate-binding loop of the second subunit and form 
part of the substrate-binding pocket of that subunit (Figure 1.31). This ‘domain swap’ bears 
some resemblance to that seen in the Drosophila alcohol dehydrogenase (Benach et al., 1998) 
(PDB code 1A4U) and is strikingly similar to some dimeric medium chain 
dehydrogenase/reductase (MDRs) (Eklund et al., 1974).  
 
 
Figure 1.31. Showing the possible domain swap in 11β-HSD1 (1XU9). It can clearly be seen that the end of 
the C-terminal helix (α3) of subunit A (green) seems to complete the substrate binding pocket of subunit B (sky 
blue). Occupying the active site in place of substrate is the steroidal detergent, CHAPS (yellow), with NADP 
depicted in red. N = N-terminus of subunit B, C = C-terminus of subunit B. Image produced using UCSF Chimera. 
 
Finally, if the overall surface charge distribution formed by the residues on these C-terminal 
helices are examined, it is clear that the region forms a non-polar plateau encircled by 
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positively charged residues (Ogg et al., 2005), with hydrophobic residues in this region 
highlighted in Figure 1.32.  
 
Figure 1.32. Putative membrane-dipping region of the guinea pig 11β-HSD1 structure (PDB code: 
1XSE).Structures and sequences are coloured by the experimentally determined hydrophobicity scale for 
proteins at membrane surfaces (Wimley and White, 1996), with hydrophobicity shown as increasing green. A – 
Surface representation of a ‘side’ view of 11β-HSD1 with the putative membrane-associating region at the bottom 
of the structure, showing protrusion of the hydrophobic patch. B – ‘Bottom’ of the protein showing the 
hydrophobic surface region that might come into contact with the membrane. Hydrophobic residues contributing 
to this region are labelled for one of the two chains. C – Sequence alignment of the C-termini of mammalian 11β-
HSD1 proteins, showing the conserved hydrophobicity. Structural images produced using UCSF Chimera. 
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Ogg et al. (2005) has suggested that in vivo the luminal domain of the 11β-HSD1 dimer, 
anchored to the ER membrane by the N-terminal transmembrane domains, will ‘sit’ on the 
luminal membrane surface with the amphipathic C-terminal helices free to interact with the 
membrane (Figure 1.33). If this orientation is to be believed, the plateau could exist in the 
non-polar centre of the membrane, with the charged residues forming salt bridges with the 
displaced phospholipid and sulpholipid head groups (Ogg et al., 2005) (Figure 1.33). Due to 
the hydrophobic nature of the substrates of 11β-HSD1, this could constitute a potential 
‘membrane dipping’ mechanism to funnel hydrophobic substrates from the membrane into 
the 11β-HSD1 active site (Ogg et al., 2005) (Figure 1.33).  Membrane dipping or ‘substrate 
re-entry’ loops are commonly found in polytopic membrane proteins. These loops can act as 
either selectivity filters as in the aquaglycerolporin family, or as gates of membrane pores as 
in the glutamate homologue transporter (Lasso et al., 2006). However, studies on eukaryotic 
microsomal cytochrome P450s (CYP450s) have revealed that they too possess regions, in 
addition to the membrane spanning N-terminus, that associate with the membrane in a 
monofacial manner (Williams et al., 2000). A report has detailed a program named TMLOOP 
which can predict the presence of membrane dipping loops (Lasso et al., 2006). However, 
since this program is designed for polytopic membrane proteins it is unable to predict either 
the monofacial membrane attachment in CYP450 or the putative region in 11β-HSD1. 
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Figure 1.33. Diagrammatic representation of how the membrane dipping hypothesis would function in 
vivo. The hydrophobic plateau of 11β-HSD1 could exist in the non-polar centre of the membrane, with the 
charged residues forming salt bridges with the displaced phospholipid and sulpholipid head groups.  The ER 
membrane is shown in cyan with the substrate binding site of one monomer shown in red. Taken from Ogg et al 
2005. 
 
Although the main structure of 11β-HSD1 is very similar in the guinea pig, human and 
mouse, differences do exist between them. Firstly, while the guinea pig and human enzymes 
contain a critical tyrosine at position 177, the equivalent position in the mouse enzyme is a 
glutamine. It has been postulated (Ogg et al., 2005) that this substitution can account for the 
specificity of the mouse enzyme for its form of glucocorticoid substrate, 11-
dehydrocorticosterone. Mutational studies of the human enzyme by Kim et al. (2006)  have 
shown that Y177 is not a hydrogen bond donor in substrate binding, by virtue of unchanged 
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Km values for cortisone when the tyrosine residue was replaced by its hydroxyl-lacking 
counterpart, phenylalanine (Kim et al., 2006). These data, supported by increased Km values 
for Y177A and Y177Q mutants, strongly suggest that in human 11β-HSD1, Y177 interacts 
with cortisone via its hydrophobic interactions. In addition, the study showed that Y177 does 
not confer substrate specificity between species as the three mutations had little effect on the 
binding of 11-deyhydrocorticosterone, the rodent substrate of 11β-HSD1 (Kim et al., 2006). 
The same group has also recently shown that Y177 together with Y280, a residue which was 
initially thought to be involved with substrate binding, are in fact involved with selective 
binding of the 11β-HSD1 inhibitor glycyrrhetinic acid (Kim et al., 2006, Kim et al., 2007). 
Interestingly, it would seem that neither residue is involved with binding of the 11β-HSD1 
inhibitor carbenoxolone, suggesting that the involvement of these residues on inhibitor 
binding is highly dependent on the chemical structure of the inhibitor (Kim et al., 2006, Kim 
et al., 2007). 
In addition to residue changes, the quaternary structure differs between the enzymes from 
different species. While the guinea pig, mouse and 2BEL human structures exist as dimers in 
the crystal structure (Ogg et al., 2005, Zhang et al., 2005), the human 1XU7/1XU9 structures 
are seen to exist as a tetramer (Hosfield et al., 2005). This group crystallized two forms of 
11β-HSD1 in what they call ‘open’ and ‘closed’ forms. Both conformations exist as a dimer 
of dimers, with the tetramerisation interface existing at the non-polar plateau at the C-
terminus of all subunits. In the closed structure, hydrophobic interactions between the non-
polar residues in the plateau occur to form the tetramer, while in the open structure this is 
mediated by steroids positioned in the cleft (Figure 1.34A) (Hosfield et al., 2005). It is 
unclear whether this structure is physiologically relevant, or has occurred as a result of 
crystallisation. However, Hosfield et al. do propose a novel idea as to how this quaternary 
structure would function in vivo (Figure 1.34B). In the first proposed functional tetramer, the 
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four N-terminal transmembrane domains (orange in Figure 1.34Ba) anchor the 11β-HSD1 
protein (blue) in a single membrane in the ER lumen. The protein is in an orientation which 
allows the C-terminal helices (black) of each dimer to stack against each other forming the 
tetramerisation interface. This would create a hydrophobic channel in the interface open 
structure which would allow substrate to diffuse into the 11β-HSD1 active sites directly from 
the membrane. The second proposed functional tetramer (Figure 1.34Bb) is similar in 
concept, although this time the interactions are possible due to two closely spaced 
membranes. This orientation may be relevant due to the highly invaginated structure of the 
ER membrane. 
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Figure 1.34. Possible tetrameric arrangement of human 11β-HSD1 (1XU7/1XU9). A - The open-closed 
hypothesis put forward for the structure of 11β-HSD1. NADP_ (yellow) and CHAPS (green) bind at two enzyme 
active sites located at the top and bottom of the enzyme tetramer. Each enzyme subunit is coloured differently 
except for the enzyme N and C termini, which are colored yellow and red, respectively. Conformationally variable 
loops between βF and α1 are colored blue. In the closed structure, hydrophobic interactions between the non-
polar residues in the plateau between a pair of dimers interact to form the tetramer while in the open structure; 
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this is mediated by steroids positioned in the cleft between the dimer-of-dimers.. B – Two ideas as to how the 
tetrameric 11β-HSD1 would function in vivo with either one membrane (a) or two membranes (b). 11β-HSD1 
(blue), N-terminal transmembrane domain (orange), C terminus (black), Trp263 and Tyr280 (yellow). Taken from 
Hosfield et al. (2001) 
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1.9. Aims 
The first aim of this research was the production of mutant 11β-HSD1 proteins in which key 
residues within the hydrophobic C-terminal region were replaced with the hydrophilic residue 
glutamate; this would be the first step towards analysing the biological significance of this 
region. These mutants would then be expressed in E.coli and analysed for any changes in 
solubility, monodispersity, activity or structure. This would hopefully reveal a mutant which 
was structurally and kinetically similar to WT but with disruption to the hydrophobicity of 
the C-terminal region. This would then allow comparison of the binding of WT and mutant 
11β-HSD1 to microsomal membranes from either mouse liver or human cells, and also to 
artificially created liposomes, with the hope of determining whether this region is important 
in membrane association 
The final aim was to develop a bacterial system that facilitates the purification of 
recombinant heterodimers (mutant/WT) of 11β-HSD1 which could then be used to analyse 
two recently-discovered, naturally-occurring mutations which are thought to cause CRD, both 
of which are found in the heterozygous state. 
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Chapter 2. Mutation of key hydrophobic C-terminal residues of 
11β-hydroxysteroid dehydrogenase type 1 
2.1. Introduction 
11β-HSD1, as discussed earlier, is a protein expression of which has wide-reaching 
implications in health and medicine. In Section 1.4, the evidence that a dysregulation of 
cortisol at a tissue level, which would indicate abnormal 11β-HSD1 activity, may be the 
underlying pathology behind a range of conditions such as type 2 diabetes and the metabolic 
syndrome was discussed. This evidence included animal studies which have shown that 11β-
HSD1 is an important regulator of hepatic glucose output and visceral adiposity with 
transgenic mice overexpressing 11β-HSD1 in liver and adipose tissue displaying features of 
the metabolic syndrome (Masuzaki et al., 2001, Masuzaki et al., 2003, Paterson et al., 2004). 
In contrast, recombinant mice lacking 11β-HSD1 show improved glucose tolerance, 
enhanced insulin sensitivity, and reduced weight gain when given a high fat diet (Kotelevtsev 
et al., 1997, Morton et al., 2001). 11β-HSD1 has therefore emerged as a novel therapeutic 
target to treat patients with obesity and insulin resistance, with selective 11β-HSD1 inhibitors 
being tested in rodent (Alberts et al., 2003) and mammalian models (Bhat et al., 2007). 
Central to studies of this key enzyme has been the development of methods for providing 
sufficient amounts of pure protein. 
2.1.1. Improvements in the expression and purification of 11β-HSD1 
High resolution structures of 11β-HSD1 which allow the development of structure-based 
drug design for the treatment of type 2 diabetes and the metabolic syndrome have only 
recently become available. This is in part due to the problems inherent in heterologous 
protein production. Unless specific eukaryotic protein modifications are required, the first 
method of choice for the production of recombinant protein is usually overexpression of the 
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target gene in E.coli.. However, despite the extensive genetic knowledge of E.coli, 
widespread availability of vector systems and host strains, ease of use, the low cost and high 
expression levels which can be obtained, the current success rate to obtain soluble eukaryotic 
protein using E.coli is around 10% (Hozjan et al., 2008).  Common causes for the low 
success rate, such as gene product toxicity, biased codon usage and mRNA secondary 
structure and stability can usually be overcome by choosing the correct combination of 
vector/host strain together with modification or redesign of target genes. However, even 
when these problems are overcome and protein expression is high, the recombinant protein 
produced can often be insoluble, as was the case 11β-HSD1. This is particularly true for 
eukaryotic proteins, no doubt because the protein-folding environment in bacteria is different 
from that within eukaryotic cells.  In the case of 11β-HSD1, this may be exacerbated by the 
fact that in contrast to most other members of the SDR family, 11β-HSD1 is a glycosylated, 
membrane-bound protein which normally folds within the lumen of the ER.   These 
properties make expression and isolation of full-length 11β-HSD1 protein a difficult, 
although not impossible, task (Hult et al., 2001, Nobel et al., 2002). Since the crystallization 
of membrane-bound proteins has a low success rate (Newman, 1996), recombinant 11β-
HSD1 which has the N-terminal transmembrane domain removed has been engineered 
(Walker et al., 2001a). Following expression of this construct in bacteria, 11β-HSD1 can be 
purified to a relatively high level of homogeneity and monodispersity, essential factors for 
crystallography (Walker et al., 2001a). Although the production of recombinant 11β-HSD1 
outlined by Walker et al. (2001) reduced the temperature from 37 °C to 15 °C in the 
induction phase, a common technique for improving the yield of soluble protein, the final 
yield of the resulting soluble protein was low (~ 0.8 mg ml-1). Improvements to this 
procedure have seen the co-expression of 11β-HSD1 with the chaperonins GroEL/GroES, 
enhancing the yield of soluble 11β-HSD1 around twofold (Elleby et al., 2004, Hult et al., 
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2006). The successful co-expression of target proteins with chaperonins has been known for 
over 10 years, with successes reported for human branched chain α-keto acid dehydrogenase 
complex, haloalkane dehalogenase and a recombinant IgG protein (Ailor and Betenbaugh, 
1998, Wynn et al., 2000, Widersten, 1998). In addition to co-expression with chaperonins, 
addition of an inhibitor of 11β-HSD1 during the induction phase has been shown to increase 
the yield of soluble human 11β-HSD1 significantly (Hozjan et al., 2008, Hult et al., 2006, 
Elleby et al., 2004). Interestingly, a recent report has shown that addition of the inhibitor 
CBX during the production of 65 (non-11β-HSD1) SDRs can increase the yield of soluble 
protein two to threefold in 22 cases, with CBX supplementation seen to be a requirement for 
the production of soluble protein in 4 of the 65 SDRs analysed (Hozjan et al., 2008).  
2.1.2. Investigation into the solvent exposed hydrophobic region in 11β-HSD1 and other 
proteins 
The presence of a solvent-exposed hydrophobic region in 11β-HSD1 which could potentially 
interact with the ER membrane is clear from the crystal structures (see Figure 1.31 and also  
Section 1.8). This may also explain the improved solubility of purified 11β-HSD1 on the 
addition of detergent (Elleby et al. 2004). In order to initiate investigations into the 
importance of this C-terminal hydrophobic region, the primary aim of this chapter was to 
determine the effect of replacing a series of key residues within the hydrophobic plateau, in 
both human and guinea pig 11β-HSD1, with the hydrophilic residue glutamate. Although 
such protein engineering studies include complications which may arise from the inability to 
control all effects of amino acid substitution on protein structure, this technique seemed the 
best approach to elucidate the importance of the hydrophobicity of this region of the protein.  
The principal residues which make up the hydrophobic plateau in the guinea pig protein are 
W263, Y266, I275, F278 and L279 (Figure 2.1); the human residues are identical apart from 
Leu at position 266. Hence these residues were chosen to be individually mutated to 
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glutamate. Although some previous studies into surface exposed hydrophobic residues have 
used milder amino acid substitutions to probe the role of specific residues on protein 
structure, e.g. a V213S mutation in cytosine-C5 methyltransferase protein (Daujotyte et al., 
2003), glutamate was chosen specifically not just for its strong hydrophilicity, but also 
because its negative charge might increase repulsion between this region of the protein and 
membrane phospholipid/sulpholipid head groups, and hence have a more deleterious effect 
on membrane association of the protein.  
It was clearly important for the planned future studies that any mutation of solvent-exposed 
hydrophobic residues to charged residues such as glutamate should not adversely affect the 
activity or general structure of the protein. Hence the studies in this Chapter report the effects 
of these mutations on the solubility, monodispersity and activity of 11β-HSD1 expressed in 
E.coli, and on the crystal structure of one of the guinea pig enzyme mutants (F278E).  
Prior to the work presented in this thesis, a bacterial expression construct containing DNA 
encoding residues 24-292 of the human 11β-HSD1 protein was generated in pET-28b(+) 
(Novagen) by PCR amplification from a previous construct (Walker et al., 2001a). A guinea-
pig expression construct containing DNA encoding residues 24-300 was a kind gift from Dr P 
Rejto (Pfizer, La Jolla, CA). Both constructs incorporated an N-terminal His6-tag to aid 
purification. A series of single point mutations were made to hydrophobic residues at the C-
terminus of both guinea pig and human 11β-HSD1 proteins. Target residues for mutation 
were chosen by analysis of the crystal structures for the human and guinea pig 11β-HSD1 
(pdb 2BEL and 1XSE respectively). The positions of these hydrophobic residues are shown 
in Figure 1.32. The human enzyme mutants L266E, I275E, F278E and L279E and the guinea 
pig enzyme mutants Y266E, I275E, F278E and L279E were introduced into the bacterial 
expression construct and analyzed for their effect on protein expression. Analysis of bacterial 
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lysates by SDS-PAGE showed that the solubility of recombinant 11β-HSD1 was dramatically 
increased by the mutations I275E, F278E and L279E, in the guinea pig sequence and F278E 
in the human sequence (Figure 2.1). This was not simply due to an increase in total protein 
expression as there was not only an increase of protein in the soluble fraction, but also a 
concomitant decrease in the amount of protein in the insoluble fraction (data not shown).  In 
this chapter, the expression of these mutants on a larger scale was explored.  
 
Figure 2.1. SDS-Page analysis of WT and mutant 11β-HSD1 recombinant proteins. Supernatant fractions 
from lysates of bacterial cultures expressing (A) guinea pig 11β-HSD1 proteins and (B) human 11β-HSD1 
proteins indicate that the I275E, F278E and L279E point mutations dramatically increased the production of 
soluble 11β-HSD1. Arrows indicate positions of respective guinea pig and human recombinant proteins.  (Images 
of gels used with kind permission of Dr E. A. Walker). 
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2.2. Materials and Methods 
2.2.1. Cloning and Expression of Recombinant 11β-HSD1 
Constructs containing 11β-HSD1 gene mutants cloned into pET-28b(+) were used to 
transform the BL21 (DE3) E.coli expression strain (Novagen). E.coli BL21(DE3) cells 
carrying the human gene were co-transformed using the pBAD-ESL plasmid (gift of Dr P 
Lund (Walker, 2000)), which contains the genes for the E.coli chaperonins GroEL/ES.  For 
the expression of the guinea pig protein, cells were grown in LB broth supplemented with 30 
µg/ml kanamycin with shaking (220 rpm) at 37 oC. Cells were induced with isopropyl-β-D-
thiogalactoside (IPTG, 1 mM) when A600 had reached a value of 0.8-1. Cells were grown with 
shaking for a further 30 min at 37 oC, then transferred to 15 oC and grown with shaking 
overnight.  For the expression of the human protein, cells were grown with shaking in LB 
broth supplemented with 30 µg/ml kanamycin and 50 µg/ml ampicillin at 37 oC. Arabinose 
(0.1% w/v) was added to the cultures at an A600 of 0.8-1, in order to induce the expression of 
the chaperonin proteins. Cells were grown with shaking for 1 h at 37 oC, before addition of 1 
mM IPTG. The 11β-HSD inhibitor carbenoxolone (CBX, 0.1 mM) was also added at this 
stage. Following a further incubation of 30 min at 37 oC, cultures were transferred to 15 oC 
and grown with shaking for 16 h. 
2.2.2. Purification of 11β-HSD1 
Cells were pelleted (3000×g, 15 min) and then resuspended in Bugbuster reagent (Novagen) 
containing protease inhibitors (Mini-Complete EDTA free, Roche Molecular Biochemicals) 
and Benzonase DNase (Novagen). Cells were incubated with shaking at room temperature for 
40 min and then cell debris was pelleted at 38,000×g for 30 min at 4˚C. Supernatant was 
loaded onto a His-Select (Sigma Aldrich) column and washed with buffer containing 25 mM 
sodium phosphate, 300 mM NaCl, 5% (v/v) glycerol, 2 mM TCEP and 0.005% (v/v) Anapoe 
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X-100 (Anatrace Inc), pH 8.0. Loosely bound protein was washed off with 3 column volumes 
of the same buffer containing 17.5 mM imidazole. Protein was then eluted with 3 volumes of 
buffer containing 175 mM imidazole. Fractions containing protein were separated by size-
exclusion chromatography on a Superdex-200 HR10/30 column (Pharmacia) running at 0.4 
ml min-1 in 25 mM sodium phosphate, 5% (v/v) glycerol, 0.005% (v/v) Anapoe X-100, pH 
8.0. The amount of protein was measured using the absorbance of a given sample at 280 nm 
using a UV spectrophotometer.  
2.2.3. Measurement of 11β-HSD1 activity 
Dehydrogenase activity of 11β-HSD1 was assayed at 37 oC in 25 mM sodium phosphate, pH 
8.0, with 200 µM NADP+ and cortisol concentrations ranging from 0.5 µM to 32 µM, using a 
Perkin-Elmer LS-5 spectrofluorimeter. Excitation and emission wavelengths were 340nm and 
456nm respectively. Amount of enzyme added was adjusted so that a linear rate of reaction 
was obtained for 5 min after cortisol addition. A calibration curve was constructed using 0-
1µM NADPH. Reductase activity of 11β-HSD1 was assayed by measuring the cortisone to 
cortisol ratio by HPLC. In this reaction, an enzyme concentration which gave no more than 
20% substrate conversion was incubated for 5 min at 37 oC in 25 mM sodium phosphate, pH 
8.0, containing 200 µM NADPH and an NADPH-regenerating system (6 mM MgCl2, 1 U/ml 
glucose-6-phosphate dehydrogenase (Sigma-Aldrich), 1 mM glucose-6-phosphate). Reactions 
were started by addition of 1-128 µM cortisone and incubated for 20 min. Reactions were 
terminated by addition of 3 ml dichloromethane. Samples were then centrifuged for 5 min at 
1000×g and the aqueous layer removed. After evaporation of the dichloromethane, samples 
were redissolved in 60µl of 50% (v/v) aq. acetonitrile and loaded onto an RP-HPLC system 
consisting of a Prevail Select C-18, 5µm column (Grace), a GP50 gradient pump and a 
UVD170S detector (Dionex). Samples were eluted with a gradient of 54% to 69% (v/v) aq. 
methanol over a period of 15 min. Substrate and product were monitored by UV absorbance 
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at 242 nm with retention times of approximately 11 and 12 min respectively. An example of a 
typical HPLC trace is shown in Figure 2.2. Rates, as a function of substrate concentration, 
were fitted to a simple Michaelis Menten equation and analysed using non-linear regression 
by Visual Enzymics (Softzymics Inc.). 
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Figure 2.2.  An example of a typical HPLC chromatogram to analyse the reductive activity of 11β-HSD1. Steroid samples were eluted using a 
gradient of 54% to 69% (v/v) aq. methanol over a period of 15 min, with this gradient represented by the blue line. Cortisone and cortisol were monitored by 
UV absorbance at 242nm with retention times of approximately 11 (peak 9) and 12 (peak 10) min respectively. Axis represent time (x) vs absorbance (y), 
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2.2.4. Measurement of turnover of enzyme-bound NADP+ 
To estimate the proportion of protein molecules with bound NADP+, human F27E or wild-
type enzyme (1 µM) was incubated in 25 mM sodium phosphate pH 8.0 at 37oC and the 
fluorescence of cofactor monitored as described above.  An excess of cortisol was then 
swiftly added to a final concentration of 50 µM, and the single turnover of the NADP+ in the 
enzyme preparation monitored.  The fluorescence increased and reached a plateau from 
which the original concentration of NADP+ could be estimated.  The system was calibrated 
by subsequent addition of a known sub-stoichiometric amount of NADP+ and monitoring the 
fluorescence increase.  Control reactions with cortisone in place of cortisol showed no change 
in fluorescence. 
2.2.5. Analytical Ultracentrifugation 
Sedimentation velocity measurements were made using a Beckman XLI analytical 
ultracentrifuge. Samples at a concentration of 0.5 mg ml-1, 0.25 mg ml-1  or 0.1 mg ml-1 were 
centrifuged at 40000 rpm in an X rotor at 4 oC for 8 hours in a buffer containing 25 mM 
sodium phosphate, 300 mM NaCl, 5% (v/v) glycerol, 2 mM TCEP and 0.005% (v/v) Anapoe 
X-100 (Anatrace Inc), pH 8.0. The concentration of protein within the cells was analysed by 
scanning each cell at 280 nm, a total 200 scans being made during each run. These data were 
then processed using the C(M) model implemented in SEDFIT (Schuck, 2000) using 
parameters for protein and buffer determined using SEDNTERP. 
2.2.6. Structure determination of the F278E mutant 
Crystals were grown using the sitting-drop vapour diffusion method with a 10 mg/ml protein 
stock solution in 25 mM sodium phosphate, 5% glycerol, 0.005% Anapoe X-100, pH 8.0, 
equilibrated against a reservoir containing 0.1 M Tris-HCl, 1.75 M ammonium sulphate and 
5% (v/v) glycerol (pH 8.0). The sitting drop contained 2 µl of protein solution and 2 µl of 
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reservoir. No NADP+ was added during purification or crystallization. Crystals of the F278E 
11β-HSD1 were soaked for 10 minutes in each of a series of artificial mother liquor solutions 
containing glycerol in 5% increments. In the final solution containing 25% (v/v) glycerol, 
crystals were soaked for 45 minutes before being flash-cooled by plunging into liquid 
nitrogen. Data were collected at 100 K at the European Synchrotron Radiation Facility, 
Grenoble, France, using beam line ID14-1. All data were indexed, integrated and scaled using 
XDS (Kabsch, 1993). Data was collected by Dr Scott White and is reproduced here with his 
kind permission with full data collection statistics shown in Table 2.1. The structure was 
determined by molecular replacement using the program Phaser with 1XSE as the search 
molecule. After initial refinement, the model was improved using Arp/wArp (Perrakis et al., 
1999), then refined using phenix.refine (Afonine, 2005). The refinement statistics are listed in 
Table 2.1.  
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Data collection statisticsa   
 Cell parameters a, b, c (Å) 78.1, 85.9, 176.3 
 Space Group P212121 
 Resolution (Å) 2.2 (2.33-2.20) 
 Completeness (%) 99.2 (96.6) 
 Multiplicity 4.7 
  I/σI 11.43 (2.8) 
 No. of observations 288,334 (39,957) 
 No. of unique observations 60,915 (9,432) 
  Rsym 9.5 (54.5) 
 
Refinement statistics 
 
 Average B factor 43.8 
 No. of non-hydrogen atoms/waters 9153/452 
 RMSD bond (Å)/angle (deg) 0.005/0.923 
 Ramachandran (%)b 90.1/9.0/0.7/0.2 
 R/Rfreec 20.0/25.5 
 PDB code 3DWF 
 a Statistics as reported by XDS. b.Percentage of non-glycine, non-proline residues in the 
core/allowed/generously allowed/disallowed regions of the Ramachandran plot. c.5% of reflections 
set aside for cross validation. 
Table 2.1. X-ray data and refinement statistics.  Data was collected by Dr Scott White and is reproduced 
here with his kind permission. 
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2.3. Results 
2.3.1. Effect of Mutations on the Expression and Purification of Recombinant 11β-
HSD1 
The effect of the various mutations on the final yield of soluble protein when the protein was 
purified from large cultures (at least 400 ml) by IMAC and gel-filtration is shown in Figure 
2.3. All the mutations increased the final yield of soluble protein, with the human F278E and 
guinea pig I275E mutants showing the most dramatic increases (approximately 8-fold and 23-
fold increases compared to respective wild-type constructs).  
 
 
Figure 2.3. Relative yields of wild type and mutant human and guinea pig 11β-HSD1 proteins. Proteins 
were produced as per materials and methods.  Levels of protein produced are shown in mg protein per litre LB 
broth with preparations performed in duplicate. Variation existed between protein preperations but since n = 2, 
reliable statistical analysis is not possible. Introduction of glutamate at position 275, 278 and 279 in the guinea-
pig sequences and 278 in the human sequence, dramatically increased the yield of recombinant 11β-HSD1 
protein. 
2.3.2. Effect of Mutations on Enzyme Kinetics 
The effect of the mutations on the kcat and Km for the steroid substrates of 11β-HSD1 was 
analyzed in both dehydrogenase and reductase directions (Tables 2.2 & 2.3). For the guinea 
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pig enzyme, the F278E mutant had virtually unchanged Km and kcat compared to wild type, in 
both dehydrogenase and reductase directions (Table 2.3). The Y266E and L279E mutants 
showed a slight decrease in turn-over rate but with little change in Km. The only pronounced 
variation from wild type was seen with the I275E mutant, which showed a marked decrease 
in Km for cortisol, and a dramatic increase in Km for cortisone (Table 2.3).  In the case of the 
human enzyme, the Km for the F278E mutant was virtually unchanged compared to wild type 
in both directions, although the kcat increased approximately 4-fold and 2-fold for the 
dehydrogenase and reductase reactions respectively (Table 2.2). The constants for the L266E 
mutant were virtually identical to the F278E mutant, except that there was a ~50% increase in 
Km for cortisone.  In contrast, both the L279E and I275E mutants showed an increase in Km 
and kcat for dehydrogenase and reductase reactions (Table 2.2). Kinetic measurements of the 
human enzyme mutant F278E with a higher concentration (500µM) of NADP+/NADPH 
showed no change in Km or kcat for both the dehydrogenase and reductase reactions. 
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 Dehydrogenase Reductase 
Protein Km  (Cortisol) kcat Km  (Cortisone) kcat 
Wild Type 7.05±2.15 0.31±0.04 8.95±0.80 0.18±0.00 
L266E 6.63±0.50 1.29±0.03 15.26±1.58 0.31±0.01 
I275E 11.68±1.13 0.98±0.04 27.93±1.80 0.22±0.01 
F278E 6.16±0.44 1.27±0.03 10.61±1.49 0.31±0.01 
L279E 12.57±1.05 0.65± 0.00 18.93±2.26 0.14±0.01 
Table 2.2. Kinetic analysis of human 11β-HSD1 wild type and mutant proteins. Assays were carried out as 
per materials and methods. Km values are given in µM with kcat values given in min-1 (mean ± SEM). Results were 
analyzed using non-linear regression by Visual Enzymics (Softzymics Inc.) and are based on the average of 
duplicate experiments. Km and kcat values for cortisone and cortisol are comparable to those reported by Shafqat 
et al., (2003) (see Table 1.2). 
 
 Dehydrogenase Reductase 
Protein Km  (Cortisol) kcat Km  (Cortisone) kcat 
Wild Type 4.59±0.49 1.02±0.04 4.09±0.35 0.57±0.01 
Y266E 2.86±0.22 0.47±0.01 3.67±0.58 0.20±0.01 
I275E 1.35±0.40 0.24±0.02 31.1±9.8 0.37±0.04 
F278E 5.73±1.13 1.12±0.08 3.13±0.63 0.48±0.02 
L279E 3.23±0.29 0.53±0.01 5.27±1.33 0.41±0.03 
Table 2.3. Kinetic analysis of guinea pig 11β-HSD1 wild type and mutant proteins. Assays were carried out 
as per materials and methods. Km values are given in µM with kcat values given in min-1 (mean ± SEM). Results 
were analyzed using non-linear regression by Visual Enzymics (Softzymics Inc.) and are based on the average of 
duplicate experiments 
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Effect of Mutations on Aggregation State - Guinea pig and human F278E and WT proteins 
were analyzed by sedimentation analytical ultracentrifugation (AUC) to assess their 
aggregation state in vitro (Figure 2.4). Both the guinea pig and human wild type proteins 
exhibited a rather broad peak with a maximum at around 200 kDa. Since the 11β-HSD1 
dimer has a size of 68 kDa and 64 kDa for the guinea pig and human enzymes respectively, 
these data suggest that the recombinant wild type proteins aggregate significantly in solution, 
with a size averaging around a hexamer. Interestingly, it was observed that the F278E 
mutation in the guinea pig enzyme converted the main species to a much narrower peak with 
a size indicative of a tetramer. This is shown by a peak at approximately 120-140 kDa. The 
human F278E mutant at 0.5 mg ml-1 also showed a main peak at 130 kDa, but in addition had 
a second major peak at 65 kDa, indicating the majority of protein existed as tetramer with a 
lesser amount as a dimeric protein.  In order to probe the equilibrium between the dimeric 
and tetrameric forms, three different concentrations of guinea pig and human F278E were 
analyzed by AUC (Figure 2.4). Dilution of the guinea pig F278E protein did not affect its 
aggregation state, with all dilutions showing one peak at around 140 kDa, indicating a stable 
tetrameric form. The human F278E mutant, however, showed a significant increase in the 
ratio of dimer to tetramer as the concentration of protein was decreased, indicating a 
concentration-dependent equilibrium between dimeric and tetrameric forms.  
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Figure 2.4. AUC analysis of the aggregation states of the human (A) and guinea pig (B) wild-type and 
F278E proteins. Also shown is the effect of dilution on the oligomerisation state of the human and guinea pig 
F278E enzymes. Images were produced using SedFit (Schuck 2000) with density, viscosity and v-bar 
measurements calculated by Sednterp. Human and guinea pig v-bar measurements were 0.7405 and 0.7391 
respectively. The buffer had a density (P) value of 1.016 and viscosity (H) value of 1.18 E-2. 
Human Guinea Pig 
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2.3.3. Crystal Structure of Guinea Pig F278E 
Due to a large yield of protein, the crystallisation of guinea pig F278E mutant protein could 
be attempted to check for changes in structure. Crystals were grown as per Materials and 
Methods with the data collection and refinements statistics given in Table I. Each monomer 
in the guinea pig F278E structure had the same overall Rossmann fold as the other published 
11β-HSD1 structures (Ogg et al., 2005, Hosfield et al., 2005, Zhang et al., 2005) and had a 
quaternary assembly of a tetramer made up of a dimer-of-dimers (Figure 2.5a). Analysis 
using the PISA server (Krissinel and Henrick, 2007) suggested tetramer to be the most 
probable quaternary structure for the guinea pig F278E protein, while the previously 
published wild type structure (1XSE) (Ogg et al., 2005) was suggested to exist as a dimer. 
The structure of the guinea pig F278E dimer is largely identical to 1XSE with the dimers 
superimposable with a root mean square displacement (RMSD) of 0.48 Å. Slight differences 
in the backbone exist in the loop region Glu221 to Pro234 and in the final helix from Leu267 
to Ala291. One clear difference is evident between chains A and D and chains B and C in the 
guinea pig F278E protein structure (Figure 2.5b). In chains A and D, Tyr123 points towards 
the active site bound NADP+, while in chains B and C, the Tyr123 points away from the 
active site. Both orientations have good electron density in both the 2fofc map and the omit 
map calculated by PHENIX.  Interestingly, strong electron density can be seen for NADP+ 
(Figure 2.5c) even though none was added at any point in the purification or crystallization 
process. Our structure also shows that the C-terminal residue, Trp299, in each chain has 
bound into a hydrophobic pocket consisting of residues Phe129, Val152, Met155, Leu197 
and Phe201. The position of this Trp residue has not been reported in any other 11β-HSD1 
structure.  
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Figure 2.5. Crystal structure of the guinea pig F278E enzyme. The three dimensional structure can be 
superimposed on the previously published guinea pig structure to a value of 0.48Å RMSD (not shown). A -
Tetrameric arrangement of the two guinea pig F278E 11β-HSD1 dimers. Two views are shown to illustrate the 
orientation of the two dimers.  B – The two orientations of Tyr123 seen in the active site of the guinea pig F278E 
mutant. 1 shows the Tyr123 residue pointing towards the active site which would block substrate binding. 2 
shows the Tyr123 residue pointing away from the active site towards bulk solvent, which would allow substrate to 
bind. C – The bound NADP+ molecule seen in all monomers of the guinea pig F278E tetramer. Map shown in B 
and C is the 2fofc map produced by Refmac5 to a value of 1.0 sigma. Image produced using PyMOL (DeLano, 
2002) 
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2.3.4. Estimation of proportion of active molecules in the human F278E and wild-type 
enzymes 
Since the crystal structure indicated the guinea pig enzyme contained bound cofactor, we 
used fluorescence to monitor the single turnover of cofactor on addition of excess steroid to a 
known amount of protein, as a means to estimate the proportion of molecules which 
contained bound cofactor and were active.  It was assumed that since NADP+ binding is 
required for correct folding of 11β-HSD1 in the bacterial expression system used, any 
enzyme which had bound NADP+ would be active. Addition of cortisol to enzyme resulted in 
a rapid rise in fluorescence due to conversion of endogenous NADP+ to NADPH, which 
reached a plateau from which the original concentration of NADP+ was estimated.  By 
contrast, addition of cortisone resulted in no change in fluorescence, confirming that the 
cofactor was present in the enzyme in the oxidized form.  Measurements on several 
preparations of the human F278E enzyme indicated that between 62 and 69% of the protein 
molecules contained NADP+ and were active.  In contrast, measurements on wild-type 
enzyme yielded values of 20-48%. 
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2.4. Discussion 
It has been hypothesized (Ogg et al., 2005) that due to the unusual charge distribution across 
the C-terminal helices in the 11β-HSD1 structures, this area could be involved in ‘membrane 
dipping’, with residues in this region forming a non-polar plateau encircled by positively 
charged residues (Figure 1.32). This plateau could exist in the non-polar centre of the 
membrane, with the charged residues forming salt bridges with the displaced phospholipid 
and sulpholipid head groups.  This conformation might increase accessibility of the enzyme 
to membrane embedded steroid substrates. The way chosen to test this hypothesis was to 
mutate the non-polar residues in this region of 11β-HSD1 to the hydrophilic residue glutamic 
acid, and observe the effect on activity of full-length protein in vivo. Firstly, however, the 
effect of such mutations on enzyme activity and protein structure in vitro, in the absence of 
membranes, had to be established.  For this purpose the mutations were introduced into an N-
terminally truncated, His-tagged enzyme, produced in a previously developed and validated 
bacterial expression system (Walker et al., 2001a). C-terminal mutations introduced into the 
human enzyme were L266E, I275E, F278E and L279E while the equivalent guinea pig 
enzyme mutants created were Y266E, I275E, F278E and L279E. On expression in E.coli, all 
mutations increased the yield of soluble 11β-HSD1, with human F278E and guinea pig I275E 
and F278E showing the most dramatic increases compared to wild-type protein (Figure 2.3). 
Presumably the pronounced surface hydrophobicity of the C-terminal region of the wild-type 
protein enhances the chance of misfolding and aggregation under the high-level expression 
conditions of the bacterial expression system.  The lack of membrane association via the N-
terminal anchor may also compound the problem.  The mutations to glutamate introduced 
here not only decrease hydrophobicity, but also promote repulsion between these regions and 
thus aid correct folding and solubility. This was evidenced by a reduced formation of 
insoluble inclusion bodies in addition to an increase in soluble protein production.  A similar 
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increase in solubility has been previously been engineered into several other proteins by 
mutation of surface hydrophobic residues (Sim and Sim, 1999, Daujotyte et al., 2003, Mosavi 
and Peng, 2003), often by substitution with negatively charged amino acids (Dale et al., 
1994, Nieba et al., 1997), indicating the general applicability of this approach to improving 
protein expression.  Also of interest is that this study indicates that the wild type guinea pig 
enzyme is naturally more soluble than its human counterpart.  This may also be related, at 
least in part, to surface hydrophobicity of the C-terminal region, in that the guinea pig 
enzyme has a number of residues with reduced hydrophobicity in this area when compared to 
the human protein (e.g. Y266 vs. L266, R262 vs. L262). 
Sedimentation AUC analysis of purified wild-type and mutant proteins endorsed the concept 
that aggregation was reduced by the C-terminal mutations (Figure 2.4).  Both human and 
guinea pig wild-type recombinant proteins existed in solution as a collection of aggregated 
species, with broad c(M) peaks averaging approximately 200 kDa.  In contrast the F278E 
mutants showed a much lower degree of aggregation and a greater degree of monodispersity, 
with the guinea pig F278E protein appearing to be a stable monodisperse tetramer, and the 
human F278E protein existing as a concentration-dependent equilibrium of dimer and 
tetramer. 
All the mutant proteins had similar kinetics (kcat and Km) for the steroid substrate as the wild-
type, in both dehydrogenase and reductase directions– a prerequisite for the use of these 
proteins in the analysis of the membrane dipping hypothesis. The F278E mutants in 
particular, seem promising for future studies. The guinea-pig F278E protein showed 
unaltered substrate affinity or turnover rate in either reaction direction, whilst the human 
F278E protein also showed unaltered Km values, although, in common with the other 
mutations to this enzyme, the apparent kcat was significantly higher than wild-type.  Since it 
had previously been shown that bacterially-expressed wild-type human 11β-HSD1 may have 
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only ~20% active enzyme molecules (Elleby et al., 2004), it seemed likely that the increased 
specific activity seen with these mutations was due to an increased proportion of active 
molecules in these preparations.  To get an estimate of the proportion of molecules which 
contained bound NADP+, and therefore the number of active molecules in our enzyme 
preparations, fluorescence was used to monitor the single turnover of enzyme-bound NADP+ 
to NADPH on addition of an excess of cortisol.  This indicated that 62-69% of the human 
F278E protein molecules contained bound cofactor and were functional, whereas the 
proportion for the wild-type was lower at 20-48%.  This supports the hypothesis that the 
increased observed kcat of this mutant is at least in part due to an increased proportion of 
active molecules in the preparation.  It is nevertheless possible that the decreased aggregation 
status of the mutant also contributes to the increase in turnover rates. 
In order to investigate the effect of the C-terminal mutations on the structure of 11β-HSD1, 
the guinea pig F278E protein was crystallized. The structure of guinea pig F278E reported 
here is of a higher resolution with a lower Rfree than that of the previously published wild-type 
guinea pig structure (PDB code: 1XSE (Ogg et al., 2005)). Of importance, the conditions 
required to crystallize the guinea pig F278E protein were different from those used 
previously; in particular it was not necessary to include guanidinium hydrochloride to 
enhance monodispersity of the enzyme (Ogg et al., 2005). The crystal structure we obtained 
indicated that the enzyme exists as a tetramer made up of a dimer-of-dimers (Figure 2.5a). 
This contrasts with the 1XSE structure, which is seen to exist as a single dimer. Analysis of 
the structure reported here using the PISA server (Krissinel and Henrick, 2007) showed that 
the interface for the two dimers is sufficient to make the tetramer the most likely quaternary 
assembly, which is in agreement with the AUC findings that the guinea pig F278E protein 
exists as a stable tetramer in solution. Apart from this quaternary difference, the structure of 
each of the guinea pig F278E dimers is largely identical to 1XSE. Interestingly, all monomers 
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of the F278E protein contained a well-defined NADP+ molecule, even though none was 
added during any step of the purification or crystallization (Figure 2.5c). This supports 
previous suggestions that cofactor is required for correct protein folding and conformational 
stability (Elleby et al., 2004).  
The only significant difference that exists between the previously published 1XSE and the 
guinea pig F278E structure reported here is the orientation of the residue Tyr123. In the 
1XSE structure, the Tyr123 in both chains A and B are pointed towards the bound NADP+ 
molecule. This would not be expected since in the active site of the murine 11β-HSD1 
structure (PDB code:1Y5R), the equivalent Gln123 residue is pointing away from the active 
site allowing the steroid substrate to bind (Filling et al., 2002). If the 1XSE structure is 
superimposed on 1Y5R, it can be seen that the Tyr123 in this orientation would sterically 
prevent glucocorticoid binding. To explain this orientation, Ogg et al. (2005) hypothesized 
that a conformational change must be a prerequisite for substrate binding (Ogg et al., 2005). 
In the structure reported here, two orientations of Tyr123 can be seen. In chains A and D, the 
Tyr123 is in the same orientation as the 1XSE structure, whilst in chains B and C, the Tyr123 
is pointing away from the active site, towards bulk solvent (Figure 2.5b). These two 
conformations of Tyr123 have also been seen in an unpublished wild-type guinea pig 11β-
HSD1 structure (Loh & Ding, pers. comm.). Each dimer therefore has one Tyr123 pointing 
into the active site and one Tyr123 pointing towards bulk solvent. If the binding of substrate 
to one subunit would alter the orientation of Tyr123 of the second subunit, thereby altering 
the affinity for binding of substrate, it could be argued that this conformation of Tyr123 is 
highly suggestive of cooperative kinetics for 11β-HSD1 (Maser et al., 2002). However, the 
data from this study and others (Arampatzis et al., 2005, Castro et al., 2007, Shafqat et al., 
2003), does not support this concept. The fact that the protein is not in its physiological 
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environment could mean that the kinetics seen here and elsewhere are not indicative of the in-
cell situation.  
In summary, in this chapter it has been shown that mutations to the C-terminus of 
recombinant 11β-HSD1 can increase yield of soluble protein without adversely affecting 
activity. It has also been shown, using one of the mutants as an example (guinea pig F278E), 
that these mutations have no adverse effects on structure compared to wild type protein. 
Hence 11β-HSD1 mutants have been engineered that will be useful, not only for probing 
membrane interactions, but also for many other future biochemical and biophysical studies of 
the enzyme due to their increased solubility, monodispersity and in some cases, activity. 
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Chapter 3. Identification and functional impact of novel 
mutations in the gene encoding 11β-hydroxysteroid 
dehydrogenase type 1 in patients with hyperandrogenism 
3.1. Introduction 
Cortisone reductase deficiency (CRD) is a human disorder in which there is a failure to 
regenerate the active glucocorticoid cortisol (F) from cortisone (E) via 11β-HSD1 
(Tomlinson et al., 2004). A lack of cortisol regeneration stimulates ACTH-mediated adrenal 
hyperandrogenism, with males manifesting in adolescence with precocious pseudopuberty 
and females presenting in midlife with hirsuitism, oligoamenorrhoea, and infertility. 
Biochemically, CRD has been diagnosed through the assessment of urinary cortisol and 
cortisone metabolites, such as measuring the ratio of tetrahydrocortisol (THF) plus 5α-THF 
to tetrahydrocortisone (THE) (Figure 1.19). In CRD patients the ratio is typically lower than 
0.1 (reference range 0.7–1.2) (Tomlinson et al., 2004). Previous cases of CRD and ACRD 
were discussed in more detail in Section 1.6. Recent work in our group has highlighted two 
cases of hyperandrogenism which could potentially be caused by defective 11β-HSD1 
activity. 
3.1.1. Urinary steroid metabolite analysis 
The two cases (A and B) presented with hyperandrogenism and premature pseudopuberty. 
Measurement of cortisone and cortisol metabolites in the urine of both case A and case B 
indicated abnormally low activity of 11β-HSD1 (Figure 3.1A & B).  Thus a low 
(THF+5αTHF)/THE ratio was observed in case A (0.26) and B (0.16); both cases were lower 
than age- and sex-specific reference cohorts. The ratio of cortols to cortolones, which also 
reflects secondary metabolism of cortisol and cortisone respectively, was also low when 
compared to age- and sex-specific reference cohorts (Figure 3.1B). In addition, absolute 
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levels of the metabolites of cortisol and cortisone were analysed (µg/24 h). While the 
metabolites of cortisol were low to normal, the metabolites of cortisone were extremely 
elevated compared to age- and sex-specific reference cohorts (Figure 3.1B), again in keeping 
with a block in 11β-HSD1-mediated cortisone to cortisol conversion.  Thus in both cases 
there were indications of a mild form of cortisone reductase deficiency (CRD), a syndrome 
previously associated with mutations in the gene encoding the cofactor-regenerating enzyme 
H6PDH. All urinary analyses were performed by Dr G.A Lavery and results reproduced here 
with his kind permission. 
3.1.2. Molecular analysis of H6PD and HSD11B1 genes 
No mutations were identified in H6PD.  However, sequencing of HSD11B1 revealed two 
novel sequence variants in cases A and B, one each in the heterozygous state, which were not 
detected in 120 control (i.e. normal) chromosomes. Case A was heterozygous for a 
maternally inherited c.409C>T mutation in exon 4 generating an arginine to cysteine 
missense mutation (R137C) (Figure 3.1C). Case B was heterozygous for a c.561G>T 
mutation in exon 5 generating a lysine to asparagine missense mutation (K187N) (Figure 
3.1C). All molecular analysis was performed by Dr E.A Walker and results reproduced here 
with her kind permission. 
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Figure 3.1.  Urinary steroid analysis and molecular genetic assessments of cases A and B. A - Schematic 
representation of the interaction between 11β-HSD1 and H6PDH. H6PDH generates NADPH, enabling 11β-
HSD1 ketoreductase activity to convert cortisone (E) to cortisol (F). Cortisone and cortisol are metabolized by 5α- 
and 5β- reductases to produce THE and 5α-THF and THF respectively. 20α- and 20β-HSDs further metabolize 
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these to cortolones and cortols. These metabolites are detectable in urine and serve as biomarkers of 11β-HSD1 
activity. B- Normal ranges for urinary steroid analysis are depicted as box-and-whisker plots and were 
determined using sex and age specific normal cohorts, which for the purposes of this report are drawn from a 
cohort of males between the ages of 10 and 16 years of age. Box-and-whisker plots describe the smallest 
observation (bottom ‘whisker’), lower quartile, median (middle line), upper quartile and largest observation (top 
‘whisker’) of the cohort. It can clearly be seen that both case A () and case B () have a low 5α-THF + 
THF/THE ratio, low cortols/cortolones ratio, low total cortisol metabolies and high total cortisone metabolites. All 
of which is indicitive of a block in 11β-HSD1 reductive activity. C- HSD11B1 gene mutations in CRD cases A and 
B. Pedigrees for each case are shown with the affected male being the filled square with unaffected parents and 
siblings shown by unfilled shapes. The gene structure for HSD11B1 is shown as filled boxes for exons and 
intervening lines as introns. A sequencing trace is shown indicating the affected nucleotide. The position and 
alteration at the nucleotide and protein levels are given above each trace. The heterozygous nature of the 
mutations are shown by the double peak underneath the red arrow. The position of the K187N missense 
mutation relative to the highly conserved YxxxK catalytic motif is shown below the gene schematic. (Images used 
with kind permission of Dr E. A. Walker.) 
 
3.1.3. Functional analysis of HSD11B1 mutations 
Sequence alignments indicate that R137 and K187 are strictly conserved within 11β-HSD1 
proteins from different species (Figure 3.2A & B). K187 is strictly conserved within the short 
chain dehydrogenase/reductase (SDR) family as a whole, being part of the core catalytic 
tetrad of Asn, Ser, Tyr and Lys required for enzyme activity (Filling et al., 2002).  
Examination of the position of R137 in crystal structures of 11β-HSD1 (PDB entries 2BEL, 
2IRW, 3FCO, 1XU7, and 1XU9) reveals a potentially vital role in dimerization of the 
enzyme via the formation of a salt bridge between R137 on one subunit with E141 on the 
opposing subunit, with the importance of this interaction discussed in Section 1.6. It seems 
reasonable to propose therefore that disruption of these strong interactions would hinder 
subunit-subunit binding and compromise dimer formation and stability. 
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Figure 3.2. The structural importance of the 11β-HSD1 mutations R137C and K187N. (A) Alignment showing 
the strict conservation of R137 (marked with *) in 11β-HSD1 protein sequences from different species. R137 
interacts to form a salt-bridge with conserved residue E141 (underlined on the alignment) on the opposing 
subunit. (B) Alignment showing the conservation of K187 (marked with *) across species. K187 forms part of the 
catalytic tetrad, which includes the adjacent residues Tyr183 and Ser170 (both underlined in the alignment). (C) 
A ribbons representation of the crystal structure of the 11β-HSD1 dimer (PDB code: 2bel, chains A and B) 
showing the salt bridges between R137 and E141 on the αE helices of opposing subunits. R137 and E141 are 
represented in ball-stick format coloured by heteroatom. (D) A closer view of the side-chain interactions between 
the two pairs of R137and E141 residues at the subunit interface of 11β-HSD1 (PDB code: 2bel, chains A and B), 
showing the close interaction (<4Å) between the heavy atoms. The salt-bridges are of the fork-fork class (Folch 
et al., 2008) in this structure, although other 11β-HSD1 crystal structures show the fork-stick type.  These 
interactions may promote correct orientation of the subunits during dimer formation in addition to stabilizing the 
final assembly. The position of K187 is shown in Figure 1.29. Structural images produced using UCSF Chimera 
from the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco 
(supported by NIH P41 RR-01081) (Pettersen et al., 2004).  Distances calculated between nitrogen and oxygen 
atoms are shown in Å.
A B 
C D 
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3.1.4. Expression in mammalian cells 
To further address the functional consequence of these mutations, the R137C and K187N 
mutants were stably expressed in vitro in HEK-293 cells and 11β-HSD1 enzyme activity 
measured by the conversion of cortisone to cortisol within the intact cells. HEK-293 cells 
mock-transfected with empty vector had no detectable activity (Figure 3.3A). Upon 
transfection with WT 11β-HSD1 robust activity was seen; however, when cells were 
transfected to similar levels (as evidenced by similar mRNA expression; Figure 3.4B) with 
the two mutant 11β-HSD1 constructs, approximately 5% of WT activity for R137C and no 
activity from the K187N mutant was detected (Figure 3.3A). Western blot analyses of total 
lysates from these cells indicated that, compared to WT, low levels of 11β-HSD1 protein 
accumulated from the R137C mutant (Figure 3.3C), whilst the K187N construct was capable 
of producing some 11β-HSD1 protein, although it was clearly inactive. All mammalian 
expression analysis was performed by Dr E.A Walker and results reproduced here with her 
kind permission 
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Figure 3.3. 11β-HSD1 ketoreductase activity, mRNA levels, and protein expression from homodimers 
expressed in stably transfected HEK293 cells (A) 11β-HSD1 enzyme activity assays in HEK 293 cells mock or 
stably transfected with the WT and mutant cDNA constructs expressed as pmol cortisol produced / mg of protein 
/ h (mean ±SE). Mock treated cells had no 11β-HSD1 ketoreductase activity; Activity in cells transfected with WT 
11β-HSD1 was 53.1±3.1 and 4.1±0.4 for the R137C mutant. No ketoreductase activity was detectable for the 
K187N mutant. (B) Real time- PCR assessment of HSD11B1 gene expression in stably transfected clones 
compared to mock transfected controls indicating over expression of HSD11B1 mRNA in transfected lines 
(expressed in arbitrary units, A.U.). (C) Western Blot analysis of whole cell extracts from HEK 293 transfected 
cells. High levels of WT protein was produced with significantly lower levels from the R137C and K187N mutants. 
(Images used with kind permission of Dr E. A. Walker). 
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3.1.5. Hybrid dimers 
To complement the work performed on mammalian cells, this chapter will investigate the 
effect of the two novel 11β-HSD1 mutations (R137C and K187N) on both protein expression 
and enzyme activity using the recombinant bacterial expression system described in Chapter 
2. However, both cases of CRD were in the heterozygous state. In order to investigate the 
heterozygous nature of the cases, the construction of a novel in vitro system which results in 
the purification of a recombinant 11β-HSD1 heterodimer has been developed. In this system, 
one monomer contains, in addition to the F278E mutation described in Chapter 2, either the 
R137C or K187N mutation. The other monomer will only contain the F278E mutation. This 
technique of creating in vitro hybrid dimers has been described previously for both the 
dimeric E.coli biotin carboxylase (Janiyani et al., 2001) and caspase-7 (Denault et al., 2006). 
Biotin carboxylase is a key enzyme involved in fatty acid synthesis and exists as a 
homodimer with each monomer containing a functional active site (Janiyani et al., 2001). In 
order to elucidate how each subunit contributes to the overall function of biotin carboxylase 
Janiyani et al. (2001) created a heterodimeric protein in which one monomer contained a 
mutation known to significantly decrease enzyme activity, while the other monomer 
contained no mutation (WT). To aid purification, mutant monomers contained an N-terminal 
His6-tag while WT monomers contained an N-terminal FLAG-tag. Expression of both 
proteins from a single plasmid, with subsequent purification using sequential 
chromatographic steps (immobilized nickel chelate followed by an anti-FLAG affinity 
matrix) yielded pure heterodimeric biotin carboxylase (Janiyani et al., 2001). When assayed 
both in vitro and in vivo, the presence of mutant monomer in heterodimeric biotin 
carboxylase showed a dominant negative effect with a 285-fold decrease in activity (Janiyani 
et al., 2001). This indicated that both subunits are required for activity and that the two 
subunits of biotin carboxylase must be in communication during enzyme function (Janiyani et 
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al., 2001). These findings have now been supported by a numerical simulation of the biotin 
carboxylase mechanism which has suggested that the two active sites of the enzyme alternate 
their catalytic cycles (de Queiroz and Waldrop, 2007). A similar system has been used to 
investigate the mechanism of dimerization in caspase-7. Caspase-7 is a cytosolic protease 
involved in apoptosis, with the protein consisting of one large and one small domain joined 
by a small region known as the interchain connector. In order for caspase-7 to be active, the 
protein is cleaved in the interchain connector region, which results in formation of the active 
homodimer (Figure 3.4) (Denault et al., 2006). However, it was not known whether this 
dimerization was via simple association of C-terminal regions or via interdigitation (Figure 
3.4).  In order to investigate this, Denault et al. (2006) constructed a system in which C-
terminal His6-tagged proteins containing either WT, R233A or C186A/R233A mutations 
were coexpressed with C-terminal FLAG-tagged WT proteins with the resulting hybrid dimer 
purified and assayed for activity (Figure 3.4). Since caspase-7 activity is dependent on the 
presence of both Cys186 and Arg233, they should be able to complement each other if 
provided individually on the separate units of a dimer if the interdigitation model is correct 
(Figure 3.4). Since the activity results matched those expected from a direct dimerization, it 
was concluded that no interdigitation took place (Denault et al., 2006). 
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Figure 3.4. The construction of hybrid dimers has shown that the active caspase-7 dimer does not form 
by interdigitation. Caspase-7 consists of one large and one small domain joined by a small region known as the 
interchain connector. Cleavage of the protein in the interchain connector region results in formation of the active 
homodimer. A – Schematic representation of the different caspase-7 mutants. ∆N represents a N-terminally 
deleted caspase-7. This N-terminal deletion allowed the different protein constructs to be distinguished on the 
basis of size and therefore allowed Denult et al. to elucidate which large subunit came from which precusor (i.e. 
FL or  ∆N). B – The possible heterodimers which will be formed. WT residues are shown in white, while mutant 
residues are shown in black. Enzyme is only active when two unmutated (white) residues come together. 
Theoretical activity is shown in percent. C – The activity of the purified heterodimers. Since the measured activity 
matches the theoretical activity of the direct dimerization model (B), it was concluded that this is the correct 
method of dimerization. Image taken from Denault et al. (2006). 
 
In contrast to the studies described above, which labelled one monomer with a poly-His tag 
and the other with a FLAG tag, in this study one monomer of 11β-HSD1 has been labelled 
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with a poly-His tag but the other with a Strep-tag due to the high level of purification this 
system can achieve. Using this system the possible dominant negative effects of the CRD 
causing mutations R137C and K187N will be analysed. 
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3.2. Materials and Methods 
3.2.1. Cloning and Expression of Recombinant 11β-HSD1 
The R137C and K187N mutations were introduced into a bacterial expression construct of 
the human 11β-HSD1 protein encoding residues 24-292 with or without F278E mutation 
described previously (Chapter 2) using Quick-change site-directed mutagenesis (Stratagene, 
La Jolla, CA). The F278E human 11β-HSD1 construct was then cloned from the existing 
pET-28b(+) (Novagen) vector into pET-51b(+) (Novagen) using BamHI and HindIII. The 
pET-51b(+) plasmid encodes an N-terminal Strep tag to aid purification, a F1 ori and 
ampicillin resistance. Three different bacterial expression constructs of the human 11β-HSD1 
protein encoding residues 24-292, the single mutant F278E and the double mutants 
F278E/R137C and F278E/K187N, were cloned from their respective existing pET-28b(+) 
(Novagen) vectors into separate pRSF-1b (Novagen) vectors using BamHI and XhoI. The 
pRSF-1b plasmid encodes an N-terminal His6-tag to aid purification, a RSF ori and 
kanamycin resistance. A summary of the different plasmids used throughout this text is 
shown in Table 3.1. 
Plasmid Promoter Ori Tag Antibiotic 
Resistance 
Copy 
Number 
pET-28b(+) T7 F1 Poly-Histidine Kanamycin ∼ 40 
pET-51b(+) T7 F1 Streptavidin Ampicillin ∼ 40 
pRSF-1b T7 RSF Poly-Histidine Kanamycin > 100 
pBAD-ESL PBAD pBR322 - Ampicillin Low 
pAJW-3 PBAD pBR322 - Chloramphenicol Low 
Table 3.1. Plasmids used for the expression of 11β-HSD1 and chaperonins throughout this thesis. Copy 
number was estimated based on gel analysis (Sektas, 2002, Held, 2003). pAJW-3 was derived from pBAD18Cm 
(Guzman et al., 1995). 
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After sequence verification, constructs were used individually or in combinations, to 
transform the BL21(DE3) E.coli expression strain (Novagen). Cells were co-transformed 
with the pAJW-3 plasmid (gift of Dr P Lund (Walker, 2000)), which contains the genes for 
the E.coli chaperonins GroEL/ES on the pBAD promoter and also for chloramphenicol 
resistance. For the expression of the 11β-HSD1 constructs, cells were grown with shaking 
(220rpm) in LB broth supplemented with either 30 µg ml-1 kanamycin (pRSF-1b and pET-
28b(+)) or 50 µg ml-1 ampicillin (pET-51b(+)) in addition to 50 µg ml-1 chloramphenicol at 
37 oC. Cells containing all 3 plasmids were grown on LB broth supplemented with 30 µg ml-
1 kanamycin, 50 µg ml-1 ampicillin and 50 µg ml-1 chloramphenicol. Arabinose (0.02% w/v) 
was added to the cultures at an A600 of 0.8-1, in order to induce the expression of the 
chaperonin proteins.. Cells were grown with shaking for 1 h at 37 °C, before addition of 
isopropyl- β-D-thiogalactoside (IPTG, 1 mM). The 11β-HSD inhibitor carbenoxolone (CBX, 
0.1 mM) was also added at this stage. Following a further incubation of 30 min at 37˚C, 
cultures were transferred to 15˚C and grown with shaking for 16 h.  
3.2.2. Purification of HIS6-tagged 11β-HSD1 
Cells were pelleted (3000 × g, 15 min) and then resuspended in Bugbuster reagent (Novagen) 
containing protease inhibitors (Mini-Complete EDTA free, Roche Molecular Biochemicals) 
and Benzonase DNase (Novagen). Cells were incubated with shaking at room temperature for 
40 min, then cell debris was pelleted at 38,000 × g for 30 min at 4˚C. Supernatant was loaded 
onto a His-Select  (Sigma Aldrich) column and washed with buffer containing 25 mM 
sodium phosphate, 300 mM NaCl, 5% glycerol, 10 mM imidazole and 0.005% Anapoe X-
100 (Anatrace Inc), pH 8.0. Protein was then eluted with 3 volumes of buffer containing 175 
mM imidazole. Fractions containing protein were separated by size-exclusion 
chromatography on a Superdex-200 HR10/30 column (Pharmacia) running at 0.4ml min-1 in 
25 mM sodium phosphate, 5% (v/v) glycerol, 0.005% (v/v) Anapoe X-100, pH 8.0. 
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3.2.3. Purification of Strep-tagged 11β-HSD1 
Cells and cell debris were pelleted as per His6-tagged protein (above). Supernatant from 
38,000 ×  g spin was loaded onto a Strep-Tactin Superflow Column (Novagen) and washed 
with buffer containing 25 mM sodium phosphate, 300 mM NaCl, 5% glycerol, 10 mM 
Imidazole and 0.005% Anapoe X-100 (Anatrace Inc), pH 8.0. Protein was then eluted with 6 
volumes of buffer containing 2.5 mM desthiobiotin, a reversibly binding analogue of biotin. 
Fractions containing protein were separated by size-exclusion chromatography as per His6-
tagged protein.  
3.2.4. Estimation of protein concentration 
Due to the presence of a high concentration of detergent in all samples in this chapter, the 
amount of protein in a given sample was measured using the enhanced BCA method (Pierce) 
(Smith et al., 1985). In this method, a standard amount of sample (100 µl) was mixed with 2 
ml of BCA working reagent (50:1, BCA Reagent A: Reagent B) in a test tube and incubated 
at 60 °C for 30 minutes. Tubes were then cooled to room temperature with the resulting 
absorbance read at 562 nm. Standard curves were constructed using known amounts of BSA. 
3.2.5. Purification of 11β-HSD1 heterodimers 
BL21(DE3) cells containing pET-51b(+):F278E, pAJW3 and either pRSF-1b:F278E, 
F278E/R137C or F278E/K187N were purified as per His6-tagged 11β-HSD1. The protein 
concentration in samples was quantified and they were diluted to a final protein concentration 
of 0.04 mg ml-1 and left for 15 h at 15˚C in a buffer containing 25 mM sodium phosphate, 
300 mM NaCl, 5% glycerol, 10 mM imidazole and 0.005% Anapoe X-100, pH 8.0. Sample 
was then loaded onto a His-Select column and eluted as per purification of HIS6-tagged 
protein. The protein concentration in samples was once again quantified and samples diluted 
to a final protein concentration of 0.04 mg ml-1 and left for 15 h at 15˚C in the above buffer. 
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Sample was then loaded onto a Strep-Tactin Superflow Column (Novagen) and eluted as per 
Strep-tagged protein. Neither tagged construct bound to the heterologous affinity column, as 
long as 10 mM imidazole was included in the wash buffer. 
3.2.6. Measurement of 11β-HSD1 activity 
Activity of 11β-HSD1 was assayed as per section 2.2.3. 
3.2.7. Western Blot Analysis 
Western blots were prepared by electro-blotting 11% SDS-polyacrylamide gels onto 
Immobilon PVDF membranes (Millipore) at 100 V for 1 h, in a buffer containing 25 mM 
Tris, 200 mM glycine and 20% (v/v) methanol. SDS-PAGE was performed using the method 
of Laemmli (1970).  Non-specific protein binding to membrane was blocked in PBS 
containing 0.1% (v/v) Tween-20 and 20% (w/v) skimmed milk powder, washed, and then 
incubated with either an anti-HIS, anti-STREP, or anti-11β-HSD1 polyclonal antibody 
(Binding Site) diluted 1/1000 in PBS containing 0.05% (v/v) Tween-20. Membrane was then 
washed and incubated with secondary antibody (peroxidase-conjugated goat anti-sheep 
antibody for 11β-HSD1 or peroxidase-conjugated goat anti-mouse antibody for HIS or 
STREP) diluted 1/25,000 in PBS containing 0.05% (v/v) Tween-20. Detection was by 
enhanced chemiluminescence (Amersham Biosciences, Bucks, UK) and band intensities were 
quantified using ImageMaster 1D (Amersham Biosciences).  Standards with known amounts 
of 11β-HSD1 protein were included on each blot. 
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3.3. Results 
3.3.1. Expression and purification of recombinant 11β-HSD1 homodimers using the 
pET-28b(+) vector 
In order to obtain more accurate kinetic data for the CRD causing mutations when compared 
to expression in HEK-293 cells, the R137C and K187N mutations were introduced into the 
recombinant E.coli system outlined in Section 2.2.1. Expression of the R137C and K187N 
mutants in the wild type protein background did not yield any soluble protein in this system 
(Figure 3.5a). In Section 2.3, it was shown that a single point mutation, F278E, to the C-
terminus of 11β-HSD1 could increase solubility of recombinant protein while not adversely 
affecting activity. Although expression of the active site mutant K187N in the human F278E 
background did not yield any soluble protein expression of the R137C mutation in the human 
F278E background did result in soluble protein, albeit with an 80% reduction in protein yield 
(Figure 3.5b). Kinetic analysis of the R137C/F278E mutant showed a pronounced reduction 
of the kcat of the enzyme from 1.27 ± 0.03min-1 to 0.48 ± 0.02min-1 for the dehydrogenase 
reaction and 0.31 ± 0.01min-1  to 0.09 ± 0.01min-1 for the reductive reaction (compared to the 
F278E control). The R137C mutation had little effect on the Km of the enzyme showing a 
small decrease in the dehydrogenase direction (6.16 ± 0.44µM to 4.82 ± 0.62µM) and a small 
increase in the reductive reaction (10.61 ± 1.49µM to 15.42 ± 5.93µM). Since soluble protein 
could only be obtained for the R137C mutant with the inclusion of the F278E mutation, this 
F278E background was therefore used for all experiments in this chapter. 
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Figure 3.5. SDS-Page analysis of expression in E.coli of the human 11 β -HSD1 mutants (R137C and 
K187N) in both wild-type (A) and F278E (B) backgrounds.   A - Insoluble (pellets) and soluble (supernatant) 
fractions from lysates of cultures expressing R137C and K187N mutants in the wild-type background. Expression 
levels of both recombinant proteins were low and neither mutant was expressed in a soluble form. B - Insoluble 
(pellets) and soluble (supernatant) fractions from lysates of cultures expressing the double mutants 
R137C/F278E and K187N/F278E. Arrows indicate position of the recombinant proteins. Although the protein 
produced was still largely insoluble, some soluble protein was evident in the supernatant for the F278E/R137C 
mutant. 
 
3.3.2. Expression and purification of recombinant 11β-HSD1 homo-oligomers using 
pRSF-1b and pET-51b(+) vectors 
In order to investigate the potential dominant negative effects of the CRD-causing mutations 
R137C and K187N on 11β-HSD1 activity, a recombinant system using two different 
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plasmids which express 11β-HSD1 was constructed. The previously used pET-28 plasmid 
could not be used as it was not suitable for dual expression analysis. Firstly, the human 11β-
HSD1 F278E construct was cloned from the pET-28b(+) plasmid into a new plasmid, pET-
51b(+), which encodes an N-terminal Strep tag, a F1 ori and ampicillin resistance. This 
plasmid was transformed into the BL21(DE3) E.coli expression strain along with the 
GroEL/GroES encoding plasmid, pAJW3. Protein was then purified as per Section 3.2.3. 
SDS-PAGE analysis of the Strep-Tactin Superflow chromatography is shown in Figure 3.6. 
After subsequent purification by gel filtration, the resulting human pET-51b(+) F278E homo-
oligomer had the same kcat and Km for cortisol as the pET-28b(+) homo-oligomer construct 
described previously, although, it is worth noting that the yield of soluble protein was lower 
than with the pET28(+) construct.  
 
 
Figure 3.6. SDS-PAGE of the purification of the pET-51b(+) 11β-HSD1 F278E construct via the Strep-
Tactin Superflow column. Fractions were eluted with 2.5 mM desthiobiotin. Eluted fractions containing protein 
were subsequently purified via gel filtration. S=supernatant applied to column; W=wash; F=flow-through; 
E=successive fractions (0.5 ml) eluted with desthiobiotin. The position of 11β-HSD1 is shown by the black arrow. 
 
Three different bacterial expression constructs encoding the human 11β-HSD1 protein 
(containing residues 24-292), the single F278E mutant and the double mutants F278E/R137C 
and F278E/K187N, were cloned from their respective existing pET-28b(+) vectors into 
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separate pRSF-1b vectors which encode an N-terminal His6-tag, a RSF ori and kanamycin 
resistance. These plasmids were transformed into the BL21(DE3) E.coli expression strain 
along with the GroEL/GroES encoding plasmid, pAJW3. Protein was then purified as per 
Section 3.2.2.  Like the pET-51b(+) construct, after subsequent purification by gel filtration, 
the resulting human pRSF-1b F278E homo-oligomer had the same kcat and Km for cortisol as 
the pET-28b(+) homo-oligomer construct described previously. Interestingly, the yield of 
soluble protein for this construct was also lower than the pET28(+) construct.  
Introduction of the gene for K187N into pRSF-1b resulted in a complete absence of any 
soluble protein, while the equivalent R137C/F278E construct yielded 6 times less soluble 
protein than F278E (Figure 3.7). The yield of total protein (soluble+insoluble) was not 
significantly affected by the mutations.  Thus both mutations drastically affected either 
subunit folding or dimer assembly/stability in this expression system. The R137C mutant 
protein also showed a small decrease in turnover rate (kcat), although there was no significant 
change in Km (Figure 3.7). This is in agreement with the studies using pET-28 constructs and 
parallels the results obtained from the mammalian expression system (Figure 3.4). Using 
AUC, the R137C/F278E mutant protein was observed to exist in a similar dimer/tetramer 
equilibrium to the background F278E protein (Figure 3.8).  
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Figure 3.7. Yield of soluble protein and kinetic parameters of homo-oligomers of 11β-HSD1 in the 
bacterial expression system. (A) Yield of soluble, purified, 11β-HSD1 protein. Values are given in mg of protein 
purified per litre of LB broth.  Bars represent SEM. (B) Turnover rates (kcat) for the conversion of cortisol to 
cortisone. The decrease observed for the R137C/F278E mutant is statistically significant (p<0.05). No data are 
available for the K187N/F278E mutant, because no soluble protein was produced. (C) Km values for cortisol for 
F278E and mutant proteins. The increase observed for the R137C/F278E mutant when compared to F278E is 
not statistically significant. No data are presented for the K187N/F278E mutant, because no soluble protein was 
produced. Bars represent SEM. 
134 
Figure 3.8. AUC analysis of the aggregation states of the R137C/F278E protein when expressed in the 
pRSF-1b vector. The mutant protein showed a main peak at 130kDa, in addition to a second major peak at 
65kDa, indicating the majority of protein existed as tetramer with a lesser amount as a dimeric protein. This 
shows that the protein exists in a similar dimer/tetramer equilibrium to the background F278E protein illustrated 
previously (Figure 2.5). Images were produced using SedFit (Schuck 2000) with density, viscosity and v-bar 
measurements calculated by Sednterp. Human and guinea pig v-bar measurements were 0.7405 and 0.7391 
respectively. The buffer had a density (P) value of 1.016 and viscosity (H) value of 1.18 E-2. 
 
3.3.3. Analysis of 11β-HSD1 hetero-oligomers in cleared lysates of bacterial cells 
In order to fully investigate the effects of the R137C & K187N mutations on heterodimer 
formation and activity, bacterial cells were simultaneously transformed with both the pRSF-1 
and the pET-51 plasmids, with one vector containing F278E 11β-HSD1 and one containing 
the F278E Construct carrying either the R137C or K187N mutant. The effect of this dual 
expression of F278E and mutant (R137C/F278E or K187N/F278E) constructs was initially 
estimated by assaying total enzyme activity, and relative amounts of His/Strep tag, in cleared 
lysates of the bacterial cells (Figure 3.9). When both plasmids contained the F278E construct, 
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the pET-51 plasmid expressed more soluble protein than pRSF-1, as evidenced by a higher 
level of Strep-tagged than His-tagged protein when quantified by Western blotting (Figure 
3.9B).  This could be due to either greater promoter efficiency or higher copy number of 
pET-51. When the R137C or K187N mutations were present in the pRSF-1 F278E plasmid, a 
decrease in total enzyme activity of 40-50% was observed (Figure 3.9A). There was also a 
significant reduction (by 55-65%) in the amount of mutant polypeptide found in the soluble 
fraction, although the level of soluble F278E subunit (from pET-51) was much less affected 
(Figure 3.9B). A greater decrease in enzyme activity, of 85-95%, was observed in the reverse 
situation, when the mutants were present in the pET-51 plasmid with pRSF-1 expressing 
F278E protein (Figure 3.9A). This was accompanied by a substantial decrease in the amount 
of both F278E and mutant polypeptide in the soluble fraction (Figure 3.9B). This suggested 
that in this situation, due to the greater amount of mutant protein produced by the pET-51 
plasmid, more F278E monomers were interacting with mutant monomers and forming 
unstable/insoluble heterodimers, or other complexes, and hence the reduction in enzyme 
activity.  
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Figure 3.9. Effect of co-expression of mutant and F278E 11β-HSD1 constructs in E.coli.. (A) Specific 
enzyme activity of cleared lysates of bacteria transformed with two plasmids: - pET-51 encoding a Strep-tagged 
protein, and pRSF-1 encoding a His6-tagged protein.  Enzyme activity was measured in the dehydrogenase 
direction (conversion of cortisol to cortisone) at saturating (128 µM) substrate concentrations. NADP(H) 
concentration was 200 µM. Expression of the mutants (R137C or K187N) from the pRSF1 plasmid resulted in a 
decrease in enzyme activity, but the decrease was much greater when the mutants were in pET-51. (B) Western 
blot densitometry analysis of relative concentrations of His- and Strep-tags in cleared bacterial lysates.  
Expression of either mutant caused a reduction in both mutant and wild-type polypeptides found in soluble form, 
but the effect was greater when the mutants were in pET-51.  Note the greater expression of Strep-tagged 
protein driven by pET-51, compared to His-tagged from pRSF-1, in the F278E/F278E control. 
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3.3.4. Purification and kinetic analysis of 11β-HSD1 heterodimers 
In order to elucidate the true effect of both the R137C and K187N mutants on heterodimer 
formation and activity, a protocol was developed to purify mutant/WT heterodimers from the 
bacterial lysates. The procedure exploited the different N-terminal tags on the different 
constructs, which meant that addition of lysate to a His-column with eluted protein applied to 
a subsequent Strep-column would theoretically isolate pure hybrid dimeric protein. However, 
several problems exist in this idealised experimental procedure for the isolation of a hybrid 
dimer. Firstly, the experiment assumes that no exchange of monomeric subunits between 
dimers occurs during the experiment. Secondly, the concentration dependent equilibrium of 
the human 11β-HSD1 mutant F278E between dimeric and tetrameric species could lead to a 
mix of species which could influence correct binding (Figure 3.11A). Both of these problems 
were tested by a control experiment in which an equal amount of homodimeric His-tagged 
F278E (2 mg) and homodimeric Strep-tagged F278E (2 mg) were mixed, diluted to 0.04 mg 
ml-1and left to equilibrate for 15 h at 15˚C. The mix of protein was then applied to a His-
select column. Protein assay showed that 2mg of protein was present in the flow-through with 
1.7 mg of protein bound to the His-resin.  The 1.7 mg of eluted protein was then diluted, left 
to equilibrate (as per His-select column) and applied to the Strep-Tactin Superflow column.  
Protein assay showed that 0.03 mg of protein bound to the Strep-resin with 1.4 mg of protein 
present in the flow-through. SDS-PAGE analysis confirmed the only protein assayed was 
11β-HSD1 (Figure 3.10). The correct stoichiometric binding of His-tagged protein to the 
HIS-Select column and subsequent lack of binding to the Strep-Tactin Superflow column 
indicates that, with the large dilution step, 11β-HSD1 is present as a dimeric species when 
applied to both columns. It can also be concluded that there was no exchange of monomeric 
subunits between dimers for the timescale of the experiment. The protocol for the purification 
of hybrid dimers is outlined in Figure 3.11. Following the procedure, the presence of true 
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heterodimers was additionally confirmed by analysis of the relative proportions of His and 
Strep tags by standardised Western blots. All purified preparations showed equal levels of the 
two tags (Figure 3.12), as expected for true heterodimers 
 
 
Figure 3.10. SDS-PAGE demonstrating that, with a dilution step, no aggregation of 11β-HSD1 dimers 
occurs. An equimolar mix of homodimeric His-tagged F278E and homodimeric Strep-tagged F278E were mixed, 
diluted, left to equilibrate and applied to a His-Select column. The gel shows that around half the protein applied 
bound to the resin. When this bound protein was eluted, diluted, left to equilibrate and applied to a Strep-Tactin 
Superflow column, no protein bound to the resin. The gel also shows that there was no exchange of monomeric 
subunits between dimers for the timescale of the experiment. FT=Flow through concentrated to 0.5ml. 
E=successive fractions eluted with imidazole. S=successive fractions eluted with desthiobiotin. An arrow 
indicates the position of 11β-HSD1. 
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Figure 3.11. An illustration of the purification strategy for the production of hybrid dimer human 11β-
HSD1. His6-tagged proteins are shown in blue, with Strep-tagged proteins shown in green. E.coli is transformed 
with two plasmids which can express a combination of F278E-F278E homodimers, F278E-R137C/F278E 
heterodimers and R137C/F278E-R137C/F278E homodimers. After a dilution step, the initial purification, using a 
His-select column, will bind only WT-R137C heterodimers and R137C-R137C homodimers. The second 
purification using a Strep-Tactin Superflow column, once again after a dilution step, will bind only the WT-R137C 
heterodimers, as the R137C-R137C homodimers do not contain a Strep-tag. This process will also be used to 
purify the human 11β-HSD1 heterodimer WT-K187N. Western blot analysis of the samples assayed confirmed 
that the purification procedure detailed here yielded samples which contained an approximate 50:50 mix of His 
and Strep-Tags indicating hybrid dimers were the species assayed (Figure 3.12). 
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Figure 3.12. Western blot analysis of the hybrid dimers of 11β-HSD1 purified from the bacterial 
expression system. (A) Western blot of the samples analysed in Table 3.1.  Anti-His and anti-Strep antibodies 
were used to detect the two different monomers in the purified heterodimers. (B) Densitometry estimation of 
concentrations of His- and Strep-tags in the purified heterodimers.  The intensity of bands in (A) was analysed 
and used to calculate the protein amount (ng) present on the blots.  The results confirmed that, for all samples, 
there was an equal amount of Strep and His tagged protein on the blot, in agreement with the production of 
hybrid dimers.  
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The F278E-F278E hybrid dimer had unchanged kcat and Km when compared to either the 
pET-51b or pRSF-1b F278E homo-oligomer (Figure 3.5 & Table 3.2). However, the yield of 
soluble protein has decreased significantly. This is perhaps not surprising as a certain amount 
of non-specific binding would be expected at each stage of the purification procedure shown 
in Figure 3.11. The F278E-R137C/F278E hybrid dimer showed a slight reduction in kcat with 
a pronounced reduction in yield compared to the F278E-F278E hybrid dimer (Table 3.2). 
Interestingly, the 75% reduction in yield and 20% reduction in kcat for the F278E-
R137C/F278E hybrid dimer is highly similar to the 80% decrease in yield and 15% decrease 
in kcat observed when homo-oligomeric pRSF-1b R137C/F278E is compared to pRSF-1b 
F278E homodimer (Figure 3.5). This is highly suggestive that the deleterious effects on 
subunit folding or dimer assembly/stability of the R137C mutation in one monomer, can 
affect the activity of other, fully active monomer. The F278E-K187N/F278E hybrid dimer 
showed a similar 75% decrease in yield compared to F278E-F278E; however the protein 
produced was inactive (Table 3.2). Once again, this suggests that the deleterious effects of the 
K187N mutation, in this case inactivity, will knock out activity of the active F278E 
monomer, leading to an inactive 11β-HSD1 protein. 
 
 
 
 
 
 
 
 
 
142 
 
Construct    
pRSF-1 
(His tag) 
pET-51 
(Strep tag) 
 
Yield (mg l-1) 
 
kcat (min-1) 
 
Km (µM) 
 
F278E F278E 0.047 ±  0.003 2.29 ± 0.17 7.62 ±  1.45 
 
R137C/F278E F278E 0.008 ± 0.001 1.73 ±  0.15 14.72 ± 2.81 
 
K187N/F278E F278E 0.008 ±  0.004 - - 
 
Table 3.2. Yield of soluble protein and kinetic parameters and for the various hybrid dimers of 11β-HSD1 
purified from the bacterial expression system. The kcat and Km values for the F278E-His/F278E-Strep 
heterodimer construct are not significantly different from the previous homodimeric F278E constructs, although 
the yield of the heterodimer is lower.  Heterodimeric R137C/F278E-F278E constructs have decreased kcat values 
and increased Km values; there is also a significant reduction in the yield of soluble protein compared to the 
F278E-F278E equivalent. Heterodimeric K187/F278E-F278E constructs have no detectable enzyme activity, in 
addition to a significant reduction in the yield of soluble protein.  Yield values are given in mg of protein per litre of 
LB broth ± SEM. Yield data is based on duplicate protein preperations with kinetic measurements reported as an 
average of duplicate measurements on each preperation.
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3.4. Discussion 
Prior to this work, deficiency in the reduction of cortisone to cortisol had previously only 
been attributed to mutations in the gene encoding H6PDH, the enzyme that supplies NADPH 
to 11β-HSD1 (Lavery et al., 2008), a condition subsequently termed Apparent Cortisone 
Reductase Deficiency (ACRD).  However this study suggests that mutations in the coding 
region of the 11β-HSD1-encoding gene itself may also be responsible in some cases, even 
when present in a heterozygous state. The HSD11B1 gene was examined in two cases 
presenting with hyperandrogenism and premature pseudopuberty, with biochemical features 
indicative of a milder form of CRD, in whom the H6PD gene was normal. Two novel 
mutations (R137C and K187N) in HSD11B1 were identified. Although the cases were only 
heterozygous for the mutations rather than homozygous it was possible that because of the 
dimeric nature of 11β-HSD1, expression of mutant subunits could in some way interfere with 
the activity of the co-expressed WT subunits i.e. the mutations could have a dominant-
negative character.  The main purpose of this chapter was therefore to address this question 
using the previously developed bacterial expression system (Walker et al., 2001a, Lawson et 
al., 2009), together with a mammalian cell expression system. 
Sequence alignment indicated that both R137 and K187 are strictly conserved within 11β-
HSD1 proteins from different species (Fig. 3.2A & B). K187 forms part of the YxxxK motif 
that is strictly conserved within the short chain dehydrogenase/reductase (SDR) family, being 
part of the core catalytic tetrad of Asn, Ser, Tyr and Lys required for enzyme activity (Filling 
et al., 2002).  In most of the SDR enzymes characterized to date, the highly conserved Tyr 
residue functions as general acid/base catalyst, while the Lys facilitates catalysis, acting as 
part of a proton relay and interacting with the nicotinamide cofactor. Site-directed 
mutagenesis of this residue in rat 11β-HSD1 resulted in complete loss of enzyme activity 
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(Obeid and White, 1992). The importance of this residue to human 11β-HSD1 activity is 
confirmed in this study; no enzyme activity could be detected when the K187N/F278E 
mutant was expressed in either mammalian or bacterial cells.  In the bacterial system, no 
soluble protein could be detected at all, indicating the probable additional importance of this 
residue to structural stability. K187 is known to ligate the 2- and 3-ribose hydroxyls of the 
nicotinamide cofactor in 11β-HSD1 (Hosfield et al., 2005), and cofactor binding may be 
essential for correct folding/stability (Figure 1.29).  
However, 11β-HSD1 is a dimeric enzyme and whilst a mutant K187N homodimer would be 
expected to be inactive the effect of heterodimer formation between wild-type and mutant 
subunits, (as could occur in heterozygous humans such as Case B), was uncertain. The two 
subunits of 11β-HSD1 are closely intertwined facilitating a close structural interplay between 
the monomers (Ogg et al., 2005, Zhang et al., 2005). It is therefore possible that the K187N 
mutation in one subunit could negatively affect the activity of an adjacent WT subunit. This 
type of effect has been reported for the enzyme biotin carboxylase where an inactivating 
mutation in the active site of one monomer of the protein had a dominant negative effect on 
the other monomer resulting in a 285-fold decrease in activity (Janiyani et al., 2001). The 
experimental evidence from the hybrid F278E-K187N/F278E dimer constructed in this study 
suggests that this is indeed the case for 11β-HSD1.  The purified heterodimer had no 
detectable enzyme activity.  However, the simultaneous expression of the K187N/F278E 
mutant had a second unexpected effect on the co-expressed F278E 11β-HSD1, in that it 
substantially reduced the yield of soluble F278E polypeptide.  It seems probable therefore 
that the mutant subunit is capable of interacting with F278E subunits to cause unstable and 
ultimately insoluble aggregates, i.e. the mutation exerts a dominant negative effect on protein 
yield as well as activity. 
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With respect to the second mutation, R137C, expression of this mutant as a homodimer in 
either mammalian or bacterial cells also resulted in a dramatic decrease in the yield of 
functional, soluble protein, coupled this time with a more minor effect on the kcat of the 
purified enzyme.  An explanation for this effect can be found in the potentially vital role of 
R137 in dimerization of the enzyme. This conserved residue forms two interfacial salt bridges 
with the similarly conserved E141 between each pair of subunits (Figure 3.2). Salt bridges, 
particularly those involving arginine, can play a prominent role in protein stability 
(Vijayakumar and Zhou, 2001, Strickler et al., 2006, Kumar and Nussinov, 2002), including 
stabilizing inter-subunit interactions (Musafia et al., 1995). In addition to this thermodynamic 
role in stabilizing protein structure it has been well established that interfacial salt bridges, by 
the long-range nature of their strong electrostatic interactions, can also have a kinetic effect 
by enhancing the diffusional encounter between two subunits, thus speeding up the 
association process and guiding the proteins to the correct docked arrangement (Vijayakumar 
et al., 1998, Gabdoulline and Wade, 2001). R137 may thus promote correct orientation of the 
subunits during dimer formation, in addition to stabilizing the final assembly. It seems 
reasonable to propose therefore that disruption of these strong interactions would hinder 
correct subunit-subunit binding and hence compromise dimer formation and/or stability.  Of 
relevance here is that an Arg-Asp salt bridge at the dimeric interface of another SDR, 3α-
hydroxysteroid dehydrogenase/carbonyl reductase, has recently been shown to be essential 
for conformational stability, oligomeric integrity and enzymatic activity (Hwang et al., 2009).  
Salt bridges may therefore be a common way in which dimer formation is promoted, and 
dimer integrity maintained, in the SDR family. 
As with the K187N mutant, co-expression of the R137C/F278E mutant with F278E 11β-
HSD1 resulted in a marked suppression of the yield of soluble protein, including F278E 
strands. Interestingly, on purifying the F278E-R137C/F278E hybrid dimer from this system it 
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showed a similar reduction in yield (ca 80%) and reduction in kcat (ca 20%) to that observed 
when homodimeric R137C/F278E was compared to homodimeric F278E (Figure 3.7). This 
implies that the deleterious effects of the R137C mutation can extend across the dimer 
interface to influence the activity of other, non-mutant, monomer.  
Once again this suggests that in the natural heterozygous situation, the negative effects of 
both the K187N and R137C mutations can extend to the normally-active ‘WT’ partner, 
leading to a marked suppression of 11β-HSD1 activity. Although further examples of the 
association of these mutations with disease would help establish causality beyond doubt, 
these dominant-negative effects help explain the condition of patients who are heterozygous 
for these mutations. True “Cortisone Reductase Deficiency” due to mutations in HSD11B1 
may thus be a further monogenic cause of hyperandrogenism/premature pseudopuberty. 
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Chapter 4. Membrane binding properties of 11β-hydroxysteroid 
dehydrogenase type 1	  
4.1. Techniques to examine the potential association of proteins with 
biological membranes 
In Section 2.3, it was shown that mutations to the surface hydrophobic residues at the C-
terminus of recombinant, N-terminally truncated 11β-HSD1 can increase yield of soluble 
protein without adversely affecting activity. It was also shown, using one of the mutants as an 
example (guinea pig F278E), that these mutations are unlikely to have any major adverse 
effects on structure compared to wild type protein. In this chapter the ability of N-terminally 
truncated human 11β-HSD1 to bind to membranes will be examined.  The effect of one of 
these mutations (F278E) on membrane binding will then be assessed. Numerous techniques 
have previously been used to examine the potential association of proteins with biological 
membranes with relevant examples discussed below. 
4.1.1. Fluorescence 
One of the most common techniques utilizes a fluorophore, which can either be intrinsic (i.e. 
a Trp residue) or artificially engineered into the protein, whose emission spectra will change 
dependent on the relative hydrophobicity of the local environment of the fluorescent species. 
For example, the removal of a Trp residue from the hydrophobic interior of the protein via 
thermal denaturation will lead to a red shifted emission spectrum (i.e. an increase in emission 
maximum wavelength) (Ostrovsky et al., 1988) while addition of detergent or membrane to a 
solvent exposed Trp will lead to a blue shifted emission spectrum (i.e. a decrease in emission 
maximum wavelength) (Neves et al., 2009) provided that the Trp residue becomes embedded 
in the hydrophobic interior of the detergent micelle or biological membrane. Due to the 
presence of a single Trp at position 263 in 11β-HSD1, which conveniently faces the exterior 
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of the C-terminal hydrophobic plateau thought to associate with membrane, it was hoped that 
decreases in the emission maximum wavelength of this residue would follow any kind of 
membrane association in this region. If both WT and F278E proteins are able to associate 
with the biological membrane, but to different amounts, any difference in the resulting 
spectrum could be interpreted as a change in the membrane binding properties of 11β-HSD1. 
A related approach to detecting membrane association and monitoring any difference in 
binding between proteins is through the use of molecules which are able to decrease the 
emission intensity of the fluorophore. These are known as quenchers. 
4.1.2. Quenching 
The differing accessibilities of quenchers to fluorophores have been used to study a wide 
range of proteins. Recently it has been used to investigate quinolone antibiotic resistance in 
the bacterial protein OmpF (Neves et al., 2009). The technique has also been used to 
investigate the membrane bound topology of helices 1 and 2 in the channel domain of the 
pore forming toxin, colicin E1 (White et al., 2006, Musse et al., 2006). In these colicin 
studies, residues which constituted two amphipathic helices thought to lie on the membrane 
surface were mutated, one by one, to cysteine. These single cysteine mutants were then 
labelled using a bimane fluorophore. The effect of either membrane-embedded (e.g.10-DN) 
or aqueous (e.g. KI) quenchers on bimane fluorescence were then compared in order to create 
a model for the membrane bound topology of these helices (Musse et al., 2006, White et al., 
2006). In order to elucidate the level of membrane association of 11β-HSD1 (WT or F278E), 
the differing accessibilities of a quencher, in this case acrylamide, to the naturally occurring 
fluorophore W263 will be used. Therefore any disruption of membrane association brought 
about by the introduction of the F278E mutation should be observed by a relatively higher 
degree of quenching compared to WT protein. 
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4.1.3. Western Blotting 
Although there were many possible approaches of detecting physical association of 11β-
HSD1 with membrane fractions (e.g. radiolabelling the protein, or monitoring enzyme 
activity),  the availability of a reliable, specific and sensitive anti-11β-HSD1 polyclonal 
antibody (Section 3.3.3) made western blotting the method of first choice.  This antibody had 
been successfully used many times before within the group (Walker et al., 2001a, Bujalska et 
al., 2008, Ricketts et al., 1998, Onyimba et al., 2006).  In addition western blotting had 
previously been used to measure the sequestration of other proteins into biological 
membranes, e.g. the binding of the signal transduction protein GlnK into the plasma 
membrane (Coutts et al., 2002, Tremblay et al., 2007). In this study the aim was to incubate 
purified recombinant 11β-HSD1 (WT or F278E) with a suspension of biological membranes. 
The membrane and soluble fractions would then be separated by ultracentrifugation and the 
amount of protein in the membrane fraction estimated by quantification of western blots. 
Therefore any disruption of membrane association brought about by the introduction of the 
F278E mutation should hopefully be evident by a decrease in intensity of the 11β-HSD1 
signal on the blots when compared to WT. 
4.1.4. Substrate association with membranes. 
Finally, the notion that two steroid substrates of 11β-HSD1, cortisone and 7-ketocholesterol, 
are able to be sequestered into biological membranes will be analysed. In Section 2.2.3 it was 
shown that cortisone can be detected using HPLC, with previous studies showing that 7-
ketocholesterol could be measured in the same way (Hult et al., 2004). Therefore in order to 
estimate the partitioning of the steroids into biological membranes, the aim was to incubate 
either cortisone or 7-ketocholesterol with a suspension of biological membranes. The 
membrane and soluble fractions will then be separated by ultracentrifugation, with the 
amount of steroid in the membrane fraction measured by HPLC. Although radioactive 
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cortisone could be used with subsequent separation by thin layer chromatography (TLC) as 
shown by Arampatzis et al. (2005), for ease of use the already established HPLC method was 
used for the steroid analysis.  It is also for this reason that the gas chromatography-mass 
spectrometry (GC-MS) technique for measuring 7-ketocholesterol outlined by Arampatzis et 
al. (2005) was not used. 
4.1.5. Choice of membrane 
In order to use the above techniques to probe the potential interaction of human 11β-HSD1 
with membrane, a suitable model for the physiologically relevant human ER membrane must 
be used. To get the clearest idea of this potential interaction, microsomes from human liver 
tissue could be utilized, but due to practical and ethical constraints experiments presented 
here will use microsomes purified from both mouse livers and human embryonic kidney 
(HEK)-293 cells. The purification of mouse liver microsomes is well documented and the 
process was in regular use in the laboratory (Lavery et al., 2006a). Due to the presence of 
native 11β-HSD1 in the mouse liver microsomes it is reasonable to assume that the 
composition of the ER membrane will be similar to human liver ER, and that our 
recombinant human 11β-HSD1 should be able to associate with them if possible. The 
presence of murine 11β-HSD1 in these microsomes should hopefully not be a problem due to 
the difference in size and charge between the full-length mouse protein which will be present 
in the microsomes, and the recombinant human protein which will be added. The purification 
of microsomes from HEK-293 cells was also in regular use within the laboratory (Lavery et 
al., 2008) and while the microsomes may perhaps not have the physiologically relevant 
composition as those from mouse livers, the absence of 11β-HSD1 in these cells may make 
interpretation of results clearer. The cell line also have the advantage of derived from human 
cells, which could perhaps lead to greater association with the human 11β-HSD1 used in this 
chapter. Both were therefore be used throughout this chapter. However, due to the presence 
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of a generally large amount of protein in microsomes from both mouse livers and HEK-293 
cells which could interfere with 11β-HSD1 fluorescence, artificial liposomes were created for 
fluorescence quenching experiments. Liposomes were created using the anionic lipid 1,2-
dimyristoyl-sn-glycero-3-phosphoglycerol (DMPG) as when in the form of a liposome, the 
lipid should have a structure relatively similar to the physiologically relevant phospholipid 
bilayer (Neves et al., 2009). 
 
152 
 
4.2. Materials and Methods 
4.2.1. Expression and purification of 11β-HSD1 
Expression and purification of both human wild-type and F278E 11β-HSD1 was carried out 
as per Section 2.2.2. 
4.2.2. Preparation of microsomes 
Mouse liver or HEK-293 cells were resuspended in a buffer containing 250 mM sucrose, 
protease inhibitors (Mini-Complete EDTA free, Roche Molecular Biochemicals) and 20 mM 
HEPES pH 7.2. Samples were homogenized using a glass homogenizer then centrifuged at 
1,000 ×  g for 10 min at 4˚C to remove large cell debris. The resulting pellet was discarded 
and supernatant was centrifuged at 12,000 ×  g for 10 min at 4˚C. Pellet was discarded and 
supernatant spun at 100,000 ×  g for 1 h at 4˚C. The resulting microsomal pellet was then 
twice washed with MOPS buffer (100 mM KCl, 20 mM NaCl, 20 mM MOPS and 1 mM 
MgCl2 pH 7.2) and recentrifuged (100,000 × g, 1 h, 4˚C). The clean pellet was then 
resuspended in MOPS buffer and flash frozen in liquid nitrogen as 50 µl aliquots. The 
amount of protein in the microsomes was estimated using the Bradford method (Bradford, 
1976) using the commercial kit from Biorad. 
4.2.3. Binding of 11β-HSD1 to microsomes 
Purified 11β-HSD1 was transferred to MOPS buffer by washing with 3 x 20 ml MOPS buffer 
using a Vivaspin 20 centrifugal concentrator. Any detergent remaining from the purification 
procedure was then removed using Extraci-Gel D (Pierce). A standard amount of 11β-HSD1 
protein (10 µg) was added to 7 ml of MOPS buffer containing either mouse liver microsomes 
or HEK-293 microsomes equivalent to around 200 µg of protein. Samples were left to 
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equilibrate with shaking (200 rpm) at room temperature for 1 h, then spun at 100,000 × g for 
1 h at 15˚C. Pellets were then resuspended in 250 µl H2O. 
4.2.4. Western blot analysis of membrane bound protein 
Resuspended pellets were mixed with 250 µl of double strength SDS-PAGE sample buffer 
(60 mM Tris-HCl pH 6.8, 4% (w/v) SDS, 10% (v/v) β-mercaptoethanol, 20% (v/v) glycerol, 
0.002% (w/v) bromophenol blue) with a volume corresponding to 6 µg of protein then 
resolved on a 12.5% acrylamide gel. Western blots were performed as per Section 3.2.7. 
Standards with known amounts of 11β-HSD1 protein were included on each blot. 
4.2.5. Binding of steroids to microsomes 
A standard amount (20 nmol) of either cortisone or 7-ketocholesterol was incubated in 7 ml 
of MOPS buffer (100 mM KCl, 20 mM NaCl, 20 mM MOPS and 1mM MgCl2 pH 7.2) 
containing mouse liver microsomes equivalent to around 200 µg of protein. This gave a 
steroid conentration of 2.86 µM. Samples were left to equilibrate with shaking at room 
temperature for 1 h, then centrifuged at 100,000 × g for 1 h at 15˚C. Pellets were resuspended 
in 250 µl H2O. Steroids were partitioned into 3 ml of dichloromethane. Samples were then 
centrifuged for 5 min at 1000 × g and the aqueous layer discarded. After evaporation of the 
dichloromethane, samples were redissolved in 60 µl of 50% (v/v) aq. acetonitrile and loaded 
onto an RP-HPLC system consisting of a Prevail Select C-18, 5 µm column (Grace), a GP50 
gradient pump and a UVD170S detector (Dionex). Cortisone was eluted with a gradient of 
54% to 69% aq. methanol over a period of 15 min while 7-ketocholesterol was eluted using a 
gradient of 0% to 98% aq. methanol over 22 min. Both substrates were monitored by UV 
absorbance at 242 nm. Examples of the HPLC traces can be seen in Figure 4.6. Amount of 
steroid bound to membrane was quantified by comparison with a series of standards.  
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4.2.6. Preparation of DMPG liposomes 
A lipid solution of 1,2-dimyristoyl-sn-glycero-3-phosphoglycerol (DMPG) (~ 5.7 µmol) in a 
1:1 mixture of chloroform/methanol was evaporated to dryness under a stream of helium in 
order to create a lipid film. The film was then dried under vacuum for 3 h. The lipid film was 
then dispersed using sonication for 3 min with a 3ml of 50 mM sodium phosphate pH 7.2 at 
37˚C. 
4.2.7. Quenching of 11β-HSD1 fluorescence by acrylamide 
Studies on fluorescence quenching were carried out by the successive additions of a constant 
volume (10 µl) of acrylamide (4.22 M) to a cuvette containing a constant amount of 11β-
HSD1 (~0.2 µM) in a solution of 3 ml 50 mM sodium phosphate pH 7.2 with or without 
DPMG liposomes. After each addition, the fluorescence spectrum was recorded using an 
excitation wavelength 278 nm, with any changes to the emission at wavelength 326nm 
documented. An example of the fluorescence spectrum is shown in Figure 4.1. All 
experiments were performed using a Hitachi F-7000 spectrofluorimeter at 37˚C. Data was 
analysed by the Stern-Volmer equation for collisional quenching (Lakowicz, 1999): 
          (2)  
where F and F0 are the fluorescence intensities in the presence and absence of quencher, Q is 
the concentration of quencher, in this case acrylamide, and Ksv is the Stern-Volmer constant.  
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Figure 4.1. Fluorescence emission spectrum of 11β-HSD1 either in buffer (blue line) or in a liposome 
suspension (black line) using an excitation wavelength of 278 nm. Note the characteristic blue shift in the 
spectrum when 11β-HSD1 is incubated with liposomes.  
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4.3. Results 
4.3.1. Binding of human 11β-HSD1 to microsomes 
The ability of recombinant, N-terminally truncated human 11β-HSD1 (either WT or F278E) 
to associate with membranes was analysed using microsomes from either mouse liver or 
HEK-293 cells, as models for the physiologically relevant ER membrane. A standard amount 
of 11β-HSD1 protein was added to a suspension containing buffer together with either mouse 
liver microsomes or HEK-293 microsomes. Samples were left to equilibrate, then pelleted by 
centrifugation. Amount of 11β-HSD1 in the microsomal pellet was then analysed by western 
blotting. A control experiment in which no recombinant human 11β-HSD1 was added to 
mouse liver microsomes showed bands at 35KDa and 60KDa, which presumably correspond 
to monomeric and dimeric full-length murine 11β-HSD1 (Figure 4.2). Importantly, no human 
11β-HSD1 band or equivalent was present in empty microsome. The same experiment using 
microsomes derived from HEK-293 cells showed no bands. 
Using mouse liver microsomes, approximately 25% of WT 11β-HSD1 incubated with the 
microsomal suspension associated with the microsomal membranes (Figure 4.3). However, 
an approximate 50% decrease in the amount of 11β-HSD1 bound was observed when the 
protein carried the F278E mutation i.e. around 12.5% protein was bound (Figure 4.3). The 
difference in the amount of membrane association between the WT and F278E proteins was 
statistically significant when analysed using an unpaired t-test (p-value = 0.006). When 
microsomes from HEK-293 cells were used, a smaller decrease in membrane association of 
20% were observed when the F278E mutant was introduced. This difference in binding, 
however, was not significant (p-value = 0.226) (Figure 4.3).  
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Figure 4.2. Western blot of mouse liver microsomes with (B) or without (A) human 11β-HSD1. The 
additional bands at 35KDa and 60KDa correspond to monomeric and dimeric full-length murine 11β-HSD1. The 
position of human 11β-HSD1 on the western blots is indicated by the arrow. 
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Figure 4.3. Binding of human 11β-HSD1 to microsomes from both mouse liver (left) and HEK-293 cells 
(right). Western blots (A) showing triplicates of bound 11β-HSD1 to membrane. Comparison to known standards 
of 11β-HSD1 were used to quantify the amount of protein which was bound to the microsomes (B). The position 
of 11β-HSD1 on the western blots is indicated by the arrow. The difference in binding between WT and F278E 
was significant when  a microsomal preparation from mouse livers was used (p-value = 0.006) but not when the 
microsomes were sourced from HEK-293 cells (p-value = 0.2255). Bars represent SEM. 
 
4.3.2. Effect of salt on the binding of human 11β-HSD1 to microsomes 
Figure 4.3 clearly shows that the F278E mutant retained some affinity for microsomes, 
despite the partial disruption of the hydrophobic plateau. This suggested that the binding of 
11β-HSD1 might possibly be more complicated than a simple hydrophobic interaction. To 
investigate the involvement of any electrostatic interaction which may occur between protein 
and membrane by virtue of the positively charged residues which surround the hydrophobic 
plateau, WT 11β-HSD1 was incubated with a solution of mouse liver microsomes in buffer 
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containing 20 mM MOPS together with either 500 mM, 100 mM or no NaCl. No other 
additives were present in this buffer system. The microsomes were then pelleted with bound 
11β-HSD1 and analysed via western blots as described in the methods (Section 4.2.4). Visual 
examination, and densitometric analysis, of the blots appeared to show that the amount of 
11β-HSD1 bound to microsomes decreased with increasing concentrations of salt, with an 
approximate 40% decrease in binding between 0 and 500 mM NaCl (Figure 4.4). One way 
ANOVA with a post-hoc Tukey test indicated a significant difference (p = 0.009) between 
the 0 and 500 mM NaCl treatments, but no difference was observed between 0 and 100 mM 
NaCl or 100 mM and 500 mM NaCl.  
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Figure 4.4. The effect of salt on the binding of human 11β-HSD1 to microsomes from mouse livers. 
Western blots (A) showing triplicates of bound 11β-HSD1 to membrane. Comparison to known standards of 11β-
HSD1 were used to quantify the amount of protein which was bound to the microsomes (B).The position of 
human 11β-HSD1 on the western blots is indicated by the arrow. The amount of 11β-HSD1 bound to microsomes 
was seen to decrease with increasing salt concentrations. One way ANOVA showed that a significant difference 
existed (p = 0.009) between the 3 groups with a post-hoc Tukey test showing that the difference was between no 
salt and 500 mM NaCl. The position of human 11β-HSD1 on the western blots is indicated by the arrow. Bars 
represent SEM. 
 
4.3.3. Binding of steroid substrates of 11β-HSD1 to microsomes 
In order to ascertain whether the substrates of 11β-HSD1 are able to associate with biological 
membranes, a standard amount (20 nmol) of either cortisone or 7-ketocholesterol was 
incubated with a suspension of mouse liver microsomes. After centrifugation, the amount of 
steroid which associated with the membrane pellet was analysed via HPLC, with examples of 
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traces shown in Figure 4.5. Quantitative analysis of peak areas revealed that relatively small 
proportions of both cortisone and 7-ketocholesterol, around 1% and 2% respectively, 
associated with the membrane (Figure 4.6). Since there was a possibility that these figures 
could represent simply steroid that was trapped within the liquid of the pellet, rather than true 
membrane-bound steroid, an attempt was made to estimate the magnitude of the effect that 
entrapment would produce. The microsomal pellets analysed had an estimated volume of 
approximately 23 µl, which assuming a composition of entirely of water, could contain no 
more than 0.33% of the steroid added to the microsome suspension. Although microsomal 
pellets are composed of a great deal more than just water, this represented a useful 
hypothetical control value of the maximum amount of steroid which could be present without 
any association with the microsomal membranes. Therefore, since this value was 
considerably lower than the 1-2% observed in the experiment, it was concluded that the 
steroid binding observed was predominantly due to a genuine interaction with the biological 
membrane present in the mouse liver microsomes.  
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Figure 4.5. HPLC traces showing the binding of cortisone (B) and 7-ketocholesterol (C) to mouse liver 
microsomes. HPLC of microsome with no steroid added is shown by A. The positions of the substrates are 
shown by the black arrows. Axes represent absorbance (y) vs. time (x). Absorbance of steroid was recorded at 
242 nm. 
163 
 
 
Figure 4.6. The binding of steroid substrates of 11β-HSD1 to mouse liver microsomes. The “control” 
represents the hypothetical percentage of total steroid which could be present in the microsomal pellet if the 
pellet is assumed to be composed entirely of water, and if there is no association of steroid and membranes. A 
significantly larger amount of both cortisone and 7-ketocholesterol are seen to associate with the membrane than 
in the control. Bars represent SEM. 
 
4.3.4. Fluorescence quenching studies on human 11β-HSD1 
Quenching studies were performed using human 11β-HSD1, WT or F278E, either free in 
solution or inserted into liposomes of the anionic lipid DPMG. The lipid was chosen as when 
in the form of a liposome, it should have a structure relatively similar to the physiologically 
relevant phospholipid bilayer (Neves et al., 2009). The single Trp residue of human 11β-
HSD1, W263, was used as the fluorophore. Acrylamide, a small polar molecule, is able to 
quench fluorophores free in solution, but unable to quench those imbedded in membranes 
(Lakowicz, 1999). Since W263 is positioned on the hydrophobic plateau, it was hoped that 
any association of the protein with the membranes of the liposomes which involved this 
region, would result in a decrease in the ability of acrylamide to quench the enzyme 
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fluorescence.  The introduction of the F278E mutation would also be expected to reduce this 
difference in quenching if it countered the membrane association.  
Quenching of both WT and F278E, either in solution or in micelles, by acrylamide gave rise 
to a linear plot of F/F0 against [Q] with an intercept of 1 indicating a similar accessibility of 
all tryptophans to quencher (Figure 4.7). However, when inserted into DPMG liposomes, a 
decrease in the gradient of the line was observed reflecting a decrease in the quenching of 
W263 by acrylamide. This is shown clearly by a 64% decrease in the quenching constant, Ksv, 
for the WT protein and a smaller, 47% decrease for F278E (Table 4.1). This implies that 
while both WT and F278E proteins are able to associate with DMPG liposomes, the charge 
introduced by the F278E mutation has disrupted the hydrophobic plateau, indicated by the 
higher Ksv (Table 4.1). 
 
 
Figure 4.7. Stern-Volmer plots of acrylamide quenching of 11β-HSD1 (WT or F278E) either in buffer (top 
two lines) or inserted into DPMG liposomes (bottom two lines). Fitted lines were generated by Enzfitter 
(Biosoft) using the Stern-Volmer equation (Lakowicz, 1999).  
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 Buffer Liposomes 
 Ksv (mM-1) S.E Ksv (mM-1) S.E 
Wild Type 0.0240 0.0003 
 
0.0086 0.0002 
F278E 0.0208 0.0004 
 
0.0110 0.0003 
Table 4.1. Stern-Volmer constants (mean ± SEM) of acrylamide quenching of 11β-HSD1 (WT or F278E) 
either in buffer or inserted into DPMG liposomes. Experiments were performed in triplicate using the same 
preperation of enzyme (either WT or F278E). 
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4.4. Discussion 
Since the publication of the crystal structure of guinea pig 11β-HSD1 in 2004, the 
physiological role of the C-terminal hydrophobic plateau (Ogg et al., 2005) has not been fully 
elucidated. The hydrophobic residues which form this region are encircled by positively 
charged residues, suggesting that the plateau could exist in the non-polar centre of the 
membrane, with the charged residues forming salt bridges with the displaced phospholipid 
and sulpholipid head groups (Ogg et al., 2005). Substrates of 11β-HSD1, by virtue of both 
general structure and partition coeffecient (logPoct/water) values, can be considered to be 
relatively hydrophobic and therefore could be present in the hydrophobic core of the lipid 
bilayer. The residues which form the protruding C-terminal hydrophobic plateau of 11β-
HSD1 could conceivably dip into the ER membrane funnelling substrate into the active site.  
Intriguingly, this proposed membrane dipping of the protein could perhaps explain the 
discrepancy between the different experimentally observed Km values for 11β-HSD1. When 
assayed in intact cells, either transfected or from primary culture, 11β-HSD1 displays 
apparent Km values between 100 and 400 nM (Jamieson et al., 1999, Shafqat et al., 2003, 
Davani et al., 2000, Leckie et al., 1998, Jamieson et al., 1995, Bujalska et al., 1999b). This is 
consistent with the physiologically relevant nanomolar circulating glucocorticoid 
concentrations. However, 11β-HSD1 derived from either homogenates or recombinant 
sources, this work included (see Section 2.3.2 & 3.3.6), displays Km values in the low 
micromolar range (Hult et al., 1998, Pu and Yang, 2000, Blum et al., 2000, Maser et al., 
2002, Quinkler et al., 1997, Stewart et al., 1987, Arampatzis et al., 2005, Shafqat et al., 2003, 
Lawson et al., 2009). Although cooperative kinetics has been proposed as an explanation for 
this discrepancy (Maser et al., 2002), this has been disproven by a number of groups 
(Jamieson et al., 1999, Shafqat et al., 2003, Davani et al., 2000, Leckie et al., 1998, Jamieson 
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et al., 1995, Bujalska et al., 1999b). A more likely explanation is that the presence of steroid 
substrate in the ER membrane allows for a local increase in substrate concentration from the 
circulating nanomolar levels to a local micromolar level, allowing for efficient 11β-HSD1 
activity. However, before this study no experimental evidence had been presented to prove 
that either the hydrophobic plateau of 11β-HSD1, or any of its steroid substrates, interacts 
with the ER membrane.  
In Section 2.3 it was shown that mutations to the C-terminus of recombinant, N-terminally 
truncated 11β-HSD1 which disrupt the hydrophobic plateau, can increase yield of soluble 
protein without adversely affecting activity. Therefore one of these mutants, F278E, was used 
to probe the effect that disruption of the hydrophobic plateau has on the binding of human 
11β-HSD1 to membranes. Microsomes from either mouse liver or HEK-293 cells were used 
as models for the physiologically relevant human ER membrane, with binding of 11β-HSD1 
to these model membranes assessed using western blot analysis. Figure 4.3 clearly shows that 
when mouse liver microsomes were used, approximately 25% of WT 11β-HSD1 associated 
with the microsomal membranes, with the F278E mutation causing a significant decrease in 
binding of around 50%.  A slightly reduced proportion of WT 11β-HSD1 (20%) was seen to 
associate with microsomes from HEK-293 cells, with a smaller, and indeed statistically 
insignificant, 20% decrease in membrane association observed when the F278E mutation is 
introduced (Figure 4.3). While the exact organelle composition of each of these types of cell 
is not known, the microsomes prepared from mouse liver will almost certainly have a higher 
proportion of both rough and smooth ER, due to the considerable protein and lipid synthesis 
performed by hepatocytes. It would also appear that ER membranes are biochemically 
distinct from other membranes, being made up of a high percentage of phosphatidylcholine 
(van Meer et al., 2008). Therefore, due to the expression of 11β-HSD1 in hepatic tissues 
(Lakshmi and Monder, 1988), the difference in binding observed between microsomes 
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derived from HEK-293 cells or mouse livers could be down to the preference for 11β-HSD1 
to interact with the larger proportion of physiologically relevant ER membranes present in the 
microsomes derived from mouse livers. 
Interestingly, the F278E mutant retains some affinity for microsomes, despite the significant 
disruption the mutation might be expected to make to the hydrophobicity of the plateau. This 
could suggest that the binding of 11β-HSD1 is more complicated than a simple hydrophobic 
interaction. As discussed previously, hydrophobic residues which form the putative 
membrane dipping region of 11β-HSD1 are encircled by positively charged residues which 
could form salt bridges with the displaced phospholipid and sulpholipid head groups. A 
similar combination of hydrophobic and charged interactions are observed in the membrane 
dipping regions of both prostaglandin H2 synthase-1 and squalene cyclase (Picot et al., 1994, 
Wendt et al., 1997). To ascertain the involvement these charged residues on the interaction 
between 11β-HSD1 and membrane, WT 11β-HSD1 was incubated with a suspension of 
mouse liver microsomes which contained 20 mM MOPS together with either 0 mM, 100 mM 
or 500 mM NaCl. Salt was included in the buffer to shield any potential electrostatic 
interactions between residues in 11β-HSD1 and phospholipid and sulpholipid head groups of 
the membrane. Increasing salt concentration is also known to increase the binding of proteins 
to hydrophobic matrices, a property exploited in hydrophobic interaction chromatography 
(Tsumoto et al., 2007).   Thus an increase in binding of 11β-HSD1 to membranes on addition 
of salt would indicate a greater importance of hydrophobic interactions, whereas a decrease in 
binding would signal a greater electrostatic contribution.  In the experiments reported here, a 
modest decrease in binding was observed with increasing salt concentration, although this 
was only significant at relatively high (500 mM) concentrations.  This suggests that positively 
charged residues, most probably Arg269 and Lys274, are contributing to the binding of 11β-
HSD1 to membranes. These important electrostatic interactions also perhaps explain the 
169 
retention of some membrane binding affinity of the F278E mutant in the previous experiment 
(see Section 4.3.1). These data, taken together with the decrease in binding observed with the 
introduction of the F278E mutation, indicate that a combination of hydrophobic and 
electrostatic interactions are required for optimum binding of 11β-HSD1 to microsomal 
membranes.  
Despite the physiological relevance of glucocorticoids, the molecular mechanism governing 
the entrance of these steroids into cells is poorly understood. In addition, knowledge of their 
intracellular distribution and concentration in cellular compartments is also scarce (Odermatt 
et al., 2006). In order for the membrane dipping to function, substrates of 11β-HSD1 would 
have to be concentrated in the biological membrane. It is currently unclear whether free 
glucocorticoid enters target cells either by endocytotic uptake or insertion into the membrane, 
although, due to thr lipid-soluble structure of glucocorticoids, it is most probably the latter 
(Laycock, 1996). A comparison of full length 11β-HSD1 facing the ER lumen with a 
K5S:K6S cytoplasmic-facing mutant showed comparable catalytic activities, indicating 
glucocorticoids may accumulate in certain regions of the ER membrane (Odermatt et al., 
1999). Indeed, by comparing physical measures of bilayer order and polarity, formation of 
detergent resistant domains, phase separation and membrane microsolubilization by 
apolipoprotein A-I, the 11β-HSD1 substrate 7-ketocholesterol is known to localize in model 
membranes both in a similar location (e.g. in phospholipids with a small interfacial surface 
area such as sphingomyelin and saturated phosphatidylcholines) and also a location distinct 
(e.g. bilayers of unsaturated phospholipids and those above their midpoint temperature of gel 
to liquid crystalline phase transition, TM) from cholesterol (Massey and Pownall, 2005). 
The studies reported here show that when a standard amount (20 nmol) of either cortisone or 
7-ketocholesterol is added to a suspension of mouse liver microsomes a small amount of 
both, around 1% and 2% respectively, associates with the membrane (Figure 4.6). Knowing 
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the approximate volume of the microsomal pellet, and assuming the steroids are evenly 
distributed within the pellet, it can be calculated that the concentrations of cortisone and 7-
ketocholesterol in the pellet are approximately 7 µM and 13 µM respectively. This compares 
with a supernatant value of 2.26 µM and 2.28 µM for 7-ketocholesterol and cortisone 
respectively.  Using the previously experimentally derived logPoct/water value for cortisone of 
1.47  (Hansch, 1995), the concentration of cortisone in the organic phase of an octanol/water 
mixture should be around 30 times greater than in water. In the system reported here, the 
concentration of cortisone in the microsomal fraction is only twice that in the supernatant. 
Although the preference of the steroids for the microsomal pellet is not that great, these 
values could still perhaps account for the discrepancies in Km values observed between in 
vivo and in vitro studies. This is due to the fact that microsomes are not purely lipid; in 
particular, a significant amount of water will be sedimented within the microsomal vesicles. 
Hence the concentration of steroid within the lipid centre of the membrane may be 
significantly higher than observed here, in which case it would certainly affect 11β-HSD1 
activity if the protein was able to dip into the membrane to utilize the associated steroid. 
Also, since the human 11β-HSD1 substrates are not physiologically relevant to the mouse 
liver microsomes used in these experiments, it is possible that the different types of lipids or 
proteins which constitute these cells may interact with 11β-HSD1 substrates differently when 
compared to human liver microsomes. Other factors, such as the presence of lipid rafts and 
associated proteins, may also affect substrate binding into the membrane. The buffer used to 
incubate microsomes and proteins in these experiments is also probably a poor mimic of 
contents of either the cytosol or the ER lumen; in particular the high amounts of solutes 
inside the cell would result in a higher ionic strength, resulting in an increased preference of 
the steroid for the membrane. Interestingly, evidence seems to suggest that the stabilization of 
lysosomal membranes, therefore preventing proteolytic enzyme release, by cortisol is 
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particularly important (Laycock, 1996). Finally, since no ATP was added at any point during 
the experiment, it can also be concluded that no active transport took place, inferring that the 
steroid substrates were either associated with a protein in the microsomal pellet, or more 
likely, were sequestered into the membrane bilayer in a similar way to that observed with 
cholesterol (Brown and Jessup, 1999). 
The differing accessibilities of quenchers to fluorophores have been used to study a wide 
range of proteins. Recently this technique has been used to investigate quinolone antibiotic 
resistance in the bacterial protein OmpF (Neves et al., 2009). The technique has also been 
used to investigate the membrane bound topology of helices 1 and 2 in the channel domain of 
the pore forming toxin, colicin E1 (White et al., 2006, Musse et al., 2006). In contrast to the 
colicin E1 study in which an artificial fluorophore was used, with 11β-HSD1 the naturally 
occurring fluorophore W263 which faces the exterior of the C-terminal hydrophobic plateau 
thought to associate with membrane was utilized. Since this is the only Trp residue in human 
11β-HSD1, we were confident that any fluorescence observed was due to this residue. 
Indeed, when 11β-HSD1 (both WT and F278E) was incubated with DPMG liposomes, a 
blue-shift in the emission spectrum was observed (Figure 4.1), indicating the normally 
solvent exposed Trp residue had become buried in the DPMG liposome. This implies that any 
interaction between  11β-HSD1 and membrane occurs in the region surrounding W263. 
Acrylamide was able to quench WT and F278E 11β-HSD1 fluorescence both in buffer and in 
a solution of DPMG liposomes (Figure 4.7). Incubation with liposomes was accompanied by 
a decrease in quenching efficiency of acrylamide for both WT and F278E proteins, indicated 
by a decrease in the Ksv value, once again suggesting insertion of the W263 residue into the 
membrane. However, the greater decrease in Ksv observed for WT (64%) compared to F278E 
(47%) when incubated with liposomes indicates that, although W263 is able to interact with 
membrane in both proteins, the F278E mutation appears to at least partially disrupted the 
172 
hydrophobic plateau leading to a decrease in association between 11β-HSD1 and membrane. 
These data once again suggest of the importance of the C-terminal hydrophobic plateau on 
the interaction of 11β-HSD1 and membrane.  
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Chapter 5. General Discussion 
For some time it has been known that dysregulation of cortisol at a tissue level, which would 
indicate abnormal 11β-HSD1 activity, may be the underlying pathology behind a range of 
conditions such as obesity, type 2 diabetes, ACRD, various neurodegenerative diseases and 
glaucoma. However, surprisingly for a protein which has such wide-reaching involvement in 
the pathology of disease, the high resolution structures which would allow the development 
of structure-based drug design for the treatment of these diseases have only become available 
in the last 5-6 years. This is can in part be attributed to the fact that, in contrast to most other 
members of the SDR family, 11β-HSD1 is a glycosylated, membrane-bound, ER luminal 
protein which has made production and purification of full length protein difficult (Hult et al., 
2001, Nobel et al., 2002). The development of recombinant 11β-HSD1 which has the N-
terminal transmembrane domain removed has allowed the protein to be expressed in E.coli 
(Walker et al., 2001a), which, together with co-expression of 11β-HSD1 with the 
chaperonins GroEL/GroES and the addition of an inhibitor of 11β-HSD1 during the induction 
phase (Hozjan et al., 2008, Hult et al., 2006, Elleby et al., 2004), has allowed purification of 
sufficient quantities of 11β-HSD1 to a relatively high level of homogeneity and 
monodispersity. 
The crystal structure of 11β-HSD1 confirmed that the protein existed as a homodimer, with a 
highly similar central scaffold to most other SDRs. However, 11β-HSD1 does show a striking 
difference to other SDR structures at the C-terminus with the last 2 helices (α2 and α3) which 
are seen to protrude and form a long structure which packs against the C-terminus of the 
other subunit in an antiparallel conformation. The residues on the surface of these C-terminal 
helices are in the form of a non-polar plateau encircled by positively charged residues (Ogg et 
al., 2005). This plateau is thought to exist in the non-polar centre of the ER membrane, with 
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the charged residues forming salt bridges with the displaced phospholipid and sulpholipid 
head groups. Due to the hydrophobic nature of the substrates of 11β-HSD1, this could 
constitute a potential ‘membrane dipping’ mechanism to funnel hydrophobic substrates from 
the membrane into the 11β-HSD1 active site (Ogg et al., 2005).  
To initiate investigations in the importance of this C-terminus of 11β-HSD1, the four residues 
which make up the hydrophobic plateau in both the human and guinea pig 11β-HSD1, were 
each mutated to the charged amino acid glutamic acid. The aim was to create a membrane 
truncated, recombinant 11β-HSD1 mutant with unchanged kinetics and structure, but altered 
membrane association properties which could subsequently be used to probe the membrane 
dipping hypothesis. On expression in E.coli, all mutations increased the yield of soluble 11β-
HSD1, with the F278E mutant in both human and guinea pig showing the most dramatic 
increases compared to wild-type protein. The increased solubility of these mutants was due to 
a decrease in protein aggregation, as shown by sedimentation AUC analysis.  All the mutant 
proteins had similar kinetics (kcat and Km) for the steroid substrate to the wild-type, in both 
dehydrogenase and reductase directions, with the guinea pig F278E mutant enzyme showing 
an overall structure largely identical to the previously published wild-type guinea pig 
structure (PDB code: 1XSE) (Ogg et al., 2005). 
Due to the increased solubility, monodispersity and activity of the human 11β-HSD1 F278E 
mutant, this protein was used to as a background to investigate two novel mutations in 11β-
HSD1 which result in cortisone reductase deficiency (CRD). CRD is a human disorder in 
which there is a failure to regenerate the cortisol from cortisone via the activity of 11β-HSD1 
(Tomlinson et al., 2004) which results ACTH-mediated adrenal hyperandrogenism. The two 
cases reported here were diagnosed via urinary steroid metabolite analysis, with molecular 
analysis of the HSD11B1 gene indicating two novel mutations (R137C and K187N) which 
were both in the heterozygous state. R137 and K187 are strictly conserved within 11β-HSD1 
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proteins, R137 forming a salt bridge vital for dimerization (together with E141) and K187 
being  a key residue in the active site of 11β-HSD1.When K187N was expressed in E.coli in 
the F278E background, no soluble protein could be detected at all, indicating the additional 
importance of this residue to structural stability.  Since K187 is known to ligate the 2- and 3-
ribose hydroxyls of the nicotinamide cofactor in 11β-HSD1 (Hosfield et al., 2005), cofactor 
binding may be essential for correct folding/stability. For R137C, expression in E.coli in the 
F278E background also resulted in a dramatic decrease in the yield of functional, soluble 
protein, coupled this time with a minor effect on the kcat of the purified enzyme. These 
decreases are presumably due to the R137C mutation interfering with correct subunit-subunit 
binding and hence compromising dimer formation and/or stability. 
However, 11β-HSD1 is a dimeric enzyme and since both cases described here were in the 
heterozygous state, the effect of heterodimer formation between wild-type and mutant 
subunits was uncertain. The data from construction of a novel system to purify hybrid dimers 
(e.g.  one monomer containing R137C/F278E and the other F278E) suggests that a mutation 
in one subunit could negatively affect the activity of an adjacent WT subunit. Each mutation 
exerted a dominant negative effect on protein yield as well as on activity, with the K187N 
mutant showing more marked suppression of both. Although further examples of the 
association of these mutations with disease would help establish causality beyond doubt, 
these dominant-negative effects help explain the condition of patients who are heterozygous 
for these mutations.  
The human 11β-HSD1 F278E mutant was an ideal protein to probe the effect of disruption of 
the hydrophobic plateau on the binding of human 11β-HSD1 to membranes. Western blot 
analysis showed that when purified, recombinant 11β-HSD1 is incubated with mouse liver 
microsomes, approximately 25% of WT 11β-HSD1 associated with the microsomal 
membranes, with the F278E mutation causing a significant decrease in binding giving only. 
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12.5% association. Inclusion of NaCl  in the incubation of WT 11β-HSD1 with a solution of 
mouse liver microsomes in a buffer containing 20 mM MOPS showed a modest decrease in 
binding with increasing salt concentration, although this was only significant at relatively 
high (500 mM) concentrations. These data indicate that a combination of hydrophobic and 
electrostatic interactions (potential salt bridges between phospholipid/sulpholipid head groups 
and R269 and/or K274 on 11β-HSD1) are required for optimum binding of 11β-HSD1 to 
microsomal membranes. Further experiments, in which the differing accessibility of 
acrylamide to W263, in either WT or F278E, supported this observation. Although 
acrylamide was able to quench the fluorescence of WT and F278E 11β-HSD1 both in buffer 
and in a solution of DPMG liposomes, the F278E mutation once again partially disrupted the 
hydrophobic plateau, as evidenced by a greater decrease in acrylamide quenching observed 
for WT 11β-HSD1 compared to F278E 11β-HSD1when inserted into liposomes.  
In order for the membrane-dipping hypothesis to function, substrates of 11β-HSD1 would 
have to be concentrated in the biological membrane. The studies reported here show that 
when a standard amount of either cortisone or 7-ketocholesterol are added to a suspension of 
mouse liver microsomes a small amount of both, around 1% and 2% respectively, associate 
with the membrane. This corresponds to a concentration of 7 µM and 13 µM in the 
microsomal pellet for cortisone and 7-ketocholesterol respectively. This indicates that there is 
two to four times the concentration of steroid in the pellet compared to the supernatant.  
Although this is not quite as great as the partition expected from the logPoct/water value of 
cortisone, the fact that 11β-HSD1 substrates are able to associate with microsomes used here 
may account for the discrepancies in Km values observed between in vivo studies in 
biological cells and in vitro studies in solution. The microsomes used in this study are not 
purely lipid due to a significant amount of water which will have sedimented within the 
microsomal vesicles. Therefore, the concentration of steroid within the lipid centre of the 
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membrane may be significantly higher than observed here, in which case it would certainly 
affect 11β-HSD1 activity if the protein was able to dip into the membrane to utilize the 
associated steroid.  
Further work to fully elucidate the binding of steroid substrates of 11β-HSD1 to membrane 
could include the use of small angle x-ray diffraction to compare the membrane interaction of 
cortisone to the interaction of both 7-ketocholesterol and cholesterol to membrane which 
have been previously characterised using this technique (Phillips et al., 2001). In this x-ray 
diffraction method, cholesterol, which has a known x-ray diffraction pattern in lipid vesicles, 
was replaced with 7-ketocholesterol which produced distinct changes in membrane structure 
as evidenced from the change in x-ray diffraction. For example, there was an increase in 
electron density associated with the upper acyl chain region corresponding to the bilayer 
location of the steroid nucleus of 7-ketocholesterol (Phillips et al., 2001). Methods which 
have been used to further characterise the interaction of 7-ketocholesterol and cholesterol to 
membrane by Massey et al. (2005) could potentially be extended to cortisone. These methods 
include comparing physical measures of bilayer order and polarity, formation of detergent 
resistant domains, phase separation and membrane microsolubilization by apolipoprotein A-I 
(Massey and Pownall, 2005). 
Future work to investigate the nature of the binding of 11β-HSD1 to membranes could 
include mutation of the charged residues R269 and K274, which would further probe the 
electrostatic contribution of these residues to the association of the protein to microsomal 
membranes. In addition, more drastic alterations to the plateau via a greater number of 
simultaneous mutations of hydrophobic residues would also help further elucidate the 
respective roles of hydrophobicity and electrostatics on the binding. Finally, improvements to 
the procedure to further mirror the in vivo environment (e.g. ionic strength and pH of buffer, 
composition of model membranes) may also be beneficial in providing a clearer picture of 
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how 11β-HSD1 may behave in the cell. However, it is worth noting that the findings 
presented here use purified, recombinant 11β-HSD1. Therefore, it would be interesting to 
express full-length 11β-HSD1 in mammalian cells and observe the effect of the F278E 
mutation.  Although the effect of the hydrophobic plateau on physical association with the 
membrane could not be measured, since the N-terminal anchor would preserve this, 
observation of changes in apparent Km might be revealing, although it is by no means easy to 
get accurate Km values from transfected cell systems.  An alternative approach might be to 
engineer a cleavage site at the end of the current signal anchor, to create a signal peptide.  If 
this worked it would deliver N-terminally truncated enzyme into the lumen of the ER when 
expressed in mammalian cell lines.  It might then be possible to monitor membrane 
association of the WT and mutant proteins, and the importance of the hydrophobic plateau, in 
a more natural situation. 
In summary, in this thesis I have described the construction of a series of mutants in which 
hydrophobic residues in the C-terminal helices of human and guinea pig 11β-HSD1 were 
mutated to glutamic acid. One of these mutants, F278E, displayed increased solubility, 
monodispersity and activity with an unchanged crystal structure. Human F278E was then 
used as a background to construct a novel hybrid dimer system to analyse the CRD causing 
mutations in 11β-HSD1 (R137C and K187N). Analysis of the resulting heterodimers 
revealed that the negative effects of both the K187N and R137C mutations can extend to the 
normally-active WT partner, leading to a marked suppression of 11β-HSD1 activity which 
could account for the phenotype observed in patients presenting with CRD. Finally, a 
comparison of human WT and F278E was used to probe the membrane association of 11β-
HSD1. A combination of western blot analysis and fluorescence quenching experiments 
revealed that the binding of 11β-HSD1 to mouse liver microsomes is via a combination of 
hydrophobic and electrostatic interactions.  
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Appendix One – Published Work 
Protein Science. 18(7): 1552-63. 
Mutations of key hydrophobic surface residues of 11 beta-hydroxysteroid dehydrogenase 
type 1 increase solubility and monodispersity in a bacterial expression system. 
 
 
